{"protocolSection":{"identificationModule":{"nctId":"NCT00083889","nctIdAliases":["NCT00098657"],"orgStudyIdInfo":{"id":"A6181034"},"organization":{"fullName":"Pfizer","class":"INDUSTRY"},"briefTitle":"SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma","officialTitle":"A Phase 3, Randomized Study Of SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma"},"statusModule":{"statusVerifiedDate":"2010-01","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2004-08"},"primaryCompletionDateStruct":{"date":"2008-09","type":"ACTUAL"},"completionDateStruct":{"date":"2008-09","type":"ACTUAL"},"studyFirstSubmitDate":"2004-06-03","studyFirstSubmitQcDate":"2004-06-03","studyFirstPostDateStruct":{"date":"2004-06-04","type":"ESTIMATED"},"resultsFirstSubmitDate":"2009-09-16","resultsFirstSubmitQcDate":"2009-11-06","resultsFirstPostDateStruct":{"date":"2009-12-10","type":"ESTIMATED"},"lastUpdateSubmitDate":"2010-01-19","lastUpdatePostDateStruct":{"date":"2010-01-26","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"oldNameTitle":"Director, Clinical Trial Disclosure Group","oldOrganization":"Pfizer Inc"},"leadSponsor":{"name":"Pfizer","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"The purpose of this study is to test whether SU011248 has activity and is safe compared to interferon-alfa as first-line therapy in patients with metastatic renal cell carcinoma (RCC)."},"conditionsModule":{"conditions":["Carcinoma, Renal Cell"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":750,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"2","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Interferon-alfa"]},{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: SU011248"]}],"interventions":[{"type":"DRUG","name":"Interferon-alfa","description":"3 MIU first week, 6 MIU second week, and 9 MIU thereafter three times a week (non-consecutive days) until progression or unacceptable toxicity","armGroupLabels":["2"],"otherNames":["Roferon"]},{"type":"DRUG","name":"SU011248","description":"50 mg orally daily for 4 weeks and 2 weeks off treatment until progression or unacceptable toxicity","armGroupLabels":["1"],"otherNames":["Sunitinib, SUTENT"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Progression-Free Survival (PFS), Core Radiology Assessment","description":"Progression-free survival (PFS) = time from randomization to first documentation of objective tumor progression or to death due to any cause, whichever occured first. If tumor progression data included more than 1 date, the first date was used. PFS = first event date minus the date of randomization + 1. On study included treatment plus 28-day follow-up periods.","timeFrame":"Day 28 of each 6-week cycle: duration of treatment phase"},{"measure":"Progression-Free Survival (PFS), Investigator's Assessment","description":"Progression-free survival = time from randomization to first documentation of objective tumor progression or to death due to any cause, whichever occured first. PFS = first event date minus the date of randomization + 1). On study included treatment plus 28-day follow-up periods.","timeFrame":"Day 28 of each 6-week cycle: duration of treatment phase"}],"secondaryOutcomes":[{"measure":"Objective Response, Core Radiology Assessment","description":"Objective response (OR) = the number of patients with confirmed complete response (CR) and confirmed partial response (PR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria, relative to all randomized patients. CR was defined as the disappearance of all target lesions. PR was defined as a ≥ 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. Confirmed responses (CR or PR) = those that persisted on repeat imaging study \\>= 4 weeks after initial documentation of response.","timeFrame":"Day 28 of each 6-week cycle: duration of treatment phase"},{"measure":"Objective Response, Investigator's Assessment","description":"Objective response (OR) = the number of patients with confirmed complete response (CR) and confirmed partial response (PR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria, relative to all randomized patients. CR was defined as the disappearance of all target lesions. PR was defined as a ≥ 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. Confirmed responses = those that persist on repeat imaging study \\>= 4 weeks after initial documentation of response.","timeFrame":"Day 28 of each 6-week cycle: duration of treatment phase"},{"measure":"Overall Survival (OS)","description":"Overall survival (OS) = time from date of randomization to date of death due to any cause. For patients not expiring, survival time was censored at the last date they were known to be alive. Patients lacking data beyond randomization had their survival times censored at the date of randomization with a duration of 1 day.","timeFrame":"Clinic visit or telephone contact every 2 months until death"},{"measure":"Time to Tumor Progression (TTP), Core Radiology Assessment","description":"TTP = time from randomization to first documentation of objective tumor progression. TTP data were censored on the day following the date of last on treatment (including 28 day follow-up period) tumor assessment documenting absence of progressive disease for subjects who did not have objective tumor progression while on treatment or who were given anti-tumor treatment other than study treatment prior to documentation of objective tumor progression. Subjects with no tumor assessments after randomization had TTP censored on the date of randomization with a duration of 1 day.","timeFrame":"Randomization to first documentation of tumor progression: duration of treatment phase"},{"measure":"Time to Tumor Progression (TTP), Investigator's Assessment","description":"TTP = time from randomization to first documentation of objective tumor progression. TTP data were censored on the day following the date of last on treatment (including 28 day follow-up period) tumor assessment documenting absence of progressive disease for subjects who did not have objective tumor progression while on treatment or who were given anti-tumor treatment other than the study treatment prior to documentation of objective tumor progression. Subjects with no tumor assessments after randomization had TTP censored on the date of randomization with a duration of 1 day.","timeFrame":"Randomization to first documentation of tumor progression: duration of treatment phase"},{"measure":"Duration of Response (DR), Core Radiology Assessement","description":"Duration of response (DR) = time from the first documentation of objective tumor response to the first documentation of objective tumor progression or to death due to any cause. DR data were censored on the day following the date of the last on treatment (including 28 day follow-up period) tumor assessment documenting absence of progressive disease for subjects without objective tumor progression who did not die due to any cause while on treatment or who were given anti-tumor treatment other than study treatment prior to observing tumor progression.","timeFrame":"Day 28 of each cycle: duraton of treatment phase"},{"measure":"Duration of Response (DR), Investigator's Assessment","description":"Duration of response (DR) = time from the first documentation of objective tumor response to the first documentaion of objective tumor progression or to death due to any cause. DR data were censored on the day following the date of the last on treatment (including 28 day follow-up period) tumor assessment documenting absence of progressive disease for subjects without objective tumor progression who did not die due to any cause while on treatment or who were given anti-tumor treatment other than study treatment prior to observing tumor progression.","timeFrame":"Day 28 of each cycle: duration of treatment phase"},{"measure":"FACT-Kidney Symptom Index-Disease Related Symptoms (FKSI-DRS) Subscale","description":"FACT-Kidney Symptom Index-Disease Related Symptoms (FKSI-DRS) subscale of the FKSI to measure advanced kidney cancer disease related symptoms. Includes 9 items: lack of energy, pain, losing weight, bone pain, fatigue, short of breath, coughing, bothered by fevers, and hematuria. Each question was answered on a five-point Likert-type scale ranging from 0 (not at all) to 4 (very much). Score = the sum score of the item scores in the subscale; total range: 0 to 36. A score greater than 0 indicates the difference favored sunitinib.","timeFrame":"Day 1 & 28 of each cycle: duration of treatment phase"},{"measure":"FACT-Kidney Symptom Index (FKSI) Subscale","description":"FACT-Kidney Symptom Index (FKSI) subscale designed to be a stand-alone instrument to measure symptoms and quality of life in patients with advanced kidney cancer. Contains 15 questions; some questions overlap with the FACT-G questions. Each question was answered on a five-point Likert-type scale ranging from 0 to 4 (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much). Total FKSI score = sum score of the 15 item scores; total range: 0 - 60; 0 (most severe symptoms and concerns) to 60 (no symptoms or concerns).","timeFrame":"Day 1 & 28 of each cycle: duration of treatment phase"},{"measure":"Functional Assessment of Cancer Therapy-General (FACT-G)","description":"Functional Assessment of Cancer Therapy-General (FACT-G): core questionnaire of the Functional Assessment of Chronic Illness Therapy (FACIT) measurement system that has been validated in a variety of cancer populations. 27 questions grouped into 4 domains that measure a patient's physical, functional, social and family, and emotional well-being. Five-point Likert-type scale ranging from 0 to 4 (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much). Score = sum score of item scores in the subscale; total range: 0 to 108 with higher score indicating better quality of life.","timeFrame":"Day 1 & 28 of each cycle: duration of treatment phase"},{"measure":"Functional Assessment of Cancer Therapy-General (FACT-G): Physical Well Being (PWB) Subscale","description":"Physical well-being (PWB) subscale of the Functional Assessment of Cancer Therapy-General (FACT-G). Each question was answered on a five-point Likert-type scale ranging from 0 to 4 (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much). Score = the sum score of the item scores in the subscale; range: 0 to 28; lower score indicates better physical well-being.","timeFrame":"Day 1 & 28 of each cycle: duration of treatment phase"},{"measure":"Functional Assessment of Cancer Therapy-General (FACT-G): Social/Family Well Being (SWB) Subscale","description":"Social/family well-being (SWB)subscale of the Functional Assessment of Cancer Therapy-General (FACT-G). Each question was answered on a five-point Likert-type scale ranging from 0 to 4 (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much). Score = the sum score of the item scores in the subscale; range: 0 to 28; lower score indicates less social/family well-being.","timeFrame":"Day 1 & 28 of each cycle: duration of treatment phase"},{"measure":"Functional Assessment of Cancer Therapy-General (FACT-G): Emotional Well Being (EWB) Subscale","description":"Emotional well-being (EWB)subscale of the Functional Assessment of Cancer Therapy-General (FACT-G). Each question was answered on a five-point Likert-type scale ranging from 0 to 4 (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much). Score = the sum score of the item scores in the subscale; range: 0 to 24; lower score indicates better emotional well-being.","timeFrame":"Day 1 & 28 of each cycle: duration of treatment phase"},{"measure":"Functional Assessment of Cancer Therapy-General (FACT-G): Functional Well Being (FWB) Subscale","description":"Functional well-being (FWB) subscale of the Functional Assessment of Cancer Therapy-General (FACT-G). Each question was answered on a five-point Likert-type scale ranging from 0 to 4 (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much). Score = the sum score of the item scores in the subscale; range: 0 to 28; higher score indicates greater functional well-being.","timeFrame":"Day 1 & 28 of each cycle: duration of treatment phase"},{"measure":"EuroQoL Five Dimension (EQ-5D) Health State Index","description":"EQ-5D Health State Index: a brief, self-administered generic health status instrument. Respondents were asked to describe their current health state on each of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety or depression) on a three-level scale (1=no problem, 2=some problem, and 3=extreme problem). A maximum score of 1 can be derived from these 5 dimensions by score conversion; range: -0.39 (worst health state)to 1.00 (best health state). This descriptive system classifies respondents into one of 243 possible distinct health states (EQ-5D descriptive system).","timeFrame":"Day 1 & 28 of each cycle: duration of treatment phase"},{"measure":"Euro-QoL Visual Analog Scale (EQ-VAS)","description":"EQ-VAS: overall self-rating rating of the patient's current health state using a 20 cm Visual Analog Scale (EQ-VAS), also called the health state thermometer) is a metric measurement (in 2 mm interval) from the visual analog scale which ranges between 0 (worse imaginable health state) and 100 (best imaginable health state).","timeFrame":"Day 1 & 28 of each cycle: duration of treatment phase"},{"measure":"Plasma Concentrations of Soluble Proteins: Plasma VEGF-A, Plasma VEGF-C, Plasma sVEGFR-3, PLASMA IL-8, and PLASMA bFGF That May be Associated With Tumor Proliferation or Angiogenesis","description":"Plasma concentrations of soluble proteins that may be associated with tumor proliferation or angiogenesis collected from a subset of patients were analyzed by enzyme-linked immunosorbent assay (ELISA) analysis. Soluble protein values: Baseline concentration (pM) and ratio to Baseline at each timepoint; ratio = plasma concentration of soluble protein (picograms per milliliter \\[pg/ml\\]) at timepoint / concentration of soluble protein (pg/ml) at baseline. Samples below the limit of quantitation and samples with insufficient volume available were excluded.","timeFrame":"Day 1 & Day 28, Cycle 1 to Cycle 4"},{"measure":"Plasma Concentrations of Soluble Proteins: Plasma Basic Fibroblast Growth Factor (bFGF) That May be Associated With Tumor Proliferation or Angiogenesis","description":"Plasma concentrations of soluble proteins that may be associated with tumor proliferation or angiogenesis collected from a subset of patients were analyzed by enzyme-linked immunosorbent assay (ELISA) analysis. Soluble protein values: Baseline concentration (pM) and ratio to Baseline at each timepoint; ratio = plasma concentration of soluble protein (picograms per milliliter \\[pg/ml\\]) at timepoint / concentration of soluble protein (pg/ml) at baseline. Samples below the limit of quantitation and samples with insufficient volume available were excluded.","timeFrame":"Day 1 & Day 28, Cycle 1 to Cycle 4"},{"measure":"Incremental Cost Effectiveness Ratio (ICER)","description":"Incremental cost effectiveness ratio (ICER) of sunitinib compared to IFN-a as first-line treatment for MRCC, defined as the ratio of the incremental cost of treatment over the incremental effectiveness; effectiveness measured as quality adjusted life year (QALY) gain. This objective was not addressed in the clinical study report, but an interim analysis of cost-effectiveness was presented separately. These results were not available for inclusion at the time of this posting.","timeFrame":"post study measurement"},{"measure":"Ctrough Concentrations of SU011248","description":"Subject observed Ctrough (trough drug) concentrations of SU011248 per cycle and study day determined by plasma trough samples collected from a subset of patients. Steady-state observed trough concentrations were dose corrected to the starting dose (reference dose) where appropriate. Concentrations below the limits of quantitation (BLQ) were set to 0. Ctrough = minimum (trough) plasma concentration (nanograms per milliliter \\[ng/mL\\]).","timeFrame":"Day 28 of Cycle 1 to Cycle 4"},{"measure":"Ctrough Concentrations of Metabolite SU012662","description":"Subject observed Ctrough (trough drug) concentrations of active metabolite SU012662 per cycle and study day determined by plasma trough samples collected from a subset of patients. Steady-state observed trough concentrations were dose corrected to the starting dose (reference dose) where appropriate. Concentrations below the limits of quantitation (BLQ) were set to 0. Ctrough = minimum (trough) plasma concentration (nanograms per milliliter \\[ng/mL\\]).","timeFrame":"Day 28 of Cycle 1 to Cycle 4"},{"measure":"Ctrough Concentrations of SU011248 and Active Metabolite SU012662","description":"Subject observed Ctrough (trough drug) concentrations of total drug (SU011248 and its active metabolite SU012662) per cycle and study day determined by plasma trough samples collected from a subset of patients. Steady-state observed trough concentrations were dose corrected to the starting dose (reference dose) where appropriate. Concentrations below the limits of quantitation (BLQ) were set to 0. Ctrough = minimum (trough) plasma concentration (nanograms per milliliter \\[ng/mL\\]).","timeFrame":"Day 28 of Cycle 1 to Cycle 4"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histologically confirmed renal cell carcinoma of clear cell histology with metastases\n* Evidence of measurable disease by radiographic technique\n* Eastern Cooperative Oncology Group \\[ECOG\\] performance status of 0 or 1\n\nExclusion Criteria:\n\n* Prior systemic (including adjuvant or neoadjuvant) therapy of any kind for RCC\n* History of or known brain metastases\n* Serious acute or chronic illness or recent history of significant cardiac abnormality","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Pfizer CT.gov Call Center","affiliation":"Pfizer","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Pfizer Investigational Site","city":"Jonesboro","state":"Arkansas","zip":"72401","country":"United States","geoPoint":{"lat":35.8423,"lon":-90.70428}},{"facility":"Pfizer Investigational Site","city":"La Jolla","state":"California","zip":"92037","country":"United States","geoPoint":{"lat":32.84727,"lon":-117.2742}},{"facility":"Pfizer Investigational Site","city":"La Jolla","state":"California","zip":"92093","country":"United States","geoPoint":{"lat":32.84727,"lon":-117.2742}},{"facility":"Pfizer Investigational Site","city":"Los Angeles","state":"California","zip":"90095","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"Pfizer Investigational Site","city":"San Diego","state":"California","zip":"92103","country":"United States","geoPoint":{"lat":32.71533,"lon":-117.15726}},{"facility":"Pfizer Investigational Site","city":"San Francisco","state":"California","zip":"94115","country":"United States","geoPoint":{"lat":37.77493,"lon":-122.41942}},{"facility":"Pfizer Investigational Site","city":"Aurora","state":"Colorado","zip":"80040-0510","country":"United States","geoPoint":{"lat":39.72943,"lon":-104.83192}},{"facility":"Pfizer Investigational Site","city":"New Haven","state":"Connecticut","zip":"06504","country":"United States","geoPoint":{"lat":41.30815,"lon":-72.92816}},{"facility":"Pfizer Investigational Site","city":"New Haven","state":"Connecticut","zip":"06511","country":"United States","geoPoint":{"lat":41.30815,"lon":-72.92816}},{"facility":"Pfizer Investigational Site","city":"New Haven","state":"Connecticut","zip":"06520","country":"United States","geoPoint":{"lat":41.30815,"lon":-72.92816}},{"facility":"Pfizer Investigational Site","city":"Miami","state":"Florida","zip":"33136","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Pfizer Investigational Site","city":"Miami","state":"Florida","zip":"33176","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Pfizer Investigational Site","city":"Tampa","state":"Florida","zip":"33612","country":"United States","geoPoint":{"lat":27.94752,"lon":-82.45843}},{"facility":"Pfizer Investigational Site","city":"Chicago","state":"Illinois","zip":"60611","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"Pfizer Investigational Site","city":"Maywood","state":"Illinois","zip":"60153","country":"United States","geoPoint":{"lat":41.8792,"lon":-87.84312}},{"facility":"Pfizer Investigational Site","city":"Kansas City","state":"Kansas","zip":"66112","country":"United States","geoPoint":{"lat":39.11417,"lon":-94.62746}},{"facility":"Pfizer Investigational Site","city":"Overland Park","state":"Kansas","zip":"66210","country":"United States","geoPoint":{"lat":38.98223,"lon":-94.67079}},{"facility":"Pfizer Investigational Site","city":"Louisville","state":"Kentucky","zip":"40207","country":"United States","geoPoint":{"lat":38.25424,"lon":-85.75941}},{"facility":"Pfizer Investigational Site","city":"Covington","state":"Louisiana","zip":"70433","country":"United States","geoPoint":{"lat":30.47549,"lon":-90.10042}},{"facility":"Pfizer Investigational Site","city":"Metairie","state":"Louisiana","zip":"70002","country":"United States","geoPoint":{"lat":29.98409,"lon":-90.15285}},{"facility":"Pfizer Investigational Site","city":"Metairie","state":"Louisiana","zip":"70006","country":"United States","geoPoint":{"lat":29.98409,"lon":-90.15285}},{"facility":"Pfizer Investigational Site","city":"Baltimore","state":"Maryland","zip":"21287","country":"United States","geoPoint":{"lat":39.29038,"lon":-76.61219}},{"facility":"Pfizer Investigational Site","city":"Boston","state":"Massachusetts","zip":"02114","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Pfizer Investigational Site","city":"Boston","state":"Massachusetts","zip":"02115","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Pfizer Investigational Site","city":"Detoit","state":"Michigan","zip":"48201","country":"United States","geoPoint":{"lat":42.33143,"lon":-83.04575}},{"facility":"Pfizer Investigational Site","city":"Detroit","state":"Michigan","zip":"48201","country":"United States","geoPoint":{"lat":42.33143,"lon":-83.04575}},{"facility":"Pfizer Investigational Site","city":"Farmington Hills","state":"Michigan","zip":"48334","country":"United States","geoPoint":{"lat":42.48531,"lon":-83.37716}},{"facility":"Pfizer Investigational Site","city":"Minneapolis","state":"Minnesota","zip":"55455","country":"United States","geoPoint":{"lat":44.97997,"lon":-93.26384}},{"facility":"Pfizer Investigational Site","city":"Columbus","state":"Mississippi","zip":"39705","country":"United States","geoPoint":{"lat":33.49567,"lon":-88.42726}},{"facility":"Pfizer Investigational Site","city":"Corinth","state":"Mississippi","zip":"38834","country":"United States","geoPoint":{"lat":34.93425,"lon":-88.52227}},{"facility":"Pfizer Investigational Site","city":"Jackson","state":"Mississippi","zip":"39213","country":"United States","geoPoint":{"lat":32.29876,"lon":-90.18481}},{"facility":"Pfizer Investigational Site","city":"Jackson","state":"Mississippi","zip":"39216","country":"United States","geoPoint":{"lat":32.29876,"lon":-90.18481}},{"facility":"Pfizer Investigational Site","city":"Southaven","state":"Mississippi","zip":"38671","country":"United States","geoPoint":{"lat":34.98898,"lon":-90.01259}},{"facility":"Pfizer Investigational Site","city":"Tupelo","state":"Mississippi","zip":"38801","country":"United States","geoPoint":{"lat":34.25807,"lon":-88.70464}},{"facility":"Pfizer Investigational Site","city":"Kansas City","state":"Missouri","zip":"64131","country":"United States","geoPoint":{"lat":39.09973,"lon":-94.57857}},{"facility":"Pfizer Investigational Site","city":"Omaha","state":"Nebraska","zip":"68198-9200","country":"United States","geoPoint":{"lat":41.25626,"lon":-95.94043}},{"facility":"Pfizer Investigational Site","city":"Lebanon","state":"New Hampshire","zip":"03756","country":"United States","geoPoint":{"lat":43.64229,"lon":-72.25176}},{"facility":"Pfizer Investigational Site","city":"Bronx","state":"New York","zip":"10466","country":"United States","geoPoint":{"lat":40.84985,"lon":-73.86641}},{"facility":"Pfizer Investigational Site","city":"New York","state":"New York","zip":"10021","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Pfizer Investigational Site","city":"New York","state":"New York","zip":"10022","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Pfizer Investigational Site","city":"Cleveland","state":"Ohio","zip":"44106-5055","country":"United States","geoPoint":{"lat":41.4995,"lon":-81.69541}},{"facility":"Pfizer Investigational Site","city":"Cleveland","state":"Ohio","zip":"44195","country":"United States","geoPoint":{"lat":41.4995,"lon":-81.69541}},{"facility":"Pfizer Investigational Site","city":"Tulsa","state":"Oklahoma","zip":"74104","country":"United States","geoPoint":{"lat":36.15398,"lon":-95.99277}},{"facility":"Pfizer Investigational Site","city":"Tulsa","state":"Oklahoma","zip":"74133","country":"United States","geoPoint":{"lat":36.15398,"lon":-95.99277}},{"facility":"Pfizer Investigational Site","city":"Tulsa","state":"Oklahoma","zip":"74136","country":"United States","geoPoint":{"lat":36.15398,"lon":-95.99277}},{"facility":"Pfizer Investigational Site","city":"Portland","state":"Oregon","zip":"97210","country":"United States","geoPoint":{"lat":45.52345,"lon":-122.67621}},{"facility":"Pfizer Investigational Site","city":"Portland","state":"Oregon","zip":"97239","country":"United States","geoPoint":{"lat":45.52345,"lon":-122.67621}},{"facility":"Pfizer Investigational Site","city":"Philadelphia","state":"Pennsylvania","zip":"19111-2497","country":"United States","geoPoint":{"lat":39.95233,"lon":-75.16379}},{"facility":"Pfizer Investigational Site","city":"Memphis","state":"Tennessee","zip":"38104","country":"United States","geoPoint":{"lat":35.14953,"lon":-90.04898}},{"facility":"Pfizer Investigational Site","city":"Memphis","state":"Tennessee","zip":"38120","country":"United States","geoPoint":{"lat":35.14953,"lon":-90.04898}},{"facility":"Pfizer Investigational Site","city":"Nashville","state":"Tennessee","zip":"37232","country":"United States","geoPoint":{"lat":36.16589,"lon":-86.78444}},{"facility":"Pfizer Investigational Site","city":"Dallas","state":"Texas","zip":"75246","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"Pfizer Investigational Site","city":"Houston","state":"Texas","zip":"77030","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Pfizer Investigational Site","city":"Tyler","state":"Texas","zip":"75702","country":"United States","geoPoint":{"lat":32.35126,"lon":-95.30106}},{"facility":"Pfizer Investigational Site","city":"Salt Lake City","state":"Utah","zip":"84112","country":"United States","geoPoint":{"lat":40.76078,"lon":-111.89105}},{"facility":"Pfizer Investigational Site","city":"Seattle","state":"Washington","zip":"98101","country":"United States","geoPoint":{"lat":47.60621,"lon":-122.33207}},{"facility":"Pfizer Investigational Site","city":"Seattle","state":"Washington","zip":"98109-1023","country":"United States","geoPoint":{"lat":47.60621,"lon":-122.33207}},{"facility":"Pfizer Investigational Site","city":"Madison","state":"Wisconsin","zip":"53792-0001","country":"United States","geoPoint":{"lat":43.07305,"lon":-89.40123}},{"facility":"Pfizer Investigational Site","city":"Lismore","state":"New South Wales","zip":"2480","country":"Australia","geoPoint":{"lat":-28.81354,"lon":153.2773}},{"facility":"Pfizer Investigational Site","city":"St. Leonards","state":"New South Wales","zip":"2065","country":"Australia","geoPoint":{"lat":-33.82344,"lon":151.19836}},{"facility":"Pfizer Investigational Site","city":"South Brisbane","state":"Queensland","zip":"4101","country":"Australia","geoPoint":{"lat":-27.48034,"lon":153.02049}},{"facility":"Pfizer Investigational Site","city":"Woodville South","state":"South Australia","zip":"5011","country":"Australia","geoPoint":{"lat":-34.88186,"lon":138.53477}},{"facility":"Pfizer Investigational Site","city":"East Melbourne","state":"Victoria","zip":"3002","country":"Australia","geoPoint":{"lat":-37.81667,"lon":144.9879}},{"facility":"Pfizer Investigational Site","city":"Perth","state":"Western Australia","zip":"6000","country":"Australia","geoPoint":{"lat":-31.95224,"lon":115.8614}},{"facility":"Pfizer Investigational Site","city":"Victoria","zip":"36184","country":"Australia"},{"facility":"Pfizer Investigational Site","city":"Rio de Janeiro","state":"RJ","zip":"20231-050","country":"Brazil","geoPoint":{"lat":-22.90278,"lon":-43.2075}},{"facility":"Pfizer Investigational Site","city":"Porto Alegre","state":"RS","zip":"90020-090","country":"Brazil","geoPoint":{"lat":-30.03306,"lon":-51.23}},{"facility":"Pfizer Investigational Site","city":"Porto Alegre","state":"RS","zip":"90610-000","country":"Brazil","geoPoint":{"lat":-30.03306,"lon":-51.23}},{"facility":"Pfizer Investigational Site","city":"Calgary","state":"Alberta","zip":"T2N 4N2","country":"Canada","geoPoint":{"lat":51.05011,"lon":-114.08529}},{"facility":"Pfizer Investigational Site","city":"Edmonton","state":"Alberta","zip":"T6G 1Z2","country":"Canada","geoPoint":{"lat":53.55014,"lon":-113.46871}},{"facility":"Pfizer Investigational Site","city":"Kelowna","state":"British Columbia","zip":"V1Y5L3","country":"Canada","geoPoint":{"lat":49.88307,"lon":-119.48568}},{"facility":"Pfizer Investigational Site","city":"Vancouver","state":"British Columbia","zip":"V5Z 4E6","country":"Canada","geoPoint":{"lat":49.24966,"lon":-123.11934}},{"facility":"Pfizer Investigational Site","city":"Victoria","state":"British Columbia","zip":"V5Z 4E6","country":"Canada","geoPoint":{"lat":48.43294,"lon":-123.3693}},{"facility":"Pfizer Investigational Site","city":"London","state":"Ontario","zip":"N6A 4L6","country":"Canada","geoPoint":{"lat":42.98339,"lon":-81.23304}},{"facility":"Pfizer Investigational Site","city":"Toronto","state":"Ontario","zip":"M4N 3M5","country":"Canada","geoPoint":{"lat":43.70011,"lon":-79.4163}},{"facility":"Pfizer Investigational Site","city":"Toronto","state":"Ontario","zip":"M5G 2M9","country":"Canada","geoPoint":{"lat":43.70011,"lon":-79.4163}},{"facility":"Pfizer Investigational Site","city":"Montreal","state":"Quebec","zip":"H2L 4M1","country":"Canada","geoPoint":{"lat":45.50884,"lon":-73.58781}},{"facility":"Pfizer Investigational Site","city":"Quebec","zip":"G1R 2J6","country":"Canada","geoPoint":{"lat":46.81228,"lon":-71.21454}},{"facility":"Pfizer Investigational Site","city":"Quebec","zip":"G1S 2L6","country":"Canada","geoPoint":{"lat":46.81228,"lon":-71.21454}},{"facility":"Pfizer Investigational Site","city":"Paris","state":"Cedex 15","zip":"75908","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"facility":"Pfizer Investigational Site","city":"Lyon","zip":"69008","country":"France","geoPoint":{"lat":45.74848,"lon":4.84669}},{"facility":"Pfizer Investigational Site","city":"Paris Cedex 13","zip":"75651","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"facility":"Pfizer Investigational Site","city":"Rennes","zip":"35042","country":"France","geoPoint":{"lat":48.11198,"lon":-1.67429}},{"facility":"Pfizer Investigational Site","city":"Saint Herblain","country":"France","geoPoint":{"lat":47.21765,"lon":-1.64841}},{"facility":"Pfizer Investigational Site","city":"Vandoeuvre Les Nancy","zip":"54511","country":"France","geoPoint":{"lat":48.65,"lon":6.18333}},{"facility":"Pfizer Investigational Site","city":"Aachen","zip":"52074","country":"Germany","geoPoint":{"lat":50.77664,"lon":6.08342}},{"facility":"Pfizer Investigational Site","city":"Essen","zip":"45122","country":"Germany","geoPoint":{"lat":51.45657,"lon":7.01228}},{"facility":"Pfizer Investigational Site","city":"Hannover","zip":"30625","country":"Germany","geoPoint":{"lat":52.37052,"lon":9.73322}},{"facility":"Pfizer Investigational Site","city":"Ulm","zip":"89075","country":"Germany","geoPoint":{"lat":48.39841,"lon":9.99155}},{"facility":"Pfizer Investigational Site","city":"Ulm","zip":"89081","country":"Germany","geoPoint":{"lat":48.39841,"lon":9.99155}},{"facility":"Pfizer Investigational Site","city":"Modena","zip":"41100","country":"Italy","geoPoint":{"lat":44.64783,"lon":10.92539}},{"facility":"Pfizer Investigational Site","city":"Napoli","zip":"80131","country":"Italy","geoPoint":{"lat":40.85216,"lon":14.26811}},{"facility":"Pfizer Investigational Site","city":"Pavia","country":"Italy","geoPoint":{"lat":45.19205,"lon":9.15917}},{"facility":"Pfizer Investigational Site","city":"Roma","zip":"00135","country":"Italy","geoPoint":{"lat":41.89193,"lon":12.51133}},{"facility":"Pfizer Investigational Site","city":"Roma","zip":"00144","country":"Italy","geoPoint":{"lat":41.89193,"lon":12.51133}},{"facility":"Pfizer Investigational Site","city":"Roma","zip":"00152","country":"Italy","geoPoint":{"lat":41.89193,"lon":12.51133}},{"facility":"Pfizer Investigational Site","city":"Moczowego","state":"Warszawa","country":"Poland"},{"facility":"Pfizer Investigational Site","city":"Gdansk","zip":"80-210","country":"Poland","geoPoint":{"lat":54.35205,"lon":18.64637}},{"facility":"Pfizer Investigational Site","city":"Krakow","zip":"31-115","country":"Poland","geoPoint":{"lat":50.06143,"lon":19.93658}},{"facility":"Pfizer Investigational Site","city":"Lodz","zip":"93-509","country":"Poland","geoPoint":{"lat":51.75,"lon":19.46667}},{"facility":"Pfizer Investigational Site","city":"Lublin","zip":"20-090","country":"Poland","geoPoint":{"lat":51.25,"lon":22.56667}},{"facility":"Pfizer Investigational Site","city":"Poznan","country":"Poland","geoPoint":{"lat":52.40692,"lon":16.92993}},{"facility":"Pfizer Investigational Site","city":"Warszawa","zip":"00-909","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"Pfizer Investigational Site","city":"Wroclaw","zip":"50-043","country":"Poland","geoPoint":{"lat":51.1,"lon":17.03333}},{"facility":"Pfizer Investigational Site","city":"Wroclaw","zip":"50-556","country":"Poland","geoPoint":{"lat":51.1,"lon":17.03333}},{"facility":"Pfizer Investigational Site","city":"Obninsk","state":"Kaluga Region","zip":"249036","country":"Russian Federation","geoPoint":{"lat":55.09681,"lon":36.61006}},{"facility":"Pfizer Investigational Site","city":"Chelyabinsk","zip":"454087","country":"Russian Federation","geoPoint":{"lat":55.15402,"lon":61.42915}},{"facility":"Pfizer Investigational Site","city":"Moscow","zip":"115478","country":"Russian Federation","geoPoint":{"lat":55.75222,"lon":37.61556}},{"facility":"Pfizer Investigational Site","city":"Moscow","zip":"117836","country":"Russian Federation","geoPoint":{"lat":55.75222,"lon":37.61556}},{"facility":"Pfizer Investigational Site","city":"Moscow","country":"Russian Federation","geoPoint":{"lat":55.75222,"lon":37.61556}},{"facility":"Pfizer Investigational Site","city":"Saint-Petersburg","zip":"197758","country":"Russian Federation","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Pfizer Investigational Site","city":"St. Petersburg","zip":"197758","country":"Russian Federation","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Pfizer Investigational Site","city":"Tomsk","zip":"634050","country":"Russian Federation","geoPoint":{"lat":56.49771,"lon":84.97437}},{"facility":"Pfizer Investigational Site","city":"Hospitalet de Llobregat","state":"Barcelona","zip":"08907","country":"Spain","geoPoint":{"lat":41.35967,"lon":2.10028}},{"facility":"Pfizer Investigational Site","city":"Pamplona","state":"Navarra","zip":"31008","country":"Spain","geoPoint":{"lat":42.81687,"lon":-1.64323}},{"facility":"Pfizer Investigational Site","city":"Madrid","zip":"28040","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Pfizer Investigational Site","city":"Madrid","zip":"28041","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Pfizer Investigational Site","city":"Sevilla","zip":"41013","country":"Spain","geoPoint":{"lat":37.38283,"lon":-5.97317}},{"facility":"Pfizer Investigational Site","city":"Whitchurch","state":"Cardiff","zip":"CF14 2 TL","country":"United Kingdom","geoPoint":{"lat":52.96667,"lon":-2.68333}},{"facility":"Pfizer Investigational Site","city":"Manchester","state":"Lancashire","zip":"M20 4BX","country":"United Kingdom","geoPoint":{"lat":53.48095,"lon":-2.23743}},{"facility":"Pfizer Investigational Site","city":"Northwood","state":"Middlesex","zip":"HA6 2RN","country":"United Kingdom"},{"facility":"Pfizer Investigational Site","city":"London","zip":"SE1 9RT","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}},{"facility":"Pfizer Investigational Site","city":"London","zip":"SW3 6JJ","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}},{"facility":"Pfizer Investigational Site","city":"Sutton Surrey","zip":"SM2 5PT","country":"United Kingdom"}]},"referencesModule":{"references":[{"pmid":"29853320","type":"DERIVED","citation":"Rini BI, Hutson TE, Figlin RA, Lechuga MJ, Valota O, Serfass L, Rosbrook B, Motzer RJ. Sunitinib in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group. Clin Genitourin Cancer. 2018 Aug;16(4):298-304. doi: 10.1016/j.clgc.2018.04.005. Epub 2018 May 4."},{"pmid":"28410911","type":"DERIVED","citation":"de Velasco G, McKay RR, Lin X, Moreira RB, Simantov R, Choueiri TK. Comprehensive Analysis of Survival Outcomes in Non-Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials. Clin Genitourin Cancer. 2017 Dec;15(6):652-660.e1. doi: 10.1016/j.clgc.2017.03.004. Epub 2017 Mar 21."},{"pmid":"27238653","type":"DERIVED","citation":"Grunwald V, Lin X, Kalanovic D, Simantov R. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma. Eur Urol. 2016 Dec;70(6):1006-1015. doi: 10.1016/j.eururo.2016.05.010. Epub 2016 May 26."},{"pmid":"25577718","type":"DERIVED","citation":"Grunwald V, McKay RR, Krajewski KM, Kalanovic D, Lin X, Perkins JJ, Simantov R, Choueiri TK. Depth of remission is a prognostic factor for survival in patients with metastatic renal cell carcinoma. Eur Urol. 2015 May;67(5):952-8. doi: 10.1016/j.eururo.2014.12.036. Epub 2015 Jan 7."},{"pmid":"20104222","type":"DERIVED","citation":"Cella D, Michaelson MD, Bushmakin AG, Cappelleri JC, Charbonneau C, Kim ST, Li JZ, Motzer RJ. Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-alpha in a phase III trial: final results and geographical analysis. Br J Cancer. 2010 Feb 16;102(4):658-64. doi: 10.1038/sj.bjc.6605552. Epub 2010 Jan 26."},{"pmid":"17215529","type":"DERIVED","citation":"Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007 Jan 11;356(2):115-24. doi: 10.1056/NEJMoa065044."}],"seeAlsoLinks":[{"label":"To obtain contact information for a study center near you, click here.","url":"https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A6181034&StudyName=SU011248%20Versus%20Interferon-Alfa%20As%20First-Line%20Systemic%20Therapy%20For%20Patients%20With%20Metastatic%20Renal%20Cell%20Carcinoma%20%20"}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Subjects were to be followed until survival data was mature (median duration of follow-up: 123 weeks).","recruitmentDetails":"A total of 101 medical centers took part in the study between 10 August 2004 and 19 September 2008.","groups":[{"id":"FG000","title":"SU011248","description":"50 mg taken orally once a day for 4 weeks followed by a 2-week off treatment cycle to form a 6-week treatment cycle. Intra-subject dose reduction to 37.5 mg/day and 25 mg/day was allowed depending on type and severity of toxicity encountered."},{"id":"FG001","title":"IFN-α","description":"Subcutaneous (SC) injection in 6-week cycles on 3 non-consecutive days per week; 3 million units (MU) per dose Week 1; 6 MU per dose Week 2; 9 MU per dose Week 3 until completion of therapy or development of toxicity."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"375"},{"groupId":"FG001","numSubjects":"375"}]},{"type":"Received Treatment","achievements":[{"groupId":"FG000","numSubjects":"375"},{"groupId":"FG001","comment":"15 subjects randomized to IFN-α discontinued before receiving their first dose of study medication.","numSubjects":"360"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","comment":"Discontinuation crossover subjects: AEs 5,consent withdrawn 2, lack efficacy 13, sponsor decision 5.","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"375"},{"groupId":"FG001","numSubjects":"375"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"76"},{"groupId":"FG001","numSubjects":"86"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"22"},{"groupId":"FG001","numSubjects":"24"}]},{"type":"Lack of Efficacy","reasons":[{"groupId":"FG000","numSubjects":"240"},{"groupId":"FG001","numSubjects":"219"}]},{"type":"Decision of sponsor","reasons":[{"groupId":"FG000","numSubjects":"32"},{"groupId":"FG001","numSubjects":"4"}]},{"type":"Randomized: did not take study drug","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"15"}]},{"type":"Completed on marketed sunitinub","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Crossover to SU011248","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"25"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"SU011248","description":"50 mg taken orally once a day for 4 weeks followed by a 2-week off treatment cycle to form a 6-week treatment cycle. Intra-subject dose reduction to 37.5 mg/day and 25 mg/day was allowed depending on type and severity of toxicity encountered."},{"id":"BG001","title":"IFN-α","description":"Subcutaneous (SC) injection in 6-week cycles on 3 non-consecutive days per week; 3 million units (MU) per dose Week 1; 6 MU per dose Week 2; 9 MU per dose Week 3 until completion of therapy or development of toxicity."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"375"},{"groupId":"BG001","value":"375"},{"groupId":"BG002","value":"750"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"223"},{"groupId":"BG001","value":"252"},{"groupId":"BG002","value":"475"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"152"},{"groupId":"BG001","value":"123"},{"groupId":"BG002","value":"275"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"108"},{"groupId":"BG001","value":"106"},{"groupId":"BG002","value":"214"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"267"},{"groupId":"BG001","value":"269"},{"groupId":"BG002","value":"536"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Progression-Free Survival (PFS), Core Radiology Assessment","description":"Progression-free survival (PFS) = time from randomization to first documentation of objective tumor progression or to death due to any cause, whichever occured first. If tumor progression data included more than 1 date, the first date was used. PFS = first event date minus the date of randomization + 1. On study included treatment plus 28-day follow-up periods.","populationDescription":"Intent to treat (ITT) population: all patients who were randomized, with study drug assignment designated according to initial randomization, regardless of whether patients received study drug or received a different drug from that to which they were randomized.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"weeks","timeFrame":"Day 28 of each 6-week cycle: duration of treatment phase","groups":[{"id":"OG000","title":"SU011248","description":"50 mg taken orally once a day for 4 weeks followed by a 2-week off treatment cycle to form a 6-week treatment cycle. Intra-subject dose reduction to 37.5 mg/day and 25 mg/day was allowed depending on type and severity of toxicity encountered."},{"id":"OG001","title":"IFN-α","description":"Subcutaneous (SC) injection in 6-week cycles on 3 non-consecutive days per week; 3 million units (MU) per dose Week 1; 6 MU per dose Week 2; 9 MU per dose Week 3 until completion of therapy or development of toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"375"},{"groupId":"OG001","value":"375"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.3","lowerLimit":"46.4","upperLimit":"58.3"},{"groupId":"OG001","value":"22.1","lowerLimit":"17.1","upperLimit":"24.0"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Unstratified analysis: Hazard Ratio (SU011248 vs IFN-α). Progression-free survival (PFS) was assessed in each treatment arm using the Kaplan-Meier method.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","pValueComment":"p-value from 2-sided, unstratified test.","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.5268","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.4316","ciUpperLimit":"0.6430","estimateComment":"Assuming proportional hazards, a hazard ratio les than 1 indicates a reduction in hazard rate in favor of SU011248; a hazard ratio greater than 1 indicates a reduction in favor of IFN-a."},{"groupIds":["OG000","OG001"],"groupDescription":"Stratified analysis: Hazard Ratio (SU011248 vs IFN-a).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.00001","pValueComment":"p-value is from 2-sided, stratified test. Stratification factors were: Lactic Dehydrogenase (LDH) \\> or \\<= 1.5 x upper limit of normal, Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, and absence or presence of prior nephrectomy.","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.5136","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.4196","ciUpperLimit":"0.6288","estimateComment":"Assuming proportional hazards, a hazard ratio less than 1 indicates a reduction in hazard rate in favor of SU011248: a hazard ratio greater than 1 indicates a reduction in favor of IFN-a."}]},{"type":"SECONDARY","title":"Objective Response, Core Radiology Assessment","description":"Objective response (OR) = the number of patients with confirmed complete response (CR) and confirmed partial response (PR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria, relative to all randomized patients. CR was defined as the disappearance of all target lesions. PR was defined as a ≥ 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. Confirmed responses (CR or PR) = those that persisted on repeat imaging study \\>= 4 weeks after initial documentation of response.","populationDescription":"ITT","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Day 28 of each 6-week cycle: duration of treatment phase","groups":[{"id":"OG000","title":"SU011248","description":"50 mg taken orally once a day for 4 weeks followed by a 2-week off treatment cycle to form a 6-week treatment cycle. Intra-subject dose reduction to 37.5 mg/day and 25 mg/day was allowed depending on type and severity of toxicity encountered."},{"id":"OG001","title":"IFN-α","description":"Subcutaneous (SC) injection in 6-week cycles on 3 non-consecutive days per week; 3 million units (MU) per dose Week 1; 6 MU per dose Week 2; 9 MU per dose Week 3 until completion of therapy or development of toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"375"},{"groupId":"OG001","value":"375"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"145"},{"groupId":"OG001","value":"29"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"Chi-squared","paramType":"treatment difference","paramValue":"30.93","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"25.31","ciUpperLimit":"36.56","estimateComment":"95% confidence interval was calculated based on a normal distribution."}]},{"type":"SECONDARY","title":"Objective Response, Investigator's Assessment","description":"Objective response (OR) = the number of patients with confirmed complete response (CR) and confirmed partial response (PR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria, relative to all randomized patients. CR was defined as the disappearance of all target lesions. PR was defined as a ≥ 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. Confirmed responses = those that persist on repeat imaging study \\>= 4 weeks after initial documentation of response.","populationDescription":"ITT","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Day 28 of each 6-week cycle: duration of treatment phase","groups":[{"id":"OG000","title":"SU011248","description":"50 mg taken orally once a day for 4 weeks followed by a 2-week off treatment cycle to form a 6-week treatment cycle. Intra-subject dose reduction to 37.5 mg/day and 25 mg/day was allowed depending on type and severity of toxicity encountered."},{"id":"OG001","title":"IFN-α","description":"Subcutaneous (SC) injection in 6-week cycles on 3 non-consecutive days per week; 3 million units (MU) per dose Week 1; 6 MU per dose Week 2; 9 MU per dose Week 3 until completion of therapy or development of toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"375"},{"groupId":"OG001","value":"375"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"45"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"Chi-squared","paramType":"treatment difference","paramValue":"33.66","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"27.62","ciUpperLimit":"39.69","estimateComment":"95% confidence interval was calculated based on a normal distribution."}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"Overall survival (OS) = time from date of randomization to date of death due to any cause. For patients not expiring, survival time was censored at the last date they were known to be alive. Patients lacking data beyond randomization had their survival times censored at the date of randomization with a duration of 1 day.","populationDescription":"ITT","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"weeks","timeFrame":"Clinic visit or telephone contact every 2 months until death","groups":[{"id":"OG000","title":"SU011248","description":"50 mg taken orally once a day for 4 weeks followed by a 2-week off treatment cycle to form a 6-week treatment cycle. Intra-subject dose reduction to 37.5 mg/day and 25 mg/day was allowed depending on type and severity of toxicity encountered."},{"id":"OG001","title":"IFN-α","description":"Subcutaneous (SC) injection in 6-week cycles on 3 non-consecutive days per week; 3 million units (MU) per dose Week 1; 6 MU per dose Week 2; 9 MU per dose Week 3 until completion of therapy or development of toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"375"},{"groupId":"OG001","value":"375"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"114.6","lowerLimit":"100.1","upperLimit":"142.9"},{"groupId":"OG001","value":"94.9","lowerLimit":"77.7","upperLimit":"117.0"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Unstratified analysis: Hazard Ratio (SU011248 vs IFN-α).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0510","pValueComment":"p-value is from 2-sided, unstratified tests.","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.8209","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.6730","ciUpperLimit":"1.0013","estimateComment":"Assuming proportional hazards, a hazard ratio less than 1 indicates a reduction in hazard rate in favor of SU011248; a hazard ratio greater than 1 indicates a reduction in hazard rate in favor of IFN-a"},{"groupIds":["OG000","OG001"],"groupDescription":"Unstratified analysis: Hazard Ratio (SU011248 vs IFN-α).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0128","pValueComment":"p-value is from 2-sided, unstratified tests.","statisticalMethod":"Wilcoxon (Mann-Whitney)","paramType":"Hazard Ratio (HR)","paramValue":"0.8209","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.6730","ciUpperLimit":"1.0013","estimateComment":"Assuming proportional hazards, a hazard ratio less than 1 indicates a reduction in hazard rate in favor of SU011248; a hazard ratio greater than 1 indicates a reduction in hazard rate in favor of IFN-a."},{"groupIds":["OG000","OG001"],"groupDescription":"Stratified analysis: Hazard Ratio (SU011248 vs IFN-α).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0490","pValueComment":"p-value is from 2-sided, stratified tests. Stratification factors were: Lactic Dehydrogenase (LDH) \\> or \\<= 1.5 x upper limit of normal, Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, and absence or presence of prior nephrectomy.","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.8179","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.6692","ciUpperLimit":"0.9995","estimateComment":"Assuming proportional hazards, a hazard ratio less than 1 indicates a reduction in hazard rate in favor of SU011248; a hazard ratio greater than 1 indicates a reduction in hazard rate in favor of IFN-a."}]},{"type":"SECONDARY","title":"Time to Tumor Progression (TTP), Core Radiology Assessment","description":"TTP = time from randomization to first documentation of objective tumor progression. TTP data were censored on the day following the date of last on treatment (including 28 day follow-up period) tumor assessment documenting absence of progressive disease for subjects who did not have objective tumor progression while on treatment or who were given anti-tumor treatment other than study treatment prior to documentation of objective tumor progression. Subjects with no tumor assessments after randomization had TTP censored on the date of randomization with a duration of 1 day.","populationDescription":"ITT","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"weeks","timeFrame":"Randomization to first documentation of tumor progression: duration of treatment phase","groups":[{"id":"OG000","title":"SU011248","description":"50 mg taken orally once a day for 4 weeks followed by a 2-week off treatment cycle to form a 6-week treatment cycle. Intra-subject dose reduction to 37.5 mg/day and 25 mg/day was allowed depending on type and severity of toxicity encountered."},{"id":"OG001","title":"IFN-α","description":"Subcutaneous (SC) injection in 6-week cycles on 3 non-consecutive days per week; 3 million units (MU) per dose Week 1; 6 MU per dose Week 2; 9 MU per dose Week 3 until completion of therapy or development of toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"375"},{"groupId":"OG001","value":"375"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49.1","lowerLimit":"46.6","upperLimit":"59.1"},{"groupId":"OG001","value":"22.4","lowerLimit":"21.9","upperLimit":"31.3"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Unstratified Analysis: Hazard Ratio (SU011248 vs IFN-a)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","pValueComment":"p-value is from 2-sided, unstratified test.","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.5332","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.4345","ciUpperLimit":"0.6544","estimateComment":"Assuming proportional hazards, a hazard ratio less than 1 indicates a reduction in hazard rate in favor of SU011248; a hazard ratio greater than 1 indicates a reduction in hazard rate in favor of IFN-a"},{"groupIds":["OG000","OG001"],"groupDescription":"Stratified Analysis: Hazard Ratio (SU011248 vs IFN-a)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.00001","pValueComment":"p-value is from 2-sided, stratified test. Stratification factors are: Lactic Dehydrogenase (LDH) \\> or \\<= 1.5 x upper limit of normal, Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, and absence or presence of prior nephrectomy.","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.5160","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.4191","ciUpperLimit":"0.6352","estimateComment":"Assuming proportional hazards, a hazard ratio less than 1 indicates a reduction in hazard rate in favor of SU011248; a hazard ratio greater than 1 indicates a reduction in hazard rate in favor of IFN-a."}]},{"type":"SECONDARY","title":"Time to Tumor Progression (TTP), Investigator's Assessment","description":"TTP = time from randomization to first documentation of objective tumor progression. TTP data were censored on the day following the date of last on treatment (including 28 day follow-up period) tumor assessment documenting absence of progressive disease for subjects who did not have objective tumor progression while on treatment or who were given anti-tumor treatment other than the study treatment prior to documentation of objective tumor progression. Subjects with no tumor assessments after randomization had TTP censored on the date of randomization with a duration of 1 day.","populationDescription":"ITT","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"weeks","timeFrame":"Randomization to first documentation of tumor progression: duration of treatment phase","groups":[{"id":"OG000","title":"SU011248","description":"50 mg taken orally once a day for 4 weeks followed by a 2-week off treatment cycle to form a 6-week treatment cycle. Intra-subject dose reduction to 37.5 mg/day and 25 mg/day was allowed depending on type and severity of toxicity encountered."},{"id":"OG001","title":"IFN-α","description":"Subcutaneous (SC) injection in 6-week cycles on 3 non-consecutive days per week; 3 million units (MU) per dose Week 1; 6 MU per dose Week 2; 9 MU per dose Week 3 until completion of therapy or development of toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"375"},{"groupId":"OG001","value":"375"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49.0","lowerLimit":"46.4","upperLimit":"59.1"},{"groupId":"OG001","value":"22.3","lowerLimit":"17.3","upperLimit":"31.6"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Unstratified Analysis: Hazard Ratio (SU011248 vs IFN-α)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","pValueComment":"p-value is from 2-sided, unstratified test.","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.5454","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.4558","ciUpperLimit":"0.6526","estimateComment":"Assuming proportional hazards, a hazard ratio \\< 1 indicates a reduction in hazard rate in favor of SU011248; a hazard ratio \\> 1 indicates a reduction in hazard rate in favor of IFN-a."},{"groupIds":["OG000","OG001"],"groupDescription":"Stratified Analysis: Hazard Ratio (SU011248 vs IFN-α)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.00001","pValueComment":"p-value is from 2-sided, stratified test. Stratification factors were: Lactic Dehydrogenase (LDH) \\> or \\<= 1.5 x upper limit of normal, Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, and absence or presence of prior nephrectomy.","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.5417","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.4519","ciUpperLimit":"0.6492","estimateComment":"Assuming proportional hazards, a hazard ratio less than 1 indicates a reduction in hazard rate in favor of SU011248; a hazard ratio greater than 1 indicates a reduction in hazard rate in favor of IFN-a."}]},{"type":"SECONDARY","title":"Duration of Response (DR), Core Radiology Assessement","description":"Duration of response (DR) = time from the first documentation of objective tumor response to the first documentation of objective tumor progression or to death due to any cause. DR data were censored on the day following the date of the last on treatment (including 28 day follow-up period) tumor assessment documenting absence of progressive disease for subjects without objective tumor progression who did not die due to any cause while on treatment or who were given anti-tumor treatment other than study treatment prior to observing tumor progression.","populationDescription":"ITT","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"weeks","timeFrame":"Day 28 of each cycle: duraton of treatment phase","groups":[{"id":"OG000","title":"SU011248","description":"50 mg taken orally once a day for 4 weeks followed by a 2-week off treatment cycle to form a 6-week treatment cycle. Intra-subject dose reduction to 37.5 mg/day and 25 mg/day was allowed depending on type and severity of toxicity encountered."},{"id":"OG001","title":"IFN-α","description":"Subcutaneous (SC) injection in 6-week cycles on 3 non-consecutive days per week; 3 million units (MU) per dose Week 1; 6 MU per dose Week 2; 9 MU per dose Week 3 until completion of therapy or development of toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"9"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52.9","lowerLimit":"46.1","upperLimit":"60.1"},{"groupId":"OG001","value":"64.9","lowerLimit":"41.9","upperLimit":"82.0"}]}]}]},{"type":"SECONDARY","title":"Duration of Response (DR), Investigator's Assessment","description":"Duration of response (DR) = time from the first documentation of objective tumor response to the first documentaion of objective tumor progression or to death due to any cause. DR data were censored on the day following the date of the last on treatment (including 28 day follow-up period) tumor assessment documenting absence of progressive disease for subjects without objective tumor progression who did not die due to any cause while on treatment or who were given anti-tumor treatment other than study treatment prior to observing tumor progression.","populationDescription":"ITT","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"weeks","timeFrame":"Day 28 of each cycle: duration of treatment phase","groups":[{"id":"OG000","title":"SU011248","description":"50 mg taken orally once a day for 4 weeks followed by a 2-week off treatment cycle to form a 6-week treatment cycle. Intra-subject dose reduction to 37.5 mg/day and 25 mg/day was allowed depending on type and severity of toxicity encountered."},{"id":"OG001","title":"IFN-α","description":"Subcutaneous (SC) injection in 6-week cycles on 3 non-consecutive days per week; 3 million units (MU) per dose Week 1; 6 MU per dose Week 2; 9 MU per dose Week 3 until completion of therapy or development of toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"122"},{"groupId":"OG001","value":"23"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.3","lowerLimit":"48.4","upperLimit":"64.9"},{"groupId":"OG001","value":"48.1","lowerLimit":"42.1","upperLimit":"120.1"}]}]}]},{"type":"SECONDARY","title":"FACT-Kidney Symptom Index-Disease Related Symptoms (FKSI-DRS) Subscale","description":"FACT-Kidney Symptom Index-Disease Related Symptoms (FKSI-DRS) subscale of the FKSI to measure advanced kidney cancer disease related symptoms. Includes 9 items: lack of energy, pain, losing weight, bone pain, fatigue, short of breath, coughing, bothered by fevers, and hematuria. Each question was answered on a five-point Likert-type scale ranging from 0 (not at all) to 4 (very much). Score = the sum score of the item scores in the subscale; total range: 0 to 36. A score greater than 0 indicates the difference favored sunitinib.","populationDescription":"ITT; summary of FKSI-DRS questionnaire results by treatment; N=number of subjects with evaluable data; n = number of subjects with evaluable data at observation, SU011248 and INF-α treatment groups, respectively.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"scores on scale","timeFrame":"Day 1 & 28 of each cycle: duration of treatment phase","groups":[{"id":"OG000","title":"SU011248","description":"50 mg taken orally once a day for 4 weeks followed by a 2-week off treatment cycle to form a 6-week treatment cycle. Intra-subject dose reduction to 37.5 mg/day and 25 mg/day was allowed depending on type and severity of toxicity encountered."},{"id":"OG001","title":"IFN-α","description":"Subcutaneous (SC) injection in 6-week cycles on 3 non-consecutive days per week; 3 million units (MU) per dose Week 1; 6 MU per dose Week 2; 9 MU per dose Week 3 until completion of therapy or development of toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"375"},{"groupId":"OG001","value":"375"}]}],"classes":[{"title":"Baseline (n=368, 351)","categories":[{"measurements":[{"groupId":"OG000","value":"29.74","spread":"5.244"},{"groupId":"OG001","value":"29.55","spread":"5.026"}]}]},{"title":"Cycle 1 Day 28 (n=348, 317)","categories":[{"measurements":[{"groupId":"OG000","value":"27.73","spread":"5.080","lowerLimit":"29.000","upperLimit":"29.663"},{"groupId":"OG001","value":"26.68","spread":"5.195","lowerLimit":"27.011","upperLimit":"27.782"}]}]},{"title":"Cycle 2 Day 1 (n=327, 246)","categories":[{"measurements":[{"groupId":"OG000","value":"29.66","spread":"4.778","lowerLimit":"29.019","upperLimit":"29.667"},{"groupId":"OG001","value":"27.59","spread":"4.908","lowerLimit":"27.016","upperLimit":"27.775"}]}]},{"title":"Cycle 2 Day 28 (n= 315, 237)","categories":[{"measurements":[{"groupId":"OG000","value":"28.49","spread":"4.748","lowerLimit":"29.051","upperLimit":"29.677"},{"groupId":"OG001","value":"27.22","spread":"4.988","lowerLimit":"27.019","upperLimit":"27.769"}]}]},{"title":"Cycle 3 Day 1 (n=294, 198)","categories":[{"measurements":[{"groupId":"OG000","value":"29.93","spread":"4.679","lowerLimit":"29.068","upperLimit":"29.684"},{"groupId":"OG001","value":"28.20","spread":"4.452","lowerLimit":"27.017","upperLimit":"27.770"}]}]},{"title":"Cycle 3 Day 28 (n=285, 195)","categories":[{"measurements":[{"groupId":"OG000","value":"28.72","spread":"4.756","lowerLimit":"29.095","upperLimit":"29.698"},{"groupId":"OG001","value":"27.81","spread":"5.040","lowerLimit":"27.006","upperLimit":"27.778"}]}]},{"title":"Cycle 4 Day 1 (n=272, 151)","categories":[{"measurements":[{"groupId":"OG000","value":"30.25","spread":"4.498"},{"groupId":"OG001","value":"28.85","spread":"4.821"}]}]},{"title":"Cycle 4 Day 28 (n=264, 142)","categories":[{"measurements":[{"groupId":"OG000","value":"29.43","spread":"4.389"},{"groupId":"OG001","value":"28.30","spread":"5.071"}]}]},{"title":"Cycle 5 Day 1 (n=248, 119 )","categories":[{"measurements":[{"groupId":"OG000","value":"30.87","spread":"3.948"},{"groupId":"OG001","value":"28.57","spread":"4.925"}]}]},{"title":"Cycle 5 Day 28 (n=242, 109)","categories":[{"measurements":[{"groupId":"OG000","value":"29.43","spread":"4.280"},{"groupId":"OG001","value":"28.37","spread":"4.726"}]}]},{"title":"Cycle 6 Day 1 (n=240, 99)","categories":[{"measurements":[{"groupId":"OG000","value":"30.80","spread":"4.214"},{"groupId":"OG001","value":"29.12","spread":"4.428"}]}]},{"title":"Cycle 6 Day 28 (n=223, 99)","categories":[{"measurements":[{"groupId":"OG000","value":"29.62","spread":"4.288"},{"groupId":"OG001","value":"28.44","spread":"4.957"}]}]},{"title":"Cycle 7 Day 1 (n=208, 79)","categories":[{"measurements":[{"groupId":"OG000","value":"30.93","spread":"4.002"},{"groupId":"OG001","value":"28.99","spread":"4.974"}]}]},{"title":"Cycle 7 Day 28 (n=203, 75 )","categories":[{"measurements":[{"groupId":"OG000","value":"29.73","spread":"4.417"},{"groupId":"OG001","value":"28.50","spread":"4.556"}]}]},{"title":"Cycle 8 Day 1 (n=192, 68)","categories":[{"measurements":[{"groupId":"OG000","value":"31.03","spread":"3.649"},{"groupId":"OG001","value":"28.76","spread":"4.847"}]}]},{"title":"Cycle 8 Day 28 (n=190, 62)","categories":[{"measurements":[{"groupId":"OG000","value":"29.76","spread":"4.096"},{"groupId":"OG001","value":"28.67","spread":"4.491"}]}]},{"title":"Cycle 9 Day 1 (n=172, 51)","categories":[{"measurements":[{"groupId":"OG000","value":"31.24","spread":"3.560"},{"groupId":"OG001","value":"29.86","spread":"4.247"}]}]},{"title":"Cycle 9 Day 28 (n=166, 46)","categories":[{"measurements":[{"groupId":"OG000","value":"29.72","spread":"4.245"},{"groupId":"OG001","value":"29.36","spread":"4.418"}]}]},{"title":"Cycle 10 Day 1 (n=161, 50)","categories":[{"measurements":[{"groupId":"OG000","value":"30.73","spread":"3.820"},{"groupId":"OG001","value":"29.43","spread":"4.455"}]}]},{"title":"Cycle 10 Day 28 (n=155, 46)","categories":[{"measurements":[{"groupId":"OG000","value":"29.78","spread":"4.034"},{"groupId":"OG001","value":"29.03","spread":"4.980"}]}]},{"title":"Cycle 11 Day 1 (n=138, 35)","categories":[{"measurements":[{"groupId":"OG000","value":"30.72","spread":"4.018"},{"groupId":"OG001","value":"29.89","spread":"4.006"}]}]},{"title":"Cycle 11 Day 28 (n=141, 33)","categories":[{"measurements":[{"groupId":"OG000","value":"29.34","spread":"4.117"},{"groupId":"OG001","value":"29.24","spread":"5.014"}]}]},{"title":"Cycle 12 Day 1 (n=132, 31)","categories":[{"measurements":[{"groupId":"OG000","value":"30.76","spread":"4.108"},{"groupId":"OG001","value":"29.54","spread":"5.607"}]}]},{"title":"Cycle 12 Day 28 (n=128, 31)","categories":[{"measurements":[{"groupId":"OG000","value":"29.63","spread":"4.362"},{"groupId":"OG001","value":"29.48","spread":"4.774"}]}]},{"title":"Cycle 13 Day 1 (113, 27)","categories":[{"measurements":[{"groupId":"OG000","value":"30.58","spread":"4.354"},{"groupId":"OG001","value":"29.81","spread":"4.923"}]}]},{"title":"Cycle 13 Day 28 (n=114, 27)","categories":[{"measurements":[{"groupId":"OG000","value":"29.30","spread":"4.424"},{"groupId":"OG001","value":"29.63","spread":"4.550"}]}]},{"title":"Cycle 14 Day 1 (n=114, 26)","categories":[{"measurements":[{"groupId":"OG000","value":"30.58","spread":"4.179"},{"groupId":"OG001","value":"29.35","spread":"4.664"}]}]},{"title":"Cycle 14 Day 28 (n=105, 25)","categories":[{"measurements":[{"groupId":"OG000","value":"28.94","spread":"4.771"},{"groupId":"OG001","value":"29.23","spread":"5.502"}]}]},{"title":"Cycle 15 Day 1 (n=100, 22)","categories":[{"measurements":[{"groupId":"OG000","value":"30.87","spread":"4.075"},{"groupId":"OG001","value":"29.18","spread":"5.917"}]}]},{"title":"Cycle 15 Day 28 (n=94, 20)","categories":[{"measurements":[{"groupId":"OG000","value":"29.26","spread":"4.320"},{"groupId":"OG001","value":"28.89","spread":"5.676"}]}]},{"title":"Cycle 16 Day 1 (n=96, 19)","categories":[{"measurements":[{"groupId":"OG000","value":"30.63","spread":"3.786"},{"groupId":"OG001","value":"27.79","spread":"5.760"}]}]},{"title":"Cycle 16 Day 28 (n=90, 18)","categories":[{"measurements":[{"groupId":"OG000","value":"29.51","spread":"4.302"},{"groupId":"OG001","value":"28.28","spread":"6.267"}]}]},{"title":"Cycle 17 Day 1 (n=85, 17)","categories":[{"measurements":[{"groupId":"OG000","value":"30.69","spread":"4.132"},{"groupId":"OG001","value":"29.26","spread":"5.434"}]}]},{"title":"Cycle 17 Day 28 (n=81, 14)","categories":[{"measurements":[{"groupId":"OG000","value":"29.73","spread":"4.155"},{"groupId":"OG001","value":"27.94","spread":"7.519"}]}]},{"title":"Cycle 18 Day 1 (n=80, 12)","categories":[{"measurements":[{"groupId":"OG000","value":"30.24","spread":"4.091"},{"groupId":"OG001","value":"28.83","spread":"7.209"}]}]},{"title":"Cycle 18 Day 28 (n=70, 11)","categories":[{"measurements":[{"groupId":"OG000","value":"29.15","spread":"4.358"},{"groupId":"OG001","value":"28.73","spread":"6.973"}]}]},{"title":"Cycle 19 Day 1 (n=71, 11)","categories":[{"measurements":[{"groupId":"OG000","value":"30.11","spread":"4.528"},{"groupId":"OG001","value":"29.64","spread":"7.061"}]}]},{"title":"Cycle 19 Day 28 (n=61, 10)","categories":[{"measurements":[{"groupId":"OG000","value":"29.48","spread":"4.678"},{"groupId":"OG001","value":"28.65","spread":"8.131"}]}]},{"title":"Cycle 20 Day 1 (n=65, 9)","categories":[{"measurements":[{"groupId":"OG000","value":"31.07","spread":"4.073"},{"groupId":"OG001","value":"28.44","spread":"8.048"}]}]},{"title":"Cycle 20 Day 28 (n=53, 9)","categories":[{"measurements":[{"groupId":"OG000","value":"29.44","spread":"4.210"},{"groupId":"OG001","value":"29.22","spread":"7.694"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 1 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-Kidney Symptom Index-Disease Related Symptoms (FKSI-DRS) baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.913","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.376","ciUpperLimit":"2.450"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 1 Day 28: Difference in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FKSI-DRS baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.935","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.421","ciUpperLimit":"2.449"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 2 Day 1: Difference in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FKSI-DRS baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.948","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.443","ciUpperLimit":"2.452"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 2 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FKSI-DRS baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.970","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.476","ciUpperLimit":"2.464"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 3 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FKSI-DRS baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.983","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.491","ciUpperLimit":"2.475"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 3 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FKSI-DRS baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.005","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.510","ciUpperLimit":"2.501"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 4 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FKSI-DRS baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.018","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.517","ciUpperLimit":"2.519"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 4 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FKSI-DRS baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.040","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.522","ciUpperLimit":"2.559"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 5 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FKSI-DRS baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.053","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.522","ciUpperLimit":"2.584"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 5 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FKSI-DRS baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.075","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.515","ciUpperLimit":"2.635"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 6 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FKSI-DRS baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.088","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.509","ciUpperLimit":"2.667"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 6 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FKSI-DRS baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.110","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.494","ciUpperLimit":"2.727"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 7 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FKSI-DRS baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.123","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.483","ciUpperLimit":"2.763"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 7 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FKSI-DRS baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.146","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.461","ciUpperLimit":"2.830"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 8 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FKSI-DRS baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Median Difference (Final Values)","paramValue":"2.158","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.447","ciUpperLimit":"2.869"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 8 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FKSI-DRS baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.181","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.420","ciUpperLimit":"2.941"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 9 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FKSI-DRS baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.193","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.404","ciUpperLimit":"2.983"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 9 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FKSI-DRS baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.216","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.373","ciUpperLimit":"3.059"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 10 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FKSI-DRS baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.228","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.355","ciUpperLimit":"3.102"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 10 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FKSI-DRS baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.251","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.321","ciUpperLimit":"3.180"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 11 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FKSI-DRS baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.263","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.302","ciUpperLimit":"3.225"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 11 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FKSI-DRS baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.286","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.266","ciUpperLimit":"3.305"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 12 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FKSI-DRS baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.298","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.246","ciUpperLimit":"3.351"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 12 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FKSI-DRS baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.321","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.209","ciUpperLimit":"3.433"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 13 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FKSI-DRS baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.333","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.188","ciUpperLimit":"3.479"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 13 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FKSI-DRS baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.356","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.150","ciUpperLimit":"3.562"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 14 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FKSI-DRS baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0002","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.369","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.128","ciUpperLimit":"3.609"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 14 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FKSI-DRS baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0003","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.391","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.089","ciUpperLimit":"3.693"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 15 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FKSI-DRS baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0004","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.404","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.067","ciUpperLimit":"3.740"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 15 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FKSI-DRS baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0007","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.426","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.027","ciUpperLimit":"3.825"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 16 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FKSI-DRS baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0009","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.439","ciPctValue":"95","ciLowerLimit":"1.005","ciUpperLimit":"3.872"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 16 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FKSI-DRS baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0013","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.461","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.964","ciUpperLimit":"3.958"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 17 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FKSI-DRS baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0016","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.474","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.942","ciUpperLimit":"4.006"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 17 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FKSI-DRS baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0022","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.496","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.901","ciUpperLimit":"4.092"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 18 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FKSI-DRS baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0026","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.509","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.878","ciUpperLimit":"4.140"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 18 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FKSI-DRS baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0034","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.531","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.836","ciUpperLimit":"4.226"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 19 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FKSI-DRS baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0040","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.544","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.813","ciUpperLimit":"4.274"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 19 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FKSI-DRS baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0051","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.566","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.772","ciUpperLimit":"4.361"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 20 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FKSI-DRS baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0058","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.579","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.748","ciUpperLimit":"4.410"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 20 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FKSI-DRS baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0071","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.602","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.706","ciUpperLimit":"4.497"}]},{"type":"SECONDARY","title":"FACT-Kidney Symptom Index (FKSI) Subscale","description":"FACT-Kidney Symptom Index (FKSI) subscale designed to be a stand-alone instrument to measure symptoms and quality of life in patients with advanced kidney cancer. Contains 15 questions; some questions overlap with the FACT-G questions. Each question was answered on a five-point Likert-type scale ranging from 0 to 4 (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much). Total FKSI score = sum score of the 15 item scores; total range: 0 - 60; 0 (most severe symptoms and concerns) to 60 (no symptoms or concerns).","populationDescription":"ITT; N=number of subjects with evaluable data; n=number of subjects with evaluable data at observation.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"scores on scale","timeFrame":"Day 1 & 28 of each cycle: duration of treatment phase","groups":[{"id":"OG000","title":"SU011248","description":"50 mg taken orally once a day for 4 weeks followed by a 2-week off treatment cycle to form a 6-week treatment cycle. Intra-subject dose reduction to 37.5 mg/day and 25 mg/day was allowed depending on type and severity of toxicity encountered."},{"id":"OG001","title":"IFN-α","description":"Subcutaneous (SC) injection in 6-week cycles on 3 non-consecutive days per week; 3 million units (MU) per dose Week 1; 6 MU per dose Week 2; 9 MU per dose Week 3 until completion of therapy or development of toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"375"},{"groupId":"OG001","value":"375"}]}],"classes":[{"title":"Baseline (n=369, 351)","categories":[{"measurements":[{"groupId":"OG000","value":"46.45","spread":"8.464"},{"groupId":"OG001","value":"46.09","spread":"8.701"}]}]},{"title":"Cycle 1 Day 28 (n=348, 317)","categories":[{"measurements":[{"groupId":"OG000","value":"42.71","spread":"8.959"},{"groupId":"OG001","value":"40.93","spread":"9.292"}]}]},{"title":"Cycle 2 Day 1 (n=327, 246)","categories":[{"measurements":[{"groupId":"OG000","value":"45.98","spread":"8.401"},{"groupId":"OG001","value":"42.33","spread":"8.733"}]}]},{"title":"Cycle 2 Day 28 (n=315, 238)","categories":[{"measurements":[{"groupId":"OG000","value":"43.75","spread":"8.607"},{"groupId":"OG001","value":"42.01","spread":"8.659"}]}]},{"title":"Cycle 3 Day 1 (n=294, 198)","categories":[{"measurements":[{"groupId":"OG000","value":"46.60","spread":"8.263"},{"groupId":"OG001","value":"43.64","spread":"7.983"}]}]},{"title":"Cycle 3 Day 28 (n=285, 195)","categories":[{"measurements":[{"groupId":"OG000","value":"44.01","spread":"8.529"},{"groupId":"OG001","value":"43.13","spread":"8.925"}]}]},{"title":"Cycle 4 Day 1 (n=272, 151)","categories":[{"measurements":[{"groupId":"OG000","value":"46.99","spread":"8.041"},{"groupId":"OG001","value":"44.78","spread":"8.328"}]}]},{"title":"Cycle 4 Day 28 (n=264, 142)","categories":[{"measurements":[{"groupId":"OG000","value":"45.08","spread":"8.017"},{"groupId":"OG001","value":"44.03","spread":"8.913"}]}]},{"title":"Cycle 5 Day 1 (n=248, 119)","categories":[{"measurements":[{"groupId":"OG000","value":"47.99","spread":"7.313"},{"groupId":"OG001","value":"44.82","spread":"8.293"}]}]},{"title":"Cycle 5 Day 28 (n=242, 109)","categories":[{"measurements":[{"groupId":"OG000","value":"44.99","spread":"7.768"},{"groupId":"OG001","value":"44.41","spread":"8.318"}]}]},{"title":"Cycle 6 Day 1 (n=240, 99)","categories":[{"measurements":[{"groupId":"OG000","value":"47.61","spread":"7.860"},{"groupId":"OG001","value":"45.38","spread":"7.995"}]}]},{"title":"Cycle 6 Day 28 (n=223, 99)","categories":[{"measurements":[{"groupId":"OG000","value":"45.40","spread":"7.840"},{"groupId":"OG001","value":"44.07","spread":"9.003"}]}]},{"title":"Cycle 7 Day 1 (n=208, 79)","categories":[{"measurements":[{"groupId":"OG000","value":"47.84","spread":"7.303"},{"groupId":"OG001","value":"45.09","spread":"9.061"}]}]},{"title":"Cycle 7 Day 28 (n=203, 75)","categories":[{"measurements":[{"groupId":"OG000","value":"45.39","spread":"8.013"},{"groupId":"OG001","value":"44.65","spread":"8.082"}]}]},{"title":"Cycle 8 Day 1 (n=192, 68)","categories":[{"measurements":[{"groupId":"OG000","value":"48.24","spread":"6.818"},{"groupId":"OG001","value":"45.38","spread":"8.597"}]}]},{"title":"Cycle 8 Day 28 (n=190, 62)","categories":[{"measurements":[{"groupId":"OG000","value":"45.83","spread":"7.589"},{"groupId":"OG001","value":"45.10","spread":"8.197"}]}]},{"title":"Cycle 9 Day 1 (n=172, 51)","categories":[{"measurements":[{"groupId":"OG000","value":"48.31","spread":"6.971"},{"groupId":"OG001","value":"46.88","spread":"7.901"}]}]},{"title":"Cycle 9 Day 28 (n=166, 46)","categories":[{"measurements":[{"groupId":"OG000","value":"45.79","spread":"7.969"},{"groupId":"OG001","value":"46.16","spread":"8.133"}]}]},{"title":"Cycle 10 Day 1 (n=161, 50)","categories":[{"measurements":[{"groupId":"OG000","value":"47.90","spread":"6.993"},{"groupId":"OG001","value":"46.22","spread":"7.778"}]}]},{"title":"Cycle 10 Day 28 (n=155, 46)","categories":[{"measurements":[{"groupId":"OG000","value":"45.70","spread":"7.372"},{"groupId":"OG001","value":"45.16","spread":"8.961"}]}]},{"title":"Cycle 11 Day 1 (n=138, 35)","categories":[{"measurements":[{"groupId":"OG000","value":"47.90","spread":"6.988"},{"groupId":"OG001","value":"46.26","spread":"7.398"}]}]},{"title":"Cycle 11 Day 28 (n=141, 33)","categories":[{"measurements":[{"groupId":"OG000","value":"45.28","spread":"7.330"},{"groupId":"OG001","value":"45.46","spread":"8.920"}]}]},{"title":"Cycle 12 Day 1 (n=132, 31)","categories":[{"measurements":[{"groupId":"OG000","value":"47.90","spread":"7.458"},{"groupId":"OG001","value":"46.08","spread":"9.456"}]}]},{"title":"Cycle 12 Day 28 (n=128, 31)","categories":[{"measurements":[{"groupId":"OG000","value":"45.67","spread":"7.696"},{"groupId":"OG001","value":"46.00","spread":"8.802"}]}]},{"title":"Cycle 13 Day 1 (n=113, 27)","categories":[{"measurements":[{"groupId":"OG000","value":"48.02","spread":"7.723"},{"groupId":"OG001","value":"46.25","spread":"8.833"}]}]},{"title":"Cycle 13 Day 28 (n=114, 27)","categories":[{"measurements":[{"groupId":"OG000","value":"45.65","spread":"7.659"},{"groupId":"OG001","value":"45.84","spread":"9.095"}]}]},{"title":"Cycle 14 Day 1 (n=114, 26)","categories":[{"measurements":[{"groupId":"OG000","value":"47.90","spread":"7.370"},{"groupId":"OG001","value":"46.08","spread":"8.621"}]}]},{"title":"Cycle 14 Day 28 (n=105, 25)","categories":[{"measurements":[{"groupId":"OG000","value":"45.10","spread":"8.641"},{"groupId":"OG001","value":"46.10","spread":"9.650"}]}]},{"title":"Cycle 15 Day 1 (n=100, 22)","categories":[{"measurements":[{"groupId":"OG000","value":"48.26","spread":"7.663"},{"groupId":"OG001","value":"45.62","spread":"9.715"}]}]},{"title":"Cycle 15 Day 28 (n=94, 20)","categories":[{"measurements":[{"groupId":"OG000","value":"45.37","spread":"8.040"},{"groupId":"OG001","value":"45.30","spread":"9.776"}]}]},{"title":"Cycle 16 Day 1 (n=96, 19)","categories":[{"measurements":[{"groupId":"OG000","value":"47.75","spread":"7.063"},{"groupId":"OG001","value":"43.64","spread":"10.688"}]}]},{"title":"Cycle 16 Day 28 (n=90, 18)","categories":[{"measurements":[{"groupId":"OG000","value":"45.95","spread":"7.625"},{"groupId":"OG001","value":"43.46","spread":"10.549"}]}]},{"title":"Cycle 17 Day 1 (n=85, 17)","categories":[{"measurements":[{"groupId":"OG000","value":"48.07","spread":"7.641"},{"groupId":"OG001","value":"45.59","spread":"10.302"}]}]},{"title":"Cycle 17 Day 28 (n=81, 14)","categories":[{"measurements":[{"groupId":"OG000","value":"46.27","spread":"8.016"},{"groupId":"OG001","value":"43.64","spread":"11.693"}]}]},{"title":"Cycle 18 Day 1 (n=80, 12)","categories":[{"measurements":[{"groupId":"OG000","value":"47.47","spread":"7.598"},{"groupId":"OG001","value":"44.92","spread":"12.391"}]}]},{"title":"Cycle 18 Day 28 (n=70, 11)","categories":[{"measurements":[{"groupId":"OG000","value":"45.36","spread":"7.585"},{"groupId":"OG001","value":"45.27","spread":"11.909"}]}]},{"title":"Cycle 19 Day 1 (n=71, 11)","categories":[{"measurements":[{"groupId":"OG000","value":"47.70","spread":"7.671"},{"groupId":"OG001","value":"46.64","spread":"12.808"}]}]},{"title":"Cycle 19 Day 28 (n=61, 10)","categories":[{"measurements":[{"groupId":"OG000","value":"46.07","spread":"8.442"},{"groupId":"OG001","value":"44.47","spread":"14.476"}]}]},{"title":"Cycle 20 Day 1 (n=65, 9)","categories":[{"measurements":[{"groupId":"OG000","value":"48.88","spread":"7.133"},{"groupId":"OG001","value":"45.00","spread":"13.811"}]}]},{"title":"Cycle 20 Day 28 (n=53, 9)","categories":[{"measurements":[{"groupId":"OG000","value":"46.26","spread":"8.065"},{"groupId":"OG001","value":"46.00","spread":"13.266"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 1 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"3.165","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.234","ciUpperLimit":"4.095"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 1 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"3.205","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.318","ciUpperLimit":"4.092"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 2 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"3.228","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.358","ciUpperLimit":"4.097"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 2 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"3.268","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.418","ciUpperLimit":"4.119"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 3 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"3.291","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.443","ciUpperLimit":"4.139"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 3 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"3.331","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.474","ciUpperLimit":"4.189"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 4 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"3.354","ciPctValue":"95","ciLowerLimit":"2.484","ciUpperLimit":"4.224"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 4 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"3.395","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.489","ciUpperLimit":"4.300"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 5 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"3.417","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.486","ciUpperLimit":"4.348"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 5 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"3.458","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.469","ciUpperLimit":"4.446"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 6 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"3.480","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.455","ciUpperLimit":"4.505"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 6 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"3.521","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.422","ciUpperLimit":"4.620"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 7 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"3.543","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.399","ciUpperLimit":"4.687"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 7 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"3.584","ciPctValue":"95","ciLowerLimit":"2.354","ciUpperLimit":"4.814"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 8 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"3.606","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.326","ciUpperLimit":"4.887"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 8 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"3.647","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.272","ciUpperLimit":"5.022"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 9 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"3.669","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.240","ciUpperLimit":"5.099"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 9 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"3.710","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.180","ciUpperLimit":"5.240"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 10 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"3.733","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.145","ciUpperLimit":"5.320"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 10 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"3.773","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.080","ciUpperLimit":"5.466"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 11 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"3.796","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.043","ciUpperLimit":"5.548"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 11 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"3.836","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.975","ciUpperLimit":"5.698"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 12 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"3.859","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.936","ciUpperLimit":"5.781"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 12 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0002","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"3.899","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.866","ciUpperLimit":"5.933"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 13 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0002","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"3.922","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.826","ciUpperLimit":"6.018"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 13 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0004","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"3.962","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.753","ciUpperLimit":"6.172"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 14 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0006","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"3.985","ciPctValue":"95","ciLowerLimit":"1.712","ciUpperLimit":"6.258"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 14 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0010","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"4.026","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.638","ciUpperLimit":"6.413"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 15 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0012","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"4.048","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.597","ciUpperLimit":"6.500"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 15 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0018","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"4.089","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.521","ciUpperLimit":"6.656"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 16 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0022","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"4.111","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.479","ciUpperLimit":"6.743"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 16 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0031","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"4.152","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.403","ciUpperLimit":"6.901"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 17 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0037","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"4.174","ciPctValue":"95","ciLowerLimit":"1.360","ciUpperLimit":"6.988"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 17 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0048","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"4.215","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.283","ciUpperLimit":"7.147"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 18 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0056","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"4.237","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.240","ciUpperLimit":"7.235"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 18 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0071","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"4.278","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.162","ciUpperLimit":"7.394"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 19 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0081","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"4.300","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.119","ciUpperLimit":"7.482"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 19 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0099","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"4.341","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.041","ciUpperLimit":"7.642"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 20 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0111","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"4.364","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.997","ciUpperLimit":"7.730"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 20 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0133","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"4.404","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.918","ciUpperLimit":"7.890"}]},{"type":"PRIMARY","title":"Progression-Free Survival (PFS), Investigator's Assessment","description":"Progression-free survival = time from randomization to first documentation of objective tumor progression or to death due to any cause, whichever occured first. PFS = first event date minus the date of randomization + 1). On study included treatment plus 28-day follow-up periods.","populationDescription":"ITT","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"weeks","timeFrame":"Day 28 of each 6-week cycle: duration of treatment phase","groups":[{"id":"OG000","title":"SU011248","description":"50 mg taken orally once a day for 4 weeks followed by a 2-week off treatment cycle to form a 6-week treatment cycle. Intra-subject dose reduction to 37.5 mg/day and 25 mg/day was allowed depending on type and severity of toxicity encountered."},{"id":"OG001","title":"IFN-α","description":"Subcutaneous (SC) injection in 6-week cycles on 3 non-consecutive days per week; 3 million units (MU) per dose Week 1; 6 MU per dose Week 2; 9 MU per dose Week 3 until completion of therapy or development of toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"375"},{"groupId":"OG001","value":"375"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.7","lowerLimit":"46.3","upperLimit":"58.1"},{"groupId":"OG001","value":"22.1","lowerLimit":"16.7","upperLimit":"27.4"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Unstratified analysis: Hazard Ratio (SU011248 vs IFN-α).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","pValueComment":"p-value is from 2-sided, unstratified test.","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.5404","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.4532","ciUpperLimit":"0.6444","estimateComment":"Assuming proportional hazards, a hazard ratio less than 1 indicates a reduction in hazard rate in favor of SU011248: a hazard ratio greater than 1 indicates a reduction in favor of IFN-a."},{"groupIds":["OG000","OG001"],"groupDescription":"Stratified analysis: Hazard Ratio (SU011248 vs IFN-α).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.00001","pValueComment":"p-value is from 2-sided, stratified test. Stratification factors are: Lactic Dehydrogenase (LDH) \\> or \\<= 1.5 x upper limit of normal, Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, and absence or presence of prior nephrectomy.","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.5418","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.4536","ciUpperLimit":"0.6473","estimateComment":"Assuming proportional hazards, a hazard ratio less than 1 indicates a reduction in hazard rate in favor of SU011248: a hazard ratio greater than 1 indicates a reduction in favor of IFN-a."}]},{"type":"SECONDARY","title":"Functional Assessment of Cancer Therapy-General (FACT-G)","description":"Functional Assessment of Cancer Therapy-General (FACT-G): core questionnaire of the Functional Assessment of Chronic Illness Therapy (FACIT) measurement system that has been validated in a variety of cancer populations. 27 questions grouped into 4 domains that measure a patient's physical, functional, social and family, and emotional well-being. Five-point Likert-type scale ranging from 0 to 4 (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much). Score = sum score of item scores in the subscale; total range: 0 to 108 with higher score indicating better quality of life.","populationDescription":"ITT; N=number of subjects with evaluable data; n=number of subjects with evaluable data at observation.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"scores on scale","timeFrame":"Day 1 & 28 of each cycle: duration of treatment phase","groups":[{"id":"OG000","title":"SU011248","description":"50 mg taken orally once a day for 4 weeks followed by a 2-week off treatment cycle to form a 6-week treatment cycle. Intra-subject dose reduction to 37.5 mg/day and 25 mg/day was allowed depending on type and severity of toxicity encountered."},{"id":"OG001","title":"IFN-α","description":"Subcutaneous (SC) injection in 6-week cycles on 3 non-consecutive days per week; 3 million units (MU) per dose Week 1; 6 MU per dose Week 2; 9 MU per dose Week 3 until completion of therapy or development of toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"375"},{"groupId":"OG001","value":"375"}]}],"classes":[{"title":"Baseline (n=368, 346)","categories":[{"measurements":[{"groupId":"OG000","value":"82.30","spread":"15.213"},{"groupId":"OG001","value":"81.22","spread":"16.030"}]}]},{"title":"Cycle 1 Day 28 (n=345, 316)","categories":[{"measurements":[{"groupId":"OG000","value":"78.75","spread":"15.702"},{"groupId":"OG001","value":"74.91","spread":"18.374"}]}]},{"title":"Cycle 2 Day 1 (n=328, 247)","categories":[{"measurements":[{"groupId":"OG000","value":"82.88","spread":"15.733"},{"groupId":"OG001","value":"77.02","spread":"16.670"}]}]},{"title":"Cycle 2 Day 28 (n=314, 237)","categories":[{"measurements":[{"groupId":"OG000","value":"80.51","spread":"16.229"},{"groupId":"OG001","value":"77.05","spread":"17.468"}]}]},{"title":"Cycle 3 Day 1 (n=293, 199)","categories":[{"measurements":[{"groupId":"OG000","value":"84.24","spread":"16.121"},{"groupId":"OG001","value":"79.35","spread":"16.862"}]}]},{"title":"Cycle 3 Day 28 (n=285, 193)","categories":[{"measurements":[{"groupId":"OG000","value":"80.59","spread":"16.144"},{"groupId":"OG001","value":"78.42","spread":"17.836"}]}]},{"title":"Cycle 4 Day 1 (n=269, 149)","categories":[{"measurements":[{"groupId":"OG000","value":"85.32","spread":"14.723"},{"groupId":"OG001","value":"80.86","spread":"16.477"}]}]},{"title":"Cycle 4 Day 28 (n=263, 142)","categories":[{"measurements":[{"groupId":"OG000","value":"82.08","spread":"15.147"},{"groupId":"OG001","value":"80.46","spread":"17.136"}]}]},{"title":"Cycle 5 Day 1 (n=247, 119)","categories":[{"measurements":[{"groupId":"OG000","value":"86.40","spread":"14.019"},{"groupId":"OG001","value":"81.96","spread":"15.286"}]}]},{"title":"Cycle 5 Day 28 (n=240, 106)","categories":[{"measurements":[{"groupId":"OG000","value":"82.23","spread":"15.124"},{"groupId":"OG001","value":"80.60","spread":"15.527"}]}]},{"title":"Cycle 6 Day 1 (n=238, 98)","categories":[{"measurements":[{"groupId":"OG000","value":"84.90","spread":"15.189"},{"groupId":"OG001","value":"81.97","spread":"15.918"}]}]},{"title":"Cycle 6 Day 28 (n=222, 97)","categories":[{"measurements":[{"groupId":"OG000","value":"82.54","spread":"15.338"},{"groupId":"OG001","value":"79.70","spread":"16.686"}]}]},{"title":"Cycle 7 Day 1 (n=206, 78)","categories":[{"measurements":[{"groupId":"OG000","value":"85.01","spread":"15.118"},{"groupId":"OG001","value":"80.39","spread":"17.811"}]}]},{"title":"Cycle 7 Day 28 (n=200, 75)","categories":[{"measurements":[{"groupId":"OG000","value":"82.16","spread":"16.207"},{"groupId":"OG001","value":"81.06","spread":"16.701"}]}]},{"title":"Cycle 8 Day 1 (n=192, 66)","categories":[{"measurements":[{"groupId":"OG000","value":"86.83","spread":"13.456"},{"groupId":"OG001","value":"81.25","spread":"17.179"}]}]},{"title":"Cycle 8 Day 28 (n=189, 61)","categories":[{"measurements":[{"groupId":"OG000","value":"83.05","spread":"14.699"},{"groupId":"OG001","value":"81.31","spread":"16.700"}]}]},{"title":"Cycle 9 Day 1 (n=170, 51)","categories":[{"measurements":[{"groupId":"OG000","value":"85.81","spread":"14.865"},{"groupId":"OG001","value":"84.50","spread":"16.174"}]}]},{"title":"Cycle 9 Day 28 (n=166, 46)","categories":[{"measurements":[{"groupId":"OG000","value":"82.71","spread":"15.276"},{"groupId":"OG001","value":"83.14","spread":"17.067"}]}]},{"title":"Cycle 10 Day 1 (n=158, 49)","categories":[{"measurements":[{"groupId":"OG000","value":"85.32","spread":"14.500"},{"groupId":"OG001","value":"84.03","spread":"16.559"}]}]},{"title":"Cycle 10 Day 28 (n=150, 45)","categories":[{"measurements":[{"groupId":"OG000","value":"82.14","spread":"15.193"},{"groupId":"OG001","value":"81.79","spread":"17.994"}]}]},{"title":"Cycle 11 Day 1 (n=134, 35)","categories":[{"measurements":[{"groupId":"OG000","value":"84.75","spread":"14.791"},{"groupId":"OG001","value":"81.60","spread":"16.729"}]}]},{"title":"Cycle 11 Day 28 (n=139, 32)","categories":[{"measurements":[{"groupId":"OG000","value":"81.91","spread":"14.865"},{"groupId":"OG001","value":"80.20","spread":"19.213"}]}]},{"title":"Cycle 12 Day 1 (n=130, 29)","categories":[{"measurements":[{"groupId":"OG000","value":"85.31","spread":"15.181"},{"groupId":"OG001","value":"80.99","spread":"20.219"}]}]},{"title":"Cycle 12 Day 28 (n=126, 31)","categories":[{"measurements":[{"groupId":"OG000","value":"82.43","spread":"15.152"},{"groupId":"OG001","value":"81.73","spread":"18.745"}]}]},{"title":"Cycle 13 Day 1 (n=113, 27)","categories":[{"measurements":[{"groupId":"OG000","value":"85.50","spread":"15.209"},{"groupId":"OG001","value":"81.18","spread":"20.198"}]}]},{"title":"Cycle 13 Day 28 (n=114, 27)","categories":[{"measurements":[{"groupId":"OG000","value":"83.61","spread":"14.445"},{"groupId":"OG001","value":"80.67","spread":"18.678"}]}]},{"title":"Cycle 14 Day 1 (n=112, 26)","categories":[{"measurements":[{"groupId":"OG000","value":"85.24","spread":"14.398"},{"groupId":"OG001","value":"81.22","spread":"17.506"}]}]},{"title":"Cycle 14 Day 28 (n=107, 24)","categories":[{"measurements":[{"groupId":"OG000","value":"82.34","spread":"16.300"},{"groupId":"OG001","value":"81.57","spread":"20.188"}]}]},{"title":"Cycle 15 Day 1 (n=101, 20)","categories":[{"measurements":[{"groupId":"OG000","value":"86.24","spread":"14.742"},{"groupId":"OG001","value":"81.66","spread":"18.326"}]}]},{"title":"Cycle 15 Day 28 (n=96, 20)","categories":[{"measurements":[{"groupId":"OG000","value":"82.64","spread":"15.722"},{"groupId":"OG001","value":"80.88","spread":"18.913"}]}]},{"title":"Cycle 16 Day 1 (n=94, 19)","categories":[{"measurements":[{"groupId":"OG000","value":"84.77","spread":"14.741"},{"groupId":"OG001","value":"78.20","spread":"18.994"}]}]},{"title":"Cycle 16 Day 28 (n=89, 18)","categories":[{"measurements":[{"groupId":"OG000","value":"83.38","spread":"15.481"},{"groupId":"OG001","value":"78.38","spread":"19.749"}]}]},{"title":"Cycle 17 Day 1 (n=84, 16)","categories":[{"measurements":[{"groupId":"OG000","value":"86.78","spread":"14.800"},{"groupId":"OG001","value":"81.80","spread":"20.161"}]}]},{"title":"Cycle 17 Day 28 (n=80, 14)","categories":[{"measurements":[{"groupId":"OG000","value":"84.42","spread":"15.106"},{"groupId":"OG001","value":"78.96","spread":"21.571"}]}]},{"title":"Cycle 18 Day 1 (n=79, 12)","categories":[{"measurements":[{"groupId":"OG000","value":"85.74","spread":"14.987"},{"groupId":"OG001","value":"82.24","spread":"23.763"}]}]},{"title":"Cycle 18 Day 28 (n=70, 11)","categories":[{"measurements":[{"groupId":"OG000","value":"83.51","spread":"14.831"},{"groupId":"OG001","value":"82.27","spread":"21.950"}]}]},{"title":"Cycle 19 Day 1 (n=71, 11)","categories":[{"measurements":[{"groupId":"OG000","value":"87.16","spread":"14.245"},{"groupId":"OG001","value":"82.48","spread":"24.198"}]}]},{"title":"Cycle 19 Day 28 (n=61, 10)","categories":[{"measurements":[{"groupId":"OG000","value":"84.54","spread":"16.679"},{"groupId":"OG001","value":"79.63","spread":"27.938"}]}]},{"title":"Cycle 20 Day 1 (n=63, 9)","categories":[{"measurements":[{"groupId":"OG000","value":"87.96","spread":"14.441"},{"groupId":"OG001","value":"81.70","spread":"27.018"}]}]},{"title":"Cycle 20 Day 28 (n=52, 8)","categories":[{"measurements":[{"groupId":"OG000","value":"84.62","spread":"16.257"},{"groupId":"OG001","value":"79.54","spread":"26.109"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 1 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline Functional Assessment of Cancer Therapy-General (FACT-G) baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"5.486","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"3.852","ciUpperLimit":"7.119"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 1 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"5.535","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"3.955","ciUpperLimit":"7.115"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 2 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"5.562","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"4.000","ciUpperLimit":"7.124"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 2 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"5.611","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"4.061","ciUpperLimit":"7.162"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 3 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"5.639","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"4.083","ciUpperLimit":"7.195"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 3 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"5.688","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"4.100","ciUpperLimit":"7.276"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 4 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"5.715","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"4.098","ciUpperLimit":"7.333"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 4 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"5.764","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"4.075","ciUpperLimit":"7.454"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 5 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"5.792","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"4.053","ciUpperLimit":"7.531"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 5 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"5.841","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"3.998","ciUpperLimit":"7.684"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 6 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"5.868","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"3.960","ciUpperLimit":"7.777"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 6 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"5.917","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"3.880","ciUpperLimit":"7.955"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 7 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"5.945","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"3.830","ciUpperLimit":"8.060"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 7 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"5.994","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"3.731","ciUpperLimit":"8.257"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 8 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"6.021","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"3.672","ciUpperLimit":"8.370"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 8 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"6.071","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"3.560","ciUpperLimit":"8.581"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 9 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"6.098","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"3.495","ciUpperLimit":"8.701"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 9 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"6.147","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"3.373","ciUpperLimit":"8.921"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 10 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"6.174","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"3.303","ciUpperLimit":"9.045"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 10 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"6.224","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"3.174","ciUpperLimit":"9.273"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 11 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"6.251","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"3.101","ciUpperLimit":"9.401"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 11 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0002","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"6.300","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.966","ciUpperLimit":"9.634"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 12 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0003","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"6.327","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.890","ciUpperLimit":"9.765"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 12 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0006","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"6.377","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.751","ciUpperLimit":"10.002"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 13 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0008","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"6.404","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.673","ciUpperLimit":"10.135"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 13 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0013","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"6.453","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.530","ciUpperLimit":"10.376"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 14 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0016","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"6.480","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.451","ciUpperLimit":"10.510"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 14 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0025","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"6.530","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.306","ciUpperLimit":"10.754"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 15 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0030","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"6.557","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.224","ciUpperLimit":"10.889"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 15 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0043","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"6.606","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.077","ciUpperLimit":"11.135"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 16 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0051","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"6.634","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.995","ciUpperLimit":"11.272"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 16 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0068","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"6.683","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.847","ciUpperLimit":"11.519"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 17 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0079","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"6.710","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.764","ciUpperLimit":"11.657"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 17 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0100","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"6.759","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.613","ciUpperLimit":"11.905"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 18 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0114","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"6.787","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.530","ciUpperLimit":"12.043"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 18 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0141","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"6.836","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.378","ciUpperLimit":"12.293"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 19 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0157","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"6.863","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.294","ciUpperLimit":"12.432"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 19 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0189","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"6.912","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.142","ciUpperLimit":"12.683"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 20 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0208","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"6.940","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.057","ciUpperLimit":"12.822"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 20 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0244","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"6.989","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.904","ciUpperLimit":"13.074"}]},{"type":"SECONDARY","title":"Functional Assessment of Cancer Therapy-General (FACT-G): Physical Well Being (PWB) Subscale","description":"Physical well-being (PWB) subscale of the Functional Assessment of Cancer Therapy-General (FACT-G). Each question was answered on a five-point Likert-type scale ranging from 0 to 4 (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much). Score = the sum score of the item scores in the subscale; range: 0 to 28; lower score indicates better physical well-being.","populationDescription":"ITT; N=number of subjects with evaluable data; n=number of subjects with evaluable data at observation.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"scores on scale","timeFrame":"Day 1 & 28 of each cycle: duration of treatment phase","groups":[{"id":"OG000","title":"SU011248","description":"50 mg taken orally once a day for 4 weeks followed by a 2-week off treatment cycle to form a 6-week treatment cycle. Intra-subject dose reduction to 37.5 mg/day and 25 mg/day was allowed depending on type and severity of toxicity encountered."},{"id":"OG001","title":"IFN-α","description":"Subcutaneous (SC) injection in 6-week cycles on 3 non-consecutive days per week; 3 million units (MU) per dose Week 1; 6 MU per dose Week 2; 9 MU per dose Week 3 until completion of therapy or development of toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"375"},{"groupId":"OG001","value":"375"}]}],"classes":[{"title":"Baseline (n=369, 348)","categories":[{"measurements":[{"groupId":"OG000","value":"23.14","spread":"5.209"},{"groupId":"OG001","value":"22.70","spread":"5.224"}]}]},{"title":"Cycle 1 Day 28 (n=348, 318)","categories":[{"measurements":[{"groupId":"OG000","value":"19.43","spread":"6.052"},{"groupId":"OG001","value":"18.85","spread":"6.168"}]}]},{"title":"Cycle 2 Day 1 (n=329, 247)","categories":[{"measurements":[{"groupId":"OG000","value":"22.22","spread":"5.161"},{"groupId":"OG001","value":"20.05","spread":"5.499"}]}]},{"title":"Cycle 2 Day 28 (n=316, 239)","categories":[{"measurements":[{"groupId":"OG000","value":"20.34","spread":"5.654"},{"groupId":"OG001","value":"19.84","spread":"5.706"}]}]},{"title":"Cycle 3 Day 1 (n=294, 200)","categories":[{"measurements":[{"groupId":"OG000","value":"22.45","spread":"5.123"},{"groupId":"OG001","value":"20.87","spread":"5.281"}]}]},{"title":"Cycle 3 Day 28 (n=286, 195)","categories":[{"measurements":[{"groupId":"OG000","value":"20.18","spread":"5.650"},{"groupId":"OG001","value":"20.63","spread":"5.395"}]}]},{"title":"Cycle 4 Day 1 (n=270, 150)","categories":[{"measurements":[{"groupId":"OG000","value":"22.72","spread":"4.641"},{"groupId":"OG001","value":"21.56","spread":"4.581"}]}]},{"title":"Cycle 4 Day 28 (n=264, 142)","categories":[{"measurements":[{"groupId":"OG000","value":"21.00","spread":"5.120"},{"groupId":"OG001","value":"21.31","spread":"5.110"}]}]},{"title":"Cycle 5 Day 1 (n=248, 120)","categories":[{"measurements":[{"groupId":"OG000","value":"23.24","spread":"4.143"},{"groupId":"OG001","value":"21.84","spread":"4.567"}]}]},{"title":"Cycle 5 Day 28 (n=241, 106)","categories":[{"measurements":[{"groupId":"OG000","value":"20.91","spread":"5.062"},{"groupId":"OG001","value":"21.23","spread":"4.867"}]}]},{"title":"Cycle 6 Day 1 (n=239, 99)","categories":[{"measurements":[{"groupId":"OG000","value":"22.99","spread":"4.385"},{"groupId":"OG001","value":"21.70","spread":"4.761"}]}]},{"title":"Cycle 6 Day 28 (n=224, 97)","categories":[{"measurements":[{"groupId":"OG000","value":"21.22","spread":"5.070"},{"groupId":"OG001","value":"20.96","spread":"5.384"}]}]},{"title":"Cycle 7 Day 1 (n=207, 79)","categories":[{"measurements":[{"groupId":"OG000","value":"23.05","spread":"4.414"},{"groupId":"OG001","value":"21.67","spread":"4.964"}]}]},{"title":"Cycle 7 Day 28 (n=201, 75)","categories":[{"measurements":[{"groupId":"OG000","value":"21.22","spread":"5.250"},{"groupId":"OG001","value":"21.66","spread":"4.595"}]}]},{"title":"Cycle 8 Day 1 (n=193, 67)","categories":[{"measurements":[{"groupId":"OG000","value":"23.58","spread":"3.715"},{"groupId":"OG001","value":"21.94","spread":"4.870"}]}]},{"title":"Cycle 8 Day 28 (n=189, 61)","categories":[{"measurements":[{"groupId":"OG000","value":"21.51","spread":"4.666"},{"groupId":"OG001","value":"21.40","spread":"4.910"}]}]},{"title":"Cycle 9 Day 1 (n=172, 51)","categories":[{"measurements":[{"groupId":"OG000","value":"23.41","spread":"4.071"},{"groupId":"OG001","value":"22.58","spread":"4.367"}]}]},{"title":"Cycle 9 Day 28 (n=166, 46)","categories":[{"measurements":[{"groupId":"OG000","value":"21.29","spread":"5.068"},{"groupId":"OG001","value":"22.38","spread":"4.400"}]}]},{"title":"Cycle 10 Day 1 (n=159, 49)","categories":[{"measurements":[{"groupId":"OG000","value":"22.94","spread":"4.053"},{"groupId":"OG001","value":"22.60","spread":"4.124"}]}]},{"title":"Cycle 10 Day 28 (n=151, 46)","categories":[{"measurements":[{"groupId":"OG000","value":"21.21","spread":"4.848"},{"groupId":"OG001","value":"21.83","spread":"5.165"}]}]},{"title":"Cycle 11 Day 1 (n=135, 35)","categories":[{"measurements":[{"groupId":"OG000","value":"23.16","spread":"4.069"},{"groupId":"OG001","value":"22.23","spread":"4.194"}]}]},{"title":"Cycle 11 Day 28 (n=140, 32)","categories":[{"measurements":[{"groupId":"OG000","value":"20.98","spread":"4.597"},{"groupId":"OG001","value":"21.88","spread":"5.173"}]}]},{"title":"Cycle 12 Day 1 (n=131, 30)","categories":[{"measurements":[{"groupId":"OG000","value":"23.03","spread":"4.291"},{"groupId":"OG001","value":"22.60","spread":"5.236"}]}]},{"title":"Cycle 12 Day 28 (n=127, 31)","categories":[{"measurements":[{"groupId":"OG000","value":"20.87","spread":"4.721"},{"groupId":"OG001","value":"21.90","spread":"4.867"}]}]},{"title":"Cycle 13 Day 1 (n=114, 27)","categories":[{"measurements":[{"groupId":"OG000","value":"23.05","spread":"4.281"},{"groupId":"OG001","value":"21.99","spread":"5.187"}]}]},{"title":"Cycle 13 Day 28 (n=114, 27)","categories":[{"measurements":[{"groupId":"OG000","value":"21.26","spread":"4.623"},{"groupId":"OG001","value":"21.80","spread":"5.369"}]}]},{"title":"Cycle 14 Day 1 (n=112, 26)","categories":[{"measurements":[{"groupId":"OG000","value":"23.02","spread":"4.401"},{"groupId":"OG001","value":"22.05","spread":"4.906"}]}]},{"title":"Cycle 14 Day 28 (n=107, 24)","categories":[{"measurements":[{"groupId":"OG000","value":"20.80","spread":"5.310"},{"groupId":"OG001","value":"22.75","spread":"4.875"}]}]},{"title":"Cycle 15 Day 1 (n=101, 21)","categories":[{"measurements":[{"groupId":"OG000","value":"23.26","spread":"4.475"},{"groupId":"OG001","value":"22.33","spread":"5.173"}]}]},{"title":"Cycle 15 Day 28 (n=96, 20)","categories":[{"measurements":[{"groupId":"OG000","value":"20.95","spread":"4.978"},{"groupId":"OG001","value":"22.07","spread":"4.908"}]}]},{"title":"Cycle 16 Day 1 (n=94, 19)","categories":[{"measurements":[{"groupId":"OG000","value":"22.60","spread":"4.337"},{"groupId":"OG001","value":"20.63","spread":"6.125"}]}]},{"title":"Cycle 16 Day 28 (n=90, 18)","categories":[{"measurements":[{"groupId":"OG000","value":"21.31","spread":"4.939"},{"groupId":"OG001","value":"21.42","spread":"6.194"}]}]},{"title":"Cycle 17 Day 1 (n=85, 16)","categories":[{"measurements":[{"groupId":"OG000","value":"22.99","spread":"4.513"},{"groupId":"OG001","value":"21.81","spread":"5.776"}]}]},{"title":"Cycle 17 Day 28 (n=80, 14)","categories":[{"measurements":[{"groupId":"OG000","value":"21.68","spread":"4.653"},{"groupId":"OG001","value":"20.50","spread":"6.757"}]}]},{"title":"Cycle 18 Day 1 (n=79, 12)","categories":[{"measurements":[{"groupId":"OG000","value":"22.85","spread":"4.388"},{"groupId":"OG001","value":"21.83","spread":"6.672"}]}]},{"title":"Cycle 18 Day 28 (n=70, 11)","categories":[{"measurements":[{"groupId":"OG000","value":"20.89","spread":"5.006"},{"groupId":"OG001","value":"22.45","spread":"5.610"}]}]},{"title":"Cycle 19 Day 1 (n=71, 11)","categories":[{"measurements":[{"groupId":"OG000","value":"23.20","spread":"4.426"},{"groupId":"OG001","value":"22.45","spread":"6.773"}]}]},{"title":"Cycle 19 Day 28 (n=61, 10)","categories":[{"measurements":[{"groupId":"OG000","value":"21.82","spread":"4.696"},{"groupId":"OG001","value":"21.60","spread":"7.457"}]}]},{"title":"Cycle 20 Day 1 (n=63, 9)","categories":[{"measurements":[{"groupId":"OG000","value":"23.68","spread":"4.204"},{"groupId":"OG001","value":"21.78","spread":"7.311"}]}]},{"title":"Cycle 20 Day 28 (n=52, 9)","categories":[{"measurements":[{"groupId":"OG000","value":"21.81","spread":"4.835"},{"groupId":"OG001","value":"22.33","spread":"6.423"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 1 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline Functional Assessment of Cancer Therapy-General (FACT-G) Physical Well Being (PWB) subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.459","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.805","ciUpperLimit":"2.114"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 1 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.453","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.827","ciUpperLimit":"2.079"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 2 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.450","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.837","ciUpperLimit":"2.063"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 2 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.444","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.847","ciUpperLimit":"2.041"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 3 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.440","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.848","ciUpperLimit":"2.032"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 3 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.434","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.844","ciUpperLimit":"2.024"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 4 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.431","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.838","ciUpperLimit":"2.023"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 4 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.424","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.819","ciUpperLimit":"2.029"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 5 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.421","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.805","ciUpperLimit":"2.037"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 5 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.415","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.774","ciUpperLimit":"2.056"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 6 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.411","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.753","ciUpperLimit":"2.069"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 6 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.405","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.711","ciUpperLimit":"2.099"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 7 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.402","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.685","ciUpperLimit":"2.119"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 7 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0003","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.396","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.634","ciUpperLimit":"2.157"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 8 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0005","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.392","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.604","ciUpperLimit":"2.180"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 8 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0012","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.386","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.547","ciUpperLimit":"2.225"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 9 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0018","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.383","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.514","ciUpperLimit":"2.252"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 9 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0035","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.376","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.451","ciUpperLimit":"2.301"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 10 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0049","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.373","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.416","ciUpperLimit":"2.330"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 10 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0084","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.367","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.350","ciUpperLimit":"2.383"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 11 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0110","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.363","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.313","ciUpperLimit":"2.414"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 11 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0168","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.357","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.245","ciUpperLimit":"2.470"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 12 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0208","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.354","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.206","ciUpperLimit":"2.501"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 12 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0293","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.348","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.136","ciUpperLimit":"2.559"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 13 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0348","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.344","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.096","ciUpperLimit":"2.592"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 13 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0459","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.338","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.024","ciUpperLimit":"2.652"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 14 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0528","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.335","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.016","ciUpperLimit":"2.685"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 14 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0663","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.328","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.090","ciUpperLimit":"2.746"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 15 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0744","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.325","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.131","ciUpperLimit":"2.780"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 15 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0898","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.319","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.205","ciUpperLimit":"2.842"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 16 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0988","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.315","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.246","ciUpperLimit":"2.877"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 16 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.1156","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.309","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.321","ciUpperLimit":"2.940"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 17 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.1252","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.306","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.363","ciUpperLimit":"2.975"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 17 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.1429","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.300","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.439","ciUpperLimit":"3.038"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 18 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.1529","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.296","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.481","ciUpperLimit":"3.074"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 18 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.1711","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.290","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.558","ciUpperLimit":"3.138"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 19 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.1813","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.287","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.600","ciUpperLimit":"3.173"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 19 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.1998","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.280","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.677","ciUpperLimit":"3.238"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 20 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.2100","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.277","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.720","ciUpperLimit":"3.273"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 20 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.2283","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.271","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.797","ciUpperLimit":"3.338"}]},{"type":"SECONDARY","title":"Functional Assessment of Cancer Therapy-General (FACT-G): Social/Family Well Being (SWB) Subscale","description":"Social/family well-being (SWB)subscale of the Functional Assessment of Cancer Therapy-General (FACT-G). Each question was answered on a five-point Likert-type scale ranging from 0 to 4 (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much). Score = the sum score of the item scores in the subscale; range: 0 to 28; lower score indicates less social/family well-being.","populationDescription":"ITT; N=number of subjects with evaluable data; n=number of subjects with evaluable data at observation.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"scores on scale","timeFrame":"Day 1 & 28 of each cycle: duration of treatment phase","groups":[{"id":"OG000","title":"SU011248","description":"50 mg taken orally once a day for 4 weeks followed by a 2-week off treatment cycle to form a 6-week treatment cycle. Intra-subject dose reduction to 37.5 mg/day and 25 mg/day was allowed depending on type and severity of toxicity encountered."},{"id":"OG001","title":"IFN-α","description":"Subcutaneous (SC) injection in 6-week cycles on 3 non-consecutive days per week; 3 million units (MU) per dose Week 1; 6 MU per dose Week 2; 9 MU per dose Week 3 until completion of therapy or development of toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"375"},{"groupId":"OG001","value":"375"}]}],"classes":[{"title":"Baseline (n=370, 349)","categories":[{"measurements":[{"groupId":"OG000","value":"23.14","spread":"4.641"},{"groupId":"OG001","value":"22.94","spread":"4.735"}]}]},{"title":"Cycle 1 Day 28 (n=348, 319)","categories":[{"measurements":[{"groupId":"OG000","value":"23.60","spread":"4.088"},{"groupId":"OG001","value":"22.20","spread":"5.076"}]}]},{"title":"Cycle 2 Day 1 (n=328, 247)","categories":[{"measurements":[{"groupId":"OG000","value":"23.50","spread":"4.344"},{"groupId":"OG001","value":"22.31","spread":"5.190"}]}]},{"title":"Cycle 2 Day 28 (n=315, 238)","categories":[{"measurements":[{"groupId":"OG000","value":"23.40","spread":"4.471"},{"groupId":"OG001","value":"22.22","spread":"5.203"}]}]},{"title":"Cycle 3 Day 1 (n=292, 200)","categories":[{"measurements":[{"groupId":"OG000","value":"23.51","spread":"4.375"},{"groupId":"OG001","value":"22.42","spread":"5.011"}]}]},{"title":"Cycle 3 Day 28 (n=284, 194)","categories":[{"measurements":[{"groupId":"OG000","value":"23.44","spread":"4.369"},{"groupId":"OG001","value":"22.12","spread":"5.289"}]}]},{"title":"Cycle 4 Day 1 (n=269, 150)","categories":[{"measurements":[{"groupId":"OG000","value":"23.73","spread":"4.072"},{"groupId":"OG001","value":"22.26","spread":"5.275"}]}]},{"title":"Cycle 4 Day 28 (n=263, 142)","categories":[{"measurements":[{"groupId":"OG000","value":"23.36","spread":"4.451"},{"groupId":"OG001","value":"22.38","spread":"5.198"}]}]},{"title":"Cycle 5 Day 1 (n=247, 120)","categories":[{"measurements":[{"groupId":"OG000","value":"23.53","spread":"4.334"},{"groupId":"OG001","value":"22.35","spread":"5.486"}]}]},{"title":"Cycle 5 Day 28 (n=241, 107)","categories":[{"measurements":[{"groupId":"OG000","value":"23.68","spread":"4.137"},{"groupId":"OG001","value":"22.36","spread":"4.956"}]}]},{"title":"Cycle 6 Day 1 (n=238, 98)","categories":[{"measurements":[{"groupId":"OG000","value":"23.35","spread":"4.428"},{"groupId":"OG001","value":"22.56","spread":"4.678"}]}]},{"title":"Cycle 6 Day 28 (n=224, 97)","categories":[{"measurements":[{"groupId":"OG000","value":"23.40","spread":"4.393"},{"groupId":"OG001","value":"22.33","spread":"4.641"}]}]},{"title":"Cycle 7 Day 1 (n=207, 79)","categories":[{"measurements":[{"groupId":"OG000","value":"23.29","spread":"4.532"},{"groupId":"OG001","value":"22.46","spread":"4.722"}]}]},{"title":"Cycle 7 Day 28 (n=200, 75)","categories":[{"measurements":[{"groupId":"OG000","value":"23.13","spread":"4.585"},{"groupId":"OG001","value":"22.10","spread":"5.286"}]}]},{"title":"Cycle 8 Day 1 (n=193, 67)","categories":[{"measurements":[{"groupId":"OG000","value":"23.67","spread":"4.225"},{"groupId":"OG001","value":"21.95","spread":"5.112"}]}]},{"title":"Cycle 8 Day 28 (n=189, 61)","categories":[{"measurements":[{"groupId":"OG000","value":"23.26","spread":"4.402"},{"groupId":"OG001","value":"22.17","spread":"5.236"}]}]},{"title":"Cycle 9 Day 1 (n=172, 51)","categories":[{"measurements":[{"groupId":"OG000","value":"23.26","spread":"4.376"},{"groupId":"OG001","value":"22.74","spread":"4.826"}]}]},{"title":"Cycle 9 Day 28 (n=166, 46)","categories":[{"measurements":[{"groupId":"OG000","value":"23.26","spread":"4.395"},{"groupId":"OG001","value":"21.96","spread":"5.418"}]}]},{"title":"Cycle 10 Day 1 (n=158, 49)","categories":[{"measurements":[{"groupId":"OG000","value":"23.08","spread":"4.348"},{"groupId":"OG001","value":"22.45","spread":"5.279"}]}]},{"title":"Cycle 10 Day 28 (n=151, 46)","categories":[{"measurements":[{"groupId":"OG000","value":"23.03","spread":"4.417"},{"groupId":"OG001","value":"22.06","spread":"5.065"}]}]},{"title":"Cycle 11 Day 1 (n=135, 35)","categories":[{"measurements":[{"groupId":"OG000","value":"23.05","spread":"4.521"},{"groupId":"OG001","value":"21.51","spread":"5.267"}]}]},{"title":"Cycle 11 Day 28 (n=140, 32)","categories":[{"measurements":[{"groupId":"OG000","value":"22.71","spread":"4.624"},{"groupId":"OG001","value":"21.09","spread":"5.957"}]}]},{"title":"Cycle 12 Day 1 (n=131, 30)","categories":[{"measurements":[{"groupId":"OG000","value":"23.23","spread":"4.563"},{"groupId":"OG001","value":"20.79","spread":"6.007"}]}]},{"title":"Cycle 12 Day 28 (n=127, 31)","categories":[{"measurements":[{"groupId":"OG000","value":"23.07","spread":"4.586"},{"groupId":"OG001","value":"21.25","spread":"5.627"}]}]},{"title":"Cycle 13 Day 1 (n=114, 27)","categories":[{"measurements":[{"groupId":"OG000","value":"23.15","spread":"4.498"},{"groupId":"OG001","value":"20.93","spread":"6.142"}]}]},{"title":"Cycle 13 Day 28 (n=114, 27)","categories":[{"measurements":[{"groupId":"OG000","value":"23.31","spread":"4.255"},{"groupId":"OG001","value":"21.30","spread":"5.491"}]}]},{"title":"Cycle 14 Day 1 (n=112, 26)","categories":[{"measurements":[{"groupId":"OG000","value":"22.82","spread":"4.647"},{"groupId":"OG001","value":"21.51","spread":"5.510"}]}]},{"title":"Cycle 14 Day 28 (n=107, 24)","categories":[{"measurements":[{"groupId":"OG000","value":"23.24","spread":"4.503"},{"groupId":"OG001","value":"20.32","spread":"6.628"}]}]},{"title":"Cycle 15 Day 1 (n=101, 21)","categories":[{"measurements":[{"groupId":"OG000","value":"23.28","spread":"4.178"},{"groupId":"OG001","value":"20.35","spread":"5.986"}]}]},{"title":"Cycle 15 Day 28 (n=96, 20)","categories":[{"measurements":[{"groupId":"OG000","value":"23.04","spread":"4.312"},{"groupId":"OG001","value":"20.23","spread":"6.162"}]}]},{"title":"Cycle 16 Day 1 (n=94, 19)","categories":[{"measurements":[{"groupId":"OG000","value":"23.11","spread":"4.335"},{"groupId":"OG001","value":"21.41","spread":"5.196"}]}]},{"title":"Cycle 16 Day 28 (n=89, 18)","categories":[{"measurements":[{"groupId":"OG000","value":"23.41","spread":"4.322"},{"groupId":"OG001","value":"21.52","spread":"5.821"}]}]},{"title":"Cycle 17 Day 1 (n=85, 16)","categories":[{"measurements":[{"groupId":"OG000","value":"23.42","spread":"4.603"},{"groupId":"OG001","value":"22.25","spread":"5.037"}]}]},{"title":"Cycle 17 Day 28 (n=80, 14)","categories":[{"measurements":[{"groupId":"OG000","value":"23.50","spread":"4.424"},{"groupId":"OG001","value":"21.75","spread":"5.680"}]}]},{"title":"Cycle 18 Day 1 (n=79, 12)","categories":[{"measurements":[{"groupId":"OG000","value":"23.53","spread":"4.428"},{"groupId":"OG001","value":"21.71","spread":"6.276"}]}]},{"title":"Cycle 18 Day 28 (n=70, 11)","categories":[{"measurements":[{"groupId":"OG000","value":"23.70","spread":"4.410"},{"groupId":"OG001","value":"21.27","spread":"6.051"}]}]},{"title":"Cycle 19 Day 1 (n=71, 11)","categories":[{"measurements":[{"groupId":"OG000","value":"23.85","spread":"4.270"},{"groupId":"OG001","value":"21.30","spread":"5.894"}]}]},{"title":"Cycle 19 Day 28 (n=61, 10)","categories":[{"measurements":[{"groupId":"OG000","value":"23.53","spread":"4.641"},{"groupId":"OG001","value":"20.73","spread":"6.816"}]}]},{"title":"Cycle 20 Day 1 (n=63, 9)","categories":[{"measurements":[{"groupId":"OG000","value":"23.60","spread":"4.045"},{"groupId":"OG001","value":"21.26","spread":"7.201"}]}]},{"title":"Cycle 20 Day 28 (n=52, 8)","categories":[{"measurements":[{"groupId":"OG000","value":"22.93","spread":"4.898"},{"groupId":"OG001","value":"20.67","spread":"6.251"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 1 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline Functional Assessment of Cancer Therapy-General (FACT-G) Social/Family Well Being (SWB) subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.214","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.719","ciUpperLimit":"1.708"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 1 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.216","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.729","ciUpperLimit":"1.703"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 2 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.217","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.731","ciUpperLimit":"1.704"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 2 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.220","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.730","ciUpperLimit":"1.710"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 3 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.221","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.727","ciUpperLimit":"1.716"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 3 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.224","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.716","ciUpperLimit":"1.732"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 4 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.225","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.707","ciUpperLimit":"1.744"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 4 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.228","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.687","ciUpperLimit":"1.769"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 5 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.229","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.673","ciUpperLimit":"1.785"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 5 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.232","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.646","ciUpperLimit":"1.818"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 6 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.233","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.629","ciUpperLimit":"1.838"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 6 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0002","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.236","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.595","ciUpperLimit":"1.876"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 7 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0003","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.237","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.575","ciUpperLimit":"1.899"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 7 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0005","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.240","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.537","ciUpperLimit":"1.942"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 8 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0008","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.241","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.515","ciUpperLimit":"1.967"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 8 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0015","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.244","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.474","ciUpperLimit":"2.013"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 9 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0021","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.245","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.450","ciUpperLimit":"2.040"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 9 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0037","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.248","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.406","ciUpperLimit":"2.089"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 10 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0048","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.249","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.382","ciUpperLimit":"2.116"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 10 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0074","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.251","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.336","ciUpperLimit":"2.167"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 11 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0092","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.253","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.310","ciUpperLimit":"2.196"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 11 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0132","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.255","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.262","ciUpperLimit":"2.248"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 12 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0159","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.257","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.236","ciUpperLimit":"2.278"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 12 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0213","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.259","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.187","ciUpperLimit":"2.332"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 13 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0248","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.261","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.160","ciUpperLimit":"2.362"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 13 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0318","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.263","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.110","ciUpperLimit":"2.416"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 14 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0360","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.265","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.083","ciUpperLimit":"2.447"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 14 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0443","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.267","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.032","ciUpperLimit":"2.502"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 15 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0493","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.269","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.004","ciUpperLimit":"2.533"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 15 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0587","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.271","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.047","ciUpperLimit":"2.589"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 16 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0642","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.273","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.075","ciUpperLimit":"2.620"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 16 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0746","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.275","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.127","ciUpperLimit":"2.677"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 17 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0806","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.276","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.155","ciUpperLimit":"2.708"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 17 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0917","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.279","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.207","ciUpperLimit":"2.765"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 18 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0980","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.280","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.236","ciUpperLimit":"2.797"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 18 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.1095","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.283","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.288","ciUpperLimit":"2.854"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 19 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.1161","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.284","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.318","ciUpperLimit":"2.886"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 19 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.1280","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.287","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.370","ciUpperLimit":"2.944"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 20 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.1346","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.288","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.399","ciUpperLimit":"2.976"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 20 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.1466","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.291","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.452","ciUpperLimit":"3.034"}]},{"type":"SECONDARY","title":"Functional Assessment of Cancer Therapy-General (FACT-G): Emotional Well Being (EWB) Subscale","description":"Emotional well-being (EWB)subscale of the Functional Assessment of Cancer Therapy-General (FACT-G). Each question was answered on a five-point Likert-type scale ranging from 0 to 4 (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much). Score = the sum score of the item scores in the subscale; range: 0 to 24; lower score indicates better emotional well-being.","populationDescription":"ITT; N=number of subjects with evaluable data; n=number of subjects with evaluable data at observation.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"scores on scale","timeFrame":"Day 1 & 28 of each cycle: duration of treatment phase","groups":[{"id":"OG000","title":"SU011248","description":"50 mg taken orally once a day for 4 weeks followed by a 2-week off treatment cycle to form a 6-week treatment cycle. Intra-subject dose reduction to 37.5 mg/day and 25 mg/day was allowed depending on type and severity of toxicity encountered."},{"id":"OG001","title":"IFN-α","description":"Subcutaneous (SC) injection in 6-week cycles on 3 non-consecutive days per week; 3 million units (MU) per dose Week 1; 6 MU per dose Week 2; 9 MU per dose Week 3 until completion of therapy or development of toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"375"},{"groupId":"OG001","value":"375"}]}],"classes":[{"title":"Baseline (370, 352)","categories":[{"measurements":[{"groupId":"OG000","value":"17.15","spread":"4.548"},{"groupId":"OG001","value":"17.06","spread":"4.609"}]}]},{"title":"Cycle 1 Day 28 (n=347, 318)","categories":[{"measurements":[{"groupId":"OG000","value":"17.76","spread":"4.347"},{"groupId":"OG001","value":"17.40","spread":"5.123"}]}]},{"title":"Cycle 2 Day 1 (n=328, 249)","categories":[{"measurements":[{"groupId":"OG000","value":"18.46","spread":"4.218"},{"groupId":"OG001","value":"17.52","spread":"4.560"}]}]},{"title":"Cycle 2 Day 28 (n=316, 237)","categories":[{"measurements":[{"groupId":"OG000","value":"18.46","spread":"4.342"},{"groupId":"OG001","value":"17.73","spread":"4.637"}]}]},{"title":"Cycle 3 Day 1 (n=294, 200)","categories":[{"measurements":[{"groupId":"OG000","value":"18.82","spread":"4.236"},{"groupId":"OG001","value":"18.13","spread":"4.603"}]}]},{"title":"Cycle 3 Day 28 (n=287, 196)","categories":[{"measurements":[{"groupId":"OG000","value":"18.53","spread":"4.494"},{"groupId":"OG001","value":"18.17","spread":"4.704"}]}]},{"title":"Cycle 4 Day 1 (n=272, 152)","categories":[{"measurements":[{"groupId":"OG000","value":"19.04","spread":"4.182"},{"groupId":"OG001","value":"18.80","spread":"4.246"}]}]},{"title":"Cycle 4 Day 28 (n=265, 142)","categories":[{"measurements":[{"groupId":"OG000","value":"18.76","spread":"4.343"},{"groupId":"OG001","value":"18.39","spread":"4.378"}]}]},{"title":"Cycle 5 Day 1 (n=249, 120)","categories":[{"measurements":[{"groupId":"OG000","value":"19.18","spread":"3.903"},{"groupId":"OG001","value":"19.00","spread":"4.062"}]}]},{"title":"Cycle 5 Day 28 (n=241, 109)","categories":[{"measurements":[{"groupId":"OG000","value":"18.63","spread":"4.298"},{"groupId":"OG001","value":"18.70","spread":"4.144"}]}]},{"title":"Cycle 6 Day 1 (n=240, 99)","categories":[{"measurements":[{"groupId":"OG000","value":"18.99","spread":"4.154"},{"groupId":"OG001","value":"18.60","spread":"4.338"}]}]},{"title":"Cycle 6 Day 28 (n=222, 99)","categories":[{"measurements":[{"groupId":"OG000","value":"18.73","spread":"4.311"},{"groupId":"OG001","value":"18.14","spread":"4.747"}]}]},{"title":"Cycle 7 Day 1 (n=208, 77)","categories":[{"measurements":[{"groupId":"OG000","value":"19.08","spread":"4.324"},{"groupId":"OG001","value":"18.08","spread":"5.010"}]}]},{"title":"Cycle 7 Day 28 (n=204, 75)","categories":[{"measurements":[{"groupId":"OG000","value":"18.69","spread":"4.595"},{"groupId":"OG001","value":"18.55","spread":"4.691"}]}]},{"title":"Cycle 8 Day 1 (n=192, 67)","categories":[{"measurements":[{"groupId":"OG000","value":"19.33","spread":"4.104"},{"groupId":"OG001","value":"18.54","spread":"4.613"}]}]},{"title":"Cycle 8 Day 28 (n=189, 62)","categories":[{"measurements":[{"groupId":"OG000","value":"18.98","spread":"4.026"},{"groupId":"OG001","value":"18.55","spread":"4.734"}]}]},{"title":"Cycle 9 Day 1 (n=171, 51)","categories":[{"measurements":[{"groupId":"OG000","value":"19.25","spread":"4.341"},{"groupId":"OG001","value":"18.98","spread":"4.654"}]}]},{"title":"Cycle 9 Day 28 (n=167, 46)","categories":[{"measurements":[{"groupId":"OG000","value":"18.93","spread":"4.376"},{"groupId":"OG001","value":"18.76","spread":"4.831"}]}]},{"title":"Cycle 10 Day 1 (n=161, 50)","categories":[{"measurements":[{"groupId":"OG000","value":"19.32","spread":"4.191"},{"groupId":"OG001","value":"18.92","spread":"4.548"}]}]},{"title":"Cycle 10 Day 28 (n=154, 45)","categories":[{"measurements":[{"groupId":"OG000","value":"18.71","spread":"4.557"},{"groupId":"OG001","value":"18.36","spread":"4.778"}]}]},{"title":"Cycle 11 Day 1 (n=138, 35)","categories":[{"measurements":[{"groupId":"OG000","value":"18.92","spread":"4.514"},{"groupId":"OG001","value":"18.97","spread":"4.225"}]}]},{"title":"Cycle 11 Day 28 (n=141, 33)","categories":[{"measurements":[{"groupId":"OG000","value":"19.10","spread":"4.209"},{"groupId":"OG001","value":"18.52","spread":"5.316"}]}]},{"title":"Cycle 12 Day 1 (n=132, 30)","categories":[{"measurements":[{"groupId":"OG000","value":"19.14","spread":"4.547"},{"groupId":"OG001","value":"18.87","spread":"4.547"}]}]},{"title":"Cycle 12 Day 28 (n=128, 31)","categories":[{"measurements":[{"groupId":"OG000","value":"19.06","spread":"4.456"},{"groupId":"OG001","value":"19.45","spread":"4.178"}]}]},{"title":"Cycle 13 Day 1 (n=114, 27)","categories":[{"measurements":[{"groupId":"OG000","value":"19.38","spread":"4.170"},{"groupId":"OG001","value":"18.63","spread":"4.853"}]}]},{"title":"Cycle 13 Day 28 (n=114, 27)","categories":[{"measurements":[{"groupId":"OG000","value":"19.39","spread":"4.034"},{"groupId":"OG001","value":"18.97","spread":"3.993"}]}]},{"title":"Cycle 14 Day 1 (n=114, 26)","categories":[{"measurements":[{"groupId":"OG000","value":"19.55","spread":"3.951"},{"groupId":"OG001","value":"18.05","spread":"4.814"}]}]},{"title":"Cycle 14 Day 28 (n=107, 25)","categories":[{"measurements":[{"groupId":"OG000","value":"19.23","spread":"4.522"},{"groupId":"OG001","value":"18.76","spread":"4.085"}]}]},{"title":"Cycle 15 Day 1 (n=101, 21)","categories":[{"measurements":[{"groupId":"OG000","value":"19.57","spread":"4.171"},{"groupId":"OG001","value":"18.24","spread":"4.795"}]}]},{"title":"Cycle 15 Day 28 (n=96, 20)","categories":[{"measurements":[{"groupId":"OG000","value":"19.41","spread":"4.459"},{"groupId":"OG001","value":"18.75","spread":"4.447"}]}]},{"title":"Cycle 16 Day 1 (n=96, 19)","categories":[{"measurements":[{"groupId":"OG000","value":"19.54","spread":"4.258"},{"groupId":"OG001","value":"17.26","spread":"5.675"}]}]},{"title":"Cycle 16 Day 28 (n=91, 18)","categories":[{"measurements":[{"groupId":"OG000","value":"19.33","spread":"4.287"},{"groupId":"OG001","value":"16.83","spread":"5.113"}]}]},{"title":"Cycle 17 Day 1 (n=84, 17)","categories":[{"measurements":[{"groupId":"OG000","value":"19.95","spread":"3.997"},{"groupId":"OG001","value":"18.28","spread":"5.151"}]}]},{"title":"Cycle 17 Day 28 (n=81, 14)","categories":[{"measurements":[{"groupId":"OG000","value":"19.66","spread":"4.420"},{"groupId":"OG001","value":"18.00","spread":"5.218"}]}]},{"title":"Cycle 18 Day 1 (n=80, 12)","categories":[{"measurements":[{"groupId":"OG000","value":"19.64","spread":"4.132"},{"groupId":"OG001","value":"19.62","spread":"4.971"}]}]},{"title":"Cycle 18 Day 28 (n=71, 11)","categories":[{"measurements":[{"groupId":"OG000","value":"19.34","spread":"4.125"},{"groupId":"OG001","value":"19.55","spread":"4.677"}]}]},{"title":"Cycle 19 Day 1 (n=71, 11)","categories":[{"measurements":[{"groupId":"OG000","value":"19.94","spread":"4.052"},{"groupId":"OG001","value":"19.09","spread":"5.224"}]}]},{"title":"Cycle 19 Day 28 (n=61, 10)","categories":[{"measurements":[{"groupId":"OG000","value":"19.61","spread":"4.469"},{"groupId":"OG001","value":"18.20","spread":"6.630"}]}]},{"title":"Cycle 20 Day 1 (n=65, 9)","categories":[{"measurements":[{"groupId":"OG000","value":"20.00","spread":"4.138"},{"groupId":"OG001","value":"18.67","spread":"5.788"}]}]},{"title":"Cycle 20 Day 28 (n=53, 9)","categories":[{"measurements":[{"groupId":"OG000","value":"19.75","spread":"4.206"},{"groupId":"OG001","value":"18.67","spread":"6.384"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 1 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline Functional Assessment of Cancer Therapy-General (FACT-G) Emotional Well Being (EWB) subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.929","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.460","ciUpperLimit":"1.398"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 1 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G EWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.922","ciPctValue":"95","ciLowerLimit":"0.469","ciUpperLimit":"1.375"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 2 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G EWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.918","ciPctValue":"95","ciLowerLimit":"0.471","ciUpperLimit":"1.365"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 2 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G EWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.911","ciPctValue":"95","ciLowerLimit":"0.469","ciUpperLimit":"1.352"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 3 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G EWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.907","ciPctValue":"95","ciLowerLimit":"0.466","ciUpperLimit":"1.348"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 3 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G EWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.899","ciPctValue":"95","ciLowerLimit":"0.453","ciUpperLimit":"1.345"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 4 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G EWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.895","ciPctValue":"95","ciLowerLimit":"0.444","ciUpperLimit":"1.347"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 4 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G EWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0002","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.888","ciPctValue":"95","ciLowerLimit":"0.421","ciUpperLimit":"1.355"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 5 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G EWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0003","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.884","ciPctValue":"95","ciLowerLimit":"0.406","ciUpperLimit":"1.362"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 5 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G EWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0006","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.877","ciPctValue":"95","ciLowerLimit":"0.375","ciUpperLimit":"1.379"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 6 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G EWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0009","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.873","ciPctValue":"95","ciLowerLimit":"0.356","ciUpperLimit":"1.390"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 6 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G EWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0020","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.866","ciPctValue":"95","ciLowerLimit":"0.318","ciUpperLimit":"1.414"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 7 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G EWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0029","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.862","ciPctValue":"95","ciLowerLimit":"0.295","ciUpperLimit":"1.428"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 7 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G EWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0055","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.854","ciPctValue":"95","ciLowerLimit":"0.251","ciUpperLimit":"1.457"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 8 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G EWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0076","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.850","ciPctValue":"95","ciLowerLimit":"0.226","ciUpperLimit":"1.475"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 8 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G EWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0129","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.843","ciPctValue":"95","ciLowerLimit":"0.179","ciUpperLimit":"1.508"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 9 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G EWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0168","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.839","ciPctValue":"95","ciLowerLimit":"0.151","ciUpperLimit":"1.527"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 9 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G EWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0257","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.832","ciPctValue":"95","ciLowerLimit":"0.101","ciUpperLimit":"1.563"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 10 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G EWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0318","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.828","ciPctValue":"95","ciLowerLimit":"0.072","ciUpperLimit":"1.583"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 10 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G EWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0447","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.821","ciPctValue":"95","ciLowerLimit":"0.019","ciUpperLimit":"1.622"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 11 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G EWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0529","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.817","ciPctValue":"95","ciLowerLimit":"-0.010","ciUpperLimit":"1.643"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 11 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G EWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0696","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.809","ciPctValue":"95","ciLowerLimit":"-0.065","ciUpperLimit":"1.683"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 12 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G EWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0797","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.805","ciPctValue":"95","ciLowerLimit":"-0.095","ciUpperLimit":"1.706"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 12 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G EWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0994","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.798","ciPctValue":"95","ciLowerLimit":"-0.151","ciUpperLimit":"1.747"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 13 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G EWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.1110","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.794","ciPctValue":"95","ciLowerLimit":"-0.182","ciUpperLimit":"1.770"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 13 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G EWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.1328","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.787","ciPctValue":"95","ciLowerLimit":"-0.239","ciUpperLimit":"1.813"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 14 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G EWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.1454","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.783","ciPctValue":"95","ciLowerLimit":"-0.271","ciUpperLimit":"1.836"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 14 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G EWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.1686","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.776","ciPctValue":"95","ciLowerLimit":"-0.329","ciUpperLimit":"1.880"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 15 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G EWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.1817","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.771","ciPctValue":"95","ciLowerLimit":"-0.361","ciUpperLimit":"1.904"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 15 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G EWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.2055","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.764","ciPctValue":"95","ciLowerLimit":"-0.419","ciUpperLimit":"1.948"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 16 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G EWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.2188","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.760","ciPctValue":"95","ciLowerLimit":"-0.452","ciUpperLimit":"1.972"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 16 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G EWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.2427","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.753","ciPctValue":"95","ciLowerLimit":"-0.510","ciUpperLimit":"2.016"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 17 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G EWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.2559","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.749","ciPctValue":"95","ciLowerLimit":"-0.543","ciUpperLimit":"2.041"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 17 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G EWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.2794","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.742","ciPctValue":"95","ciLowerLimit":"-0.602","ciUpperLimit":"2.086"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 18 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G EWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.2923","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.738","ciPctValue":"95","ciLowerLimit":"-0.635","ciUpperLimit":"2.111"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 18 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G EWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.3152","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.730","ciPctValue":"95","ciLowerLimit":"-0.695","ciUpperLimit":"2.156"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 19 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G EWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.3276","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.726","ciPctValue":"95","ciLowerLimit":"-0.728","ciUpperLimit":"2.181"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 19 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G EWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.3497","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.719","ciPctValue":"95","ciLowerLimit":"-0.788","ciUpperLimit":"2.227"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 20 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G EWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.3616","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.715","ciPctValue":"95","ciLowerLimit":"-0.822","ciUpperLimit":"2.252"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 20 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G EWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.3827","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.708","ciPctValue":"95","ciLowerLimit":"-0.882","ciUpperLimit":"2.298"}]},{"type":"SECONDARY","title":"Functional Assessment of Cancer Therapy-General (FACT-G): Functional Well Being (FWB) Subscale","description":"Functional well-being (FWB) subscale of the Functional Assessment of Cancer Therapy-General (FACT-G). Each question was answered on a five-point Likert-type scale ranging from 0 to 4 (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much). Score = the sum score of the item scores in the subscale; range: 0 to 28; higher score indicates greater functional well-being.","populationDescription":"ITT","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"scores on scale","timeFrame":"Day 1 & 28 of each cycle: duration of treatment phase","groups":[{"id":"OG000","title":"SU011248","description":"50 mg taken orally once a day for 4 weeks followed by a 2-week off treatment cycle to form a 6-week treatment cycle. Intra-subject dose reduction to 37.5 mg/day and 25 mg/day was allowed depending on type and severity of toxicity encountered."},{"id":"OG001","title":"IFN-α","description":"Subcutaneous (SC) injection in 6-week cycles on 3 non-consecutive days per week; 3 million units (MU) per dose Week 1; 6 MU per dose Week 2; 9 MU per dose Week 3 until completion of therapy or development of toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"375"},{"groupId":"OG001","value":"375"}]}],"classes":[{"title":"Baseline (n=371, 353)","categories":[{"measurements":[{"groupId":"OG000","value":"18.93","spread":"6.107"},{"groupId":"OG001","value":"18.51","spread":"6.389"}]}]},{"title":"Cycle 1 Day 28 (n=347, 318)","categories":[{"measurements":[{"groupId":"OG000","value":"17.92","spread":"6.083"},{"groupId":"OG001","value":"16.37","spread":"6.694"}]}]},{"title":"Cycle 2 Day 1 (n=328, 249)","categories":[{"measurements":[{"groupId":"OG000","value":"18.78","spread":"6.001"},{"groupId":"OG001","value":"17.08","spread":"6.279"}]}]},{"title":"Cycle 2 Day 28 (n=315, 238)","categories":[{"measurements":[{"groupId":"OG000","value":"18.37","spread":"6.210"},{"groupId":"OG001","value":"17.18","spread":"6.673"}]}]},{"title":"Cycle 3 Day 1 (n=294, 200)","categories":[{"measurements":[{"groupId":"OG000","value":"19.51","spread":"6.073"},{"groupId":"OG001","value":"17.92","spread":"6.251"}]}]},{"title":"Cycle 3 Day 28 (n=287, 195)","categories":[{"measurements":[{"groupId":"OG000","value":"18.58","spread":"5.994"},{"groupId":"OG001","value":"17.56","spread":"6.762"}]}]},{"title":"Cycle 4 Day 1 (n=272, 152)","categories":[{"measurements":[{"groupId":"OG000","value":"19.93","spread":"5.625"},{"groupId":"OG001","value":"18.40","spread":"6.382"}]}]},{"title":"Cycle 4 Day 28 (n=265, 142)","categories":[{"measurements":[{"groupId":"OG000","value":"18.86","spread":"5.694"},{"groupId":"OG001","value":"18.37","spread":"6.430"}]}]},{"title":"Cycle 5 Day 1 (n=249, 120)","categories":[{"measurements":[{"groupId":"OG000","value":"20.27","spread":"5.593"},{"groupId":"OG001","value":"18.81","spread":"5.697"}]}]},{"title":"Cycle 5 Day 28 (n=241, 109)","categories":[{"measurements":[{"groupId":"OG000","value":"19.02","spread":"5.829"},{"groupId":"OG001","value":"18.47","spread":"6.065"}]}]},{"title":"Cycle 6 Day 1 (n=239, 99)","categories":[{"measurements":[{"groupId":"OG000","value":"19.74","spread":"5.608"},{"groupId":"OG001","value":"19.02","spread":"6.114"}]}]},{"title":"Cycle 6 Day 28 (n=222, 99)","categories":[{"measurements":[{"groupId":"OG000","value":"19.21","spread":"5.678"},{"groupId":"OG001","value":"18.24","spread":"6.273"}]}]},{"title":"Cycle 7 Day 1 (n=208, 79)","categories":[{"measurements":[{"groupId":"OG000","value":"19.69","spread":"5.645"},{"groupId":"OG001","value":"18.45","spread":"6.761"}]}]},{"title":"Cycle 7 Day 28 (n=204, 75)","categories":[{"measurements":[{"groupId":"OG000","value":"19.12","spread":"5.798"},{"groupId":"OG001","value":"18.76","spread":"6.036"}]}]},{"title":"Cycle 8 Day 1 (n=192, 67)","categories":[{"measurements":[{"groupId":"OG000","value":"20.29","spread":"5.285"},{"groupId":"OG001","value":"19.22","spread":"5.828"}]}]},{"title":"Cycle 8 Day 28 (n=190, 62)","categories":[{"measurements":[{"groupId":"OG000","value":"19.33","spread":"5.627"},{"groupId":"OG001","value":"19.10","spread":"6.098"}]}]},{"title":"Cycle 9 Day 1 (n=170, 51)","categories":[{"measurements":[{"groupId":"OG000","value":"19.87","spread":"5.635"},{"groupId":"OG001","value":"20.20","spread":"5.455"}]}]},{"title":"Cycle 9 Day 28 (n=167, 46)","categories":[{"measurements":[{"groupId":"OG000","value":"19.27","spread":"5.701"},{"groupId":"OG001","value":"20.04","spread":"5.929"}]}]},{"title":"Cycle 10 Day 1 (n=161, 50)","categories":[{"measurements":[{"groupId":"OG000","value":"19.95","spread":"5.420"},{"groupId":"OG001","value":"19.88","spread":"5.903"}]}]},{"title":"Cycle 10 Day 28 (n=154, 46)","categories":[{"measurements":[{"groupId":"OG000","value":"19.22","spread":"5.494"},{"groupId":"OG001","value":"19.40","spread":"6.126"}]}]},{"title":"Cycle 11 Day 1 (n=137, 35)","categories":[{"measurements":[{"groupId":"OG000","value":"19.81","spread":"5.368"},{"groupId":"OG001","value":"18.89","spread":"6.014"}]}]},{"title":"Cycle 11 Day 28 (n=140, 33)","categories":[{"measurements":[{"groupId":"OG000","value":"19.12","spread":"5.749"},{"groupId":"OG001","value":"18.81","spread":"6.441"}]}]},{"title":"Cycle 12 Day 1 (n=132, 30)","categories":[{"measurements":[{"groupId":"OG000","value":"19.98","spread":"5.618"},{"groupId":"OG001","value":"18.80","spread":"6.599"}]}]},{"title":"Cycle 12 Day 28 (n=128, 31)","categories":[{"measurements":[{"groupId":"OG000","value":"19.42","spread":"5.755"},{"groupId":"OG001","value":"19.13","spread":"6.270"}]}]},{"title":"Cycle 13 Day 1 (n=114, 27)","categories":[{"measurements":[{"groupId":"OG000","value":"20.02","spread":"5.703"},{"groupId":"OG001","value":"19.63","spread":"6.918"}]}]},{"title":"Cycle 13 Day 28 (n=114, 27)","categories":[{"measurements":[{"groupId":"OG000","value":"19.65","spread":"5.216"},{"groupId":"OG001","value":"18.59","spread":"6.795"}]}]},{"title":"Cycle 14 Day 1 (n=114, 26)","categories":[{"measurements":[{"groupId":"OG000","value":"20.04","spread":"5.556"},{"groupId":"OG001","value":"19.62","spread":"6.020"}]}]},{"title":"Cycle 14 Day 28 (n=107, 25)","categories":[{"measurements":[{"groupId":"OG000","value":"19.07","spread":"6.025"},{"groupId":"OG001","value":"19.72","spread":"6.662"}]}]},{"title":"Cycle 15 Day 1 (n=101, 21)","categories":[{"measurements":[{"groupId":"OG000","value":"20.13","spread":"5.654"},{"groupId":"OG001","value":"19.86","spread":"6.327"}]}]},{"title":"Cycle 15 Day 28 (n=96, 20)","categories":[{"measurements":[{"groupId":"OG000","value":"19.24","spread":"5.589"},{"groupId":"OG001","value":"19.83","spread":"5.736"}]}]},{"title":"Cycle 16 Day 1 (n=96, 19)","categories":[{"measurements":[{"groupId":"OG000","value":"19.80","spread":"5.469"},{"groupId":"OG001","value":"18.89","spread":"6.154"}]}]},{"title":"Cycle 16 Day 28 (n=91, 18)","categories":[{"measurements":[{"groupId":"OG000","value":"19.53","spread":"5.313"},{"groupId":"OG001","value":"18.61","spread":"6.464"}]}]},{"title":"Cycle 17 Day 1 (n=85, 17)","categories":[{"measurements":[{"groupId":"OG000","value":"20.20","spread":"5.606"},{"groupId":"OG001","value":"19.35","spread":"6.103"}]}]},{"title":"Cycle 17 Day 28 (n=81, 14)","categories":[{"measurements":[{"groupId":"OG000","value":"19.67","spread":"5.662"},{"groupId":"OG001","value":"18.71","spread":"6.557"}]}]},{"title":"Cycle 18 Day 1 (n=80, 12)","categories":[{"measurements":[{"groupId":"OG000","value":"19.76","spread":"5.862"},{"groupId":"OG001","value":"19.08","spread":"7.317"}]}]},{"title":"Cycle 18 Day 28 (n=71, 11)","categories":[{"measurements":[{"groupId":"OG000","value":"19.47","spread":"5.526"},{"groupId":"OG001","value":"19.00","spread":"7.155"}]}]},{"title":"Cycle 19 Day 1 (n=71, 11)","categories":[{"measurements":[{"groupId":"OG000","value":"20.18","spread":"5.563"},{"groupId":"OG001","value":"19.64","spread":"7.500"}]}]},{"title":"Cycle 19 Day 28 (n=61, 10)","categories":[{"measurements":[{"groupId":"OG000","value":"19.59","spread":"6.326"},{"groupId":"OG001","value":"19.10","spread":"8.048"}]}]},{"title":"Cycle 20 Day 1 (n=65, 9)","categories":[{"measurements":[{"groupId":"OG000","value":"20.50","spread":"5.425"},{"groupId":"OG001","value":"20.00","spread":"7.826"}]}]},{"title":"Cycle 20 Day 28 (n=53, 9)","categories":[{"measurements":[{"groupId":"OG000","value":"20.15","spread":"5.819"},{"groupId":"OG001","value":"20.22","spread":"7.694"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 1 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline Functional Assessment of Cancer Therapy-General (FACT-G) Functional Well Being (FWB) subscale baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.897","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.261","ciUpperLimit":"2.533"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 1 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G FWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.924","ciPctValue":"95","ciLowerLimit":"1.309","ciUpperLimit":"2.539"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 2 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G FWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.939","ciPctValue":"95","ciLowerLimit":"1.331","ciUpperLimit":"2.546"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 2 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G FWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.965","ciPctValue":"95","ciLowerLimit":"1.363","ciUpperLimit":"2.568"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 3 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G FWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.980","ciPctValue":"95","ciLowerLimit":"1.376","ciUpperLimit":"2.584"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 3 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G FWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.007","ciPctValue":"95","ciLowerLimit":"1.392","ciUpperLimit":"2.622"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 4 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G FWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.022","ciPctValue":"95","ciLowerLimit":"1.396","ciUpperLimit":"2.647"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 4 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G FWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.048","ciPctValue":"95","ciLowerLimit":"1.397","ciUpperLimit":"2.700"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 5 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G FWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.063","ciPctValue":"95","ciLowerLimit":"1.394","ciUpperLimit":"2.732"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 5 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G FWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.090","ciPctValue":"95","ciLowerLimit":"1.383","ciUpperLimit":"2.797"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 6 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G FWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.105","ciPctValue":"95","ciLowerLimit":"1.374","ciUpperLimit":"2.836"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 6 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G FWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.132","ciPctValue":"95","ciLowerLimit":"1.353","ciUpperLimit":"2.910"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 7 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G FWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.146","ciPctValue":"95","ciLowerLimit":"1.339","ciUpperLimit":"2.954"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 7 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G FWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.173","ciPctValue":"95","ciLowerLimit":"1.311","ciUpperLimit":"3.036"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 8 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G FWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.188","ciPctValue":"95","ciLowerLimit":"1.294","ciUpperLimit":"3.082"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 8 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G FWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.215","ciPctValue":"95","ciLowerLimit":"1.260","ciUpperLimit":"3.169"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 9 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G FWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.230","ciPctValue":"95","ciLowerLimit":"1.241","ciUpperLimit":"3.219"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 9 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G FWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.256","ciPctValue":"95","ciLowerLimit":"1.203","ciUpperLimit":"3.309"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 10 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G FWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.271","ciPctValue":"95","ciLowerLimit":"1.182","ciUpperLimit":"3.361"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 10 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G FWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.298","ciPctValue":"95","ciLowerLimit":"1.142","ciUpperLimit":"3.454"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 11 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G FWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.313","ciPctValue":"95","ciLowerLimit":"1.119","ciUpperLimit":"3.507"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 11 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G FWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0003","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.340","ciPctValue":"95","ciLowerLimit":"1.076","ciUpperLimit":"3.603"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 12 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G FWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0004","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.354","ciPctValue":"95","ciLowerLimit":"1.052","ciUpperLimit":"3.657"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 12 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G FWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0007","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.381","ciPctValue":"95","ciLowerLimit":"1.008","ciUpperLimit":"3.754"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 13 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G FWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0009","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.396","ciPctValue":"95","ciLowerLimit":"0.983","ciUpperLimit":"3.809"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 13 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G FWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0014","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.423","ciPctValue":"95","ciLowerLimit":"0.938","ciUpperLimit":"3.908"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 14 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G FWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0017","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.438","ciPctValue":"95","ciLowerLimit":"0.912","ciUpperLimit":"3.963"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 14 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G FWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0025","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.464","ciPctValue":"95","ciLowerLimit":"0.866","ciUpperLimit":"4.063"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 15 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G FWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0030","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.479","ciPctValue":"95","ciLowerLimit":"0.840","ciUpperLimit":"4.119"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 15 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G FWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0042","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.506","ciPctValue":"95","ciLowerLimit":"0.792","ciUpperLimit":"4.219"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 16 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G FWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0049","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.521","ciPctValue":"95","ciLowerLimit":"0.766","ciUpperLimit":"4.275"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 16 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G FWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0064","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.547","ciPctValue":"95","ciLowerLimit":"0.718","ciUpperLimit":"4.377"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 17 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G FWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0073","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.562","ciPctValue":"95","ciLowerLimit":"0.691","ciUpperLimit":"4.433"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 17 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G FWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0091","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.589","ciPctValue":"95","ciLowerLimit":"0.643","ciUpperLimit":"4.535"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 18 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G FWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0103","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.604","ciPctValue":"95","ciLowerLimit":"0.616","ciUpperLimit":"4.592"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 18 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G FWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0125","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.631","ciPctValue":"95","ciLowerLimit":"0.567","ciUpperLimit":"4.695"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 19 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G FWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0138","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.645","ciPctValue":"95","ciLowerLimit":"0.539","ciUpperLimit":"4.752"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 19 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G FWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0164","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.672","ciPctValue":"95","ciLowerLimit":"0.490","ciUpperLimit":"4.855"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 20 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G FWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0179","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.687","ciPctValue":"95","ciLowerLimit":"0.462","ciUpperLimit":"4.912"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 20 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline FACT-G FWB subscale baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0208","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.714","ciPctValue":"95","ciLowerLimit":"0.413","ciUpperLimit":"5.015"}]},{"type":"SECONDARY","title":"EuroQoL Five Dimension (EQ-5D) Health State Index","description":"EQ-5D Health State Index: a brief, self-administered generic health status instrument. Respondents were asked to describe their current health state on each of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety or depression) on a three-level scale (1=no problem, 2=some problem, and 3=extreme problem). A maximum score of 1 can be derived from these 5 dimensions by score conversion; range: -0.39 (worst health state)to 1.00 (best health state). This descriptive system classifies respondents into one of 243 possible distinct health states (EQ-5D descriptive system).","populationDescription":"ITT; N=number of subjects with evaluable data; n=number of subjects with evaluable data at observation.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"scores on scale","timeFrame":"Day 1 & 28 of each cycle: duration of treatment phase","groups":[{"id":"OG000","title":"SU011248","description":"50 mg taken orally once a day for 4 weeks followed by a 2-week off treatment cycle to form a 6-week treatment cycle. Intra-subject dose reduction to 37.5 mg/day and 25 mg/day was allowed depending on type and severity of toxicity encountered."},{"id":"OG001","title":"IFN-α","description":"Subcutaneous (SC) injection in 6-week cycles on 3 non-consecutive days per week; 3 million units (MU) per dose Week 1; 6 MU per dose Week 2; 9 MU per dose Week 3 until completion of therapy or development of toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"375"},{"groupId":"OG001","value":"375"}]}],"classes":[{"title":"Baseline (n=363, 352)","categories":[{"measurements":[{"groupId":"OG000","value":"0.76","spread":"0.225"},{"groupId":"OG001","value":"0.76","spread":"0.234"}]}]},{"title":"Cycle 1 Day 28 (346, 315)","categories":[{"measurements":[{"groupId":"OG000","value":"0.72","spread":"0.262"},{"groupId":"OG001","value":"0.70","spread":"0.274"}]}]},{"title":"Cycle 2 Day 1 (326, 244)","categories":[{"measurements":[{"groupId":"OG000","value":"0.78","spread":"0.230"},{"groupId":"OG001","value":"0.75","spread":"0.231"}]}]},{"title":"Cycle 2 Day 28 (311, 233)","categories":[{"measurements":[{"groupId":"OG000","value":"0.73","spread":"0.246"},{"groupId":"OG001","value":"0.74","spread":"0.230"}]}]},{"title":"Cycle 3 Day 1 (287, 200)","categories":[{"measurements":[{"groupId":"OG000","value":"0.78","spread":"0.220"},{"groupId":"OG001","value":"0.76","spread":"0.222"}]}]},{"title":"Cycle 3 Day 28 (283, 195)","categories":[{"measurements":[{"groupId":"OG000","value":"0.75","spread":"0.231"},{"groupId":"OG001","value":"0.75","spread":"0.218"}]}]},{"title":"Cycle 4 Day 1 (269, 150)","categories":[{"measurements":[{"groupId":"OG000","value":"0.80","spread":"0.199"},{"groupId":"OG001","value":"0.80","spread":"0.190"}]}]},{"title":"Cycle 4 Day 28 (261, 142)","categories":[{"measurements":[{"groupId":"OG000","value":"0.76","spread":"0.218"},{"groupId":"OG001","value":"0.79","spread":"0.216"}]}]},{"title":"Cycle 5 Day 1 (247, 120)","categories":[{"measurements":[{"groupId":"OG000","value":"0.80","spread":"0.209"},{"groupId":"OG001","value":"0.79","spread":"0.194"}]}]},{"title":"Cycle 5 Day 28 (240, 106)","categories":[{"measurements":[{"groupId":"OG000","value":"0.76","spread":"0.223"},{"groupId":"OG001","value":"0.78","spread":"0.201"}]}]},{"title":"Cycle 6 Day 1 (240, 98)","categories":[{"measurements":[{"groupId":"OG000","value":"0.80","spread":"0.249"},{"groupId":"OG001","value":"0.80","spread":"0.178"}]}]},{"title":"Cycle 6 Day 28 (224, 100)","categories":[{"measurements":[{"groupId":"OG000","value":"0.77","spread":"0.206"},{"groupId":"OG001","value":"0.80","spread":"0.187"}]}]},{"title":"Cycle 7 Day 1 (205, 79)","categories":[{"measurements":[{"groupId":"OG000","value":"0.81","spread":"0.192"},{"groupId":"OG001","value":"0.80","spread":"0.185"}]}]},{"title":"Cycle 7 Day 28 (204, 74)","categories":[{"measurements":[{"groupId":"OG000","value":"0.77","spread":"0.221"},{"groupId":"OG001","value":"0.81","spread":"0.156"}]}]},{"title":"Cycle 8 Day 1 (192, 68)","categories":[{"measurements":[{"groupId":"OG000","value":"0.82","spread":"0.180"},{"groupId":"OG001","value":"0.82","spread":"0.158"}]}]},{"title":"Cycle 8 Day 28 (190, 61)","categories":[{"measurements":[{"groupId":"OG000","value":"0.77","spread":"0.222"},{"groupId":"OG001","value":"0.81","spread":"0.163"}]}]},{"title":"Cycle 9 Day 1 (170, 51)","categories":[{"measurements":[{"groupId":"OG000","value":"0.80","spread":"0.196"},{"groupId":"OG001","value":"0.84","spread":"0.162"}]}]},{"title":"Cycle 9 Day 28 (168, 45)","categories":[{"measurements":[{"groupId":"OG000","value":"0.78","spread":"0.194"},{"groupId":"OG001","value":"0.84","spread":"0.147"}]}]},{"title":"Cycle 10 Day 1 (161, 50)","categories":[{"measurements":[{"groupId":"OG000","value":"0.81","spread":"0.209"},{"groupId":"OG001","value":"0.85","spread":"0.161"}]}]},{"title":"Cycle 10 Day 28 (153, 46)","categories":[{"measurements":[{"groupId":"OG000","value":"0.78","spread":"0.200"},{"groupId":"OG001","value":"0.82","spread":"0.185"}]}]},{"title":"Cycle 11 Day 1 (138, 34)","categories":[{"measurements":[{"groupId":"OG000","value":"0.80","spread":"0.192"},{"groupId":"OG001","value":"0.85","spread":"0.159"}]}]},{"title":"Cycle 11 Day 28 (138, 32)","categories":[{"measurements":[{"groupId":"OG000","value":"0.75","spread":"0.189"},{"groupId":"OG001","value":"0.84","spread":"0.185"}]}]},{"title":"Cycle 12 Day 1 (132, 31)","categories":[{"measurements":[{"groupId":"OG000","value":"0.81","spread":"0.187"},{"groupId":"OG001","value":"0.82","spread":"0.283"}]}]},{"title":"Cycle 12 Day 28 (127, 31)","categories":[{"measurements":[{"groupId":"OG000","value":"0.77","spread":"0.182"},{"groupId":"OG001","value":"0.85","spread":"0.165"}]}]},{"title":"Cycle 13 Day 1 (114, 26)","categories":[{"measurements":[{"groupId":"OG000","value":"0.81","spread":"0.176"},{"groupId":"OG001","value":"0.83","spread":"0.231"}]}]},{"title":"Cycle 13 Day 28 (115, 27)","categories":[{"measurements":[{"groupId":"OG000","value":"0.77","spread":"0.186"},{"groupId":"OG001","value":"0.82","spread":"0.260"}]}]},{"title":"Cycle 14 Day 1 (114, 25)","categories":[{"measurements":[{"groupId":"OG000","value":"0.81","spread":"0.181"},{"groupId":"OG001","value":"0.86","spread":"0.148"}]}]},{"title":"Cycle 14 Day 28 (107, 24)","categories":[{"measurements":[{"groupId":"OG000","value":"0.75","spread":"0.224"},{"groupId":"OG001","value":"0.87","spread":"0.160"}]}]},{"title":"Cycle 15 Day 1 (100, 21)","categories":[{"measurements":[{"groupId":"OG000","value":"0.80","spread":"0.190"},{"groupId":"OG001","value":"0.88","spread":"0.146"}]}]},{"title":"Cycle 15 Day 28 (95, 20)","categories":[{"measurements":[{"groupId":"OG000","value":"0.75","spread":"0.209"},{"groupId":"OG001","value":"0.88","spread":"0.141"}]}]},{"title":"Cycle 16 Day 1 (96, 19)","categories":[{"measurements":[{"groupId":"OG000","value":"0.79","spread":"0.194"},{"groupId":"OG001","value":"0.84","spread":"0.163"}]}]},{"title":"Cycle 16 Day 28 (93, 18)","categories":[{"measurements":[{"groupId":"OG000","value":"0.76","spread":"0.181"},{"groupId":"OG001","value":"0.83","spread":"0.164"}]}]},{"title":"Cycle 17 Day 1 (84, 15)","categories":[{"measurements":[{"groupId":"OG000","value":"0.79","spread":"0.194"},{"groupId":"OG001","value":"0.88","spread":"0.169"}]}]},{"title":"Cycle 17 Day 28 (82, 14)","categories":[{"measurements":[{"groupId":"OG000","value":"0.77","spread":"0.168"},{"groupId":"OG001","value":"0.83","spread":"0.174"}]}]},{"title":"Cycle 18 Day 1 (80, 12)","categories":[{"measurements":[{"groupId":"OG000","value":"0.81","spread":"0.187"},{"groupId":"OG001","value":"0.86","spread":"0.274"}]}]},{"title":"Cycle 18 Day 28 (71, 10)","categories":[{"measurements":[{"groupId":"OG000","value":"0.76","spread":"0.166"},{"groupId":"OG001","value":"0.84","spread":"0.279"}]}]},{"title":"Cycle 19 Day 1 (69, 11)","categories":[{"measurements":[{"groupId":"OG000","value":"0.81","spread":"0.183"},{"groupId":"OG001","value":"0.88","spread":"0.184"}]}]},{"title":"Cycle 19 Day 28 (62, 11)","categories":[{"measurements":[{"groupId":"OG000","value":"0.78","spread":"0.165"},{"groupId":"OG001","value":"0.72","spread":"0.436"}]}]},{"title":"Cycle 20 Day 1 (63, 8)","categories":[{"measurements":[{"groupId":"OG000","value":"0.81","spread":"0.162"},{"groupId":"OG001","value":"0.85","spread":"0.182"}]}]},{"title":"Cycle 20 Day 28 (54, 9)","categories":[{"measurements":[{"groupId":"OG000","value":"0.77","spread":"0.181"},{"groupId":"OG001","value":"0.86","spread":"0.215"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 1 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EuroQoL Five Dimension (EQ-5D): Health state index baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0004","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.049","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.022","ciUpperLimit":"0.076"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 1 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-5D Health state index baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0003","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.048","ciPctValue":"95","ciLowerLimit":"0.022","ciUpperLimit":"0.075"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 2 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-5D Health state index baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0003","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.048","ciPctValue":"95","ciLowerLimit":"0.022","ciUpperLimit":"0.074"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 2 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-5D Health state index baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0003","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.047","ciPctValue":"95","ciLowerLimit":"0.021","ciUpperLimit":"0.072"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 3 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-5D Health state index baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0004","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.046","ciPctValue":"95","ciLowerLimit":"0.021","ciUpperLimit":"0.072"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 3 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-5D Health state index baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0005","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.045","ciPctValue":"95","ciLowerLimit":"0.020","ciUpperLimit":"0.071"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 4 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-5D Health state index baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0007","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.045","ciPctValue":"95","ciLowerLimit":"0.019","ciUpperLimit":"0.070"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 4 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-5D Health state index baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0011","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.044","ciPctValue":"95","ciLowerLimit":"0.017","ciUpperLimit":"0.070"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 5 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-5D Health state index baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0016","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.043","ciPctValue":"95","ciLowerLimit":"0.016","ciUpperLimit":"0.070"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 5 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-5D Health state index baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0029","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.042","ciPctValue":"95","ciLowerLimit":"0.014","ciUpperLimit":"0.070"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 6 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-5D Health state index baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0041","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.042","ciPctValue":"95","ciLowerLimit":"0.013","ciUpperLimit":"0.070"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 6 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-5D Health state index baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0076","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.041","ciPctValue":"95","ciLowerLimit":"0.011","ciUpperLimit":"0.071"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 7 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-5D Health state index baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0105","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.040","ciPctValue":"95","ciLowerLimit":"0.009","ciUpperLimit":"0.071"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 7 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-5D Health state index baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0179","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.039","ciPctValue":"95","ciLowerLimit":"0.007","ciUpperLimit":"0.072"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 8 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-5D Health state index baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0236","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.039","ciPctValue":"95","ciLowerLimit":"0.005","ciUpperLimit":"0.072"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 8 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-5D Health state index baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0370","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.038","ciPctValue":"95","ciLowerLimit":"0.002","ciUpperLimit":"0.073"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 9 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-5D Health state index baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0464","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.037","ciPctValue":"95","ciLowerLimit":"0.001","ciUpperLimit":"0.074"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 9 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-5D Health state index baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0667","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.036","ciPctValue":"95","ciLowerLimit":"-0.002","ciUpperLimit":"0.075"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 10 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-5D Health state index baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0800","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.036","ciPctValue":"95","ciLowerLimit":"-0.004","ciUpperLimit":"0.076"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 10 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-5D Health state index baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.1070","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.035","ciPctValue":"95","ciLowerLimit":"-0.007","ciUpperLimit":"0.077"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 11 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-5D Health state index baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.1237","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.034","ciPctValue":"95","ciLowerLimit":"-0.009","ciUpperLimit":"0.078"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 11 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-5D Health state index baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.1561","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.033","ciPctValue":"95","ciLowerLimit":"-0.013","ciUpperLimit":"0.079"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 12 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-5D Health state index baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.1752","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.033","ciPctValue":"95","ciLowerLimit":"-0.015","ciUpperLimit":"0.080"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 12 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-5D Health state index baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.2112","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.032","ciPctValue":"95","ciLowerLimit":"-0.018","ciUpperLimit":"0.081"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 13 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-5D Health state index baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.2319","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.031","ciPctValue":"95","ciLowerLimit":"-0.020","ciUpperLimit":"0.082"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 13 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-5D Health state index baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.2698","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.030","ciPctValue":"95","ciLowerLimit":"-0.023","ciUpperLimit":"0.084"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 14 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-5D Health state index baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.2910","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.030","ciPctValue":"95","ciLowerLimit":"-0.025","ciUpperLimit":"0.085"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 14 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-5D Health state index baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.3293","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.029","ciPctValue":"95","ciLowerLimit":"-0.029","ciUpperLimit":"0.086"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 15 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-5D Health state index baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.3504","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.028","ciPctValue":"95","ciLowerLimit":"-0.031","ciUpperLimit":"0.087"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 15 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-5D Health state index baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.3881","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.027","ciPctValue":"95","ciLowerLimit":"-0.034","ciUpperLimit":"0.089"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 16 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-5D Health state index baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.4086","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.027","ciPctValue":"95","ciLowerLimit":"-0.036","ciUpperLimit":"0.090"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 16 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-5D Health state index baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.4449","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.026","ciPctValue":"95","ciLowerLimit":"-0.040","ciUpperLimit":"0.091"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 17 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-5D Health state index baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.4646","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.025","ciPctValue":"95","ciLowerLimit":"-0.042","ciUpperLimit":"0.092"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 17 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-5D Health state index baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.4990","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.024","ciPctValue":"95","ciLowerLimit":"-0.046","ciUpperLimit":"0.094"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 18 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-5D Health state index baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.5176","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.024","ciPctValue":"95","ciLowerLimit":"-0.048","ciUpperLimit":"0.095"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 18 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-5D Health state index baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.5501","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.023","ciPctValue":"95","ciLowerLimit":"-0.051","ciUpperLimit":"0.097"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 19 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-5D Health state index baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.5675","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.022","ciPctValue":"95","ciLowerLimit":"-0.054","ciUpperLimit":"0.098"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 19 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-5D Health state index baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.5979","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.021","ciPctValue":"95","ciLowerLimit":"-0.057","ciUpperLimit":"0.099"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 20 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-5D Health state index baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.6141","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.021","ciPctValue":"95","ciLowerLimit":"-0.059","ciUpperLimit":"0.100"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 20 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-5D Health state index baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.6424","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.020","ciPctValue":"95","ciLowerLimit":"-0.063","ciUpperLimit":"0.102"}]},{"type":"SECONDARY","title":"Euro-QoL Visual Analog Scale (EQ-VAS)","description":"EQ-VAS: overall self-rating rating of the patient's current health state using a 20 cm Visual Analog Scale (EQ-VAS), also called the health state thermometer) is a metric measurement (in 2 mm interval) from the visual analog scale which ranges between 0 (worse imaginable health state) and 100 (best imaginable health state).","populationDescription":"ITT; N=number of subjects with evaluable data; n=number of subjects with evaluable data at observation.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"scores on scale","timeFrame":"Day 1 & 28 of each cycle: duration of treatment phase","groups":[{"id":"OG000","title":"SU011248","description":"50 mg taken orally once a day for 4 weeks followed by a 2-week off treatment cycle to form a 6-week treatment cycle. Intra-subject dose reduction to 37.5 mg/day and 25 mg/day was allowed depending on type and severity of toxicity encountered."},{"id":"OG001","title":"IFN-α","description":"Subcutaneous (SC) injection in 6-week cycles on 3 non-consecutive days per week; 3 million units (MU) per dose Week 1; 6 MU per dose Week 2; 9 MU per dose Week 3 until completion of therapy or development of toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"375"},{"groupId":"OG001","value":"375"}]}],"classes":[{"title":"Baseline (n=365, 352)","categories":[{"measurements":[{"groupId":"OG000","value":"73.80","spread":"18.498"},{"groupId":"OG001","value":"71.43","spread":"19.507"}]}]},{"title":"Cycle 1 Day 28 (n=347, 315)","categories":[{"measurements":[{"groupId":"OG000","value":"69.35","spread":"18.992"},{"groupId":"OG001","value":"67.66","spread":"20.058"}]}]},{"title":"Cycle 2 Day 1 (n=323, 247)","categories":[{"measurements":[{"groupId":"OG000","value":"75.05","spread":"17.964"},{"groupId":"OG001","value":"70.45","spread":"17.653"}]}]},{"title":"Cycle 2 Day 28 (n=314, 237)","categories":[{"measurements":[{"groupId":"OG000","value":"72.06","spread":"18.297"},{"groupId":"OG001","value":"70.70","spread":"18.271"}]}]},{"title":"Cycle 3 Day 1 (n=293, 198)","categories":[{"measurements":[{"groupId":"OG000","value":"76.23","spread":"17.171"},{"groupId":"OG001","value":"72.68","spread":"17.162"}]}]},{"title":"Cycle 3 Day 28 (n=287, 193)","categories":[{"measurements":[{"groupId":"OG000","value":"72.33","spread":"18.472"},{"groupId":"OG001","value":"71.45","spread":"18.315"}]}]},{"title":"Cycle 4 Day 1 (n=270, 152)","categories":[{"measurements":[{"groupId":"OG000","value":"77.46","spread":"16.024"},{"groupId":"OG001","value":"72.74","spread":"17.678"}]}]},{"title":"Cycle 4 Day 28 (n=264, 139)","categories":[{"measurements":[{"groupId":"OG000","value":"75.15","spread":"16.406"},{"groupId":"OG001","value":"72.20","spread":"18.098"}]}]},{"title":"Cycle 5 Day 1 (n=248, 118)","categories":[{"measurements":[{"groupId":"OG000","value":"79.83","spread":"13.554"},{"groupId":"OG001","value":"73.44","spread":"16.204"}]}]},{"title":"Cycle 5 Day 28 (n=240, 104)","categories":[{"measurements":[{"groupId":"OG000","value":"75.13","spread":"16.771"},{"groupId":"OG001","value":"72.57","spread":"16.007"}]}]},{"title":"Cycle 6 Day 1 (n=237, 99)","categories":[{"measurements":[{"groupId":"OG000","value":"78.83","spread":"15.359"},{"groupId":"OG001","value":"73.68","spread":"16.537"}]}]},{"title":"Cycle 6 Day 28 (n=223, 98)","categories":[{"measurements":[{"groupId":"OG000","value":"76.81","spread":"15.204"},{"groupId":"OG001","value":"72.26","spread":"18.452"}]}]},{"title":"Cycle 7 Day 1 (n=209, 77)","categories":[{"measurements":[{"groupId":"OG000","value":"79.39","spread":"14.601"},{"groupId":"OG001","value":"73.80","spread":"18.868"}]}]},{"title":"Cycle 7 Day 28 (n=201, 74)","categories":[{"measurements":[{"groupId":"OG000","value":"76.09","spread":"16.693"},{"groupId":"OG001","value":"73.46","spread":"17.380"}]}]},{"title":"Cycle 8 Day 1 (n=192, 67)","categories":[{"measurements":[{"groupId":"OG000","value":"81.34","spread":"13.020"},{"groupId":"OG001","value":"74.27","spread":"18.067"}]}]},{"title":"Cycle 8 Day 28 (n=191, 60)","categories":[{"measurements":[{"groupId":"OG000","value":"77.53","spread":"14.374"},{"groupId":"OG001","value":"74.33","spread":"18.407"}]}]},{"title":"Cycle 9 Day 1 (n=172, 50)","categories":[{"measurements":[{"groupId":"OG000","value":"80.08","spread":"13.812"},{"groupId":"OG001","value":"77.66","spread":"15.987"}]}]},{"title":"Cycle 9 Day 28 (n=168, 46)","categories":[{"measurements":[{"groupId":"OG000","value":"76.24","spread":"15.740"},{"groupId":"OG001","value":"76.57","spread":"17.924"}]}]},{"title":"Cycle 10 Day 1 (n=160, 50)","categories":[{"measurements":[{"groupId":"OG000","value":"79.18","spread":"14.912"},{"groupId":"OG001","value":"76.64","spread":"17.886"}]}]},{"title":"Cycle 10 Day 28 (n=154, 45)","categories":[{"measurements":[{"groupId":"OG000","value":"76.44","spread":"16.106"},{"groupId":"OG001","value":"76.69","spread":"19.123"}]}]},{"title":"Cycle 11 Day 1 (n=138, 34)","categories":[{"measurements":[{"groupId":"OG000","value":"79.72","spread":"15.685"},{"groupId":"OG001","value":"75.06","spread":"20.179"}]}]},{"title":"Cycle 11 Day 28 (n=141, 33)","categories":[{"measurements":[{"groupId":"OG000","value":"76.81","spread":"15.128"},{"groupId":"OG001","value":"72.21","spread":"23.202"}]}]},{"title":"Cycle 12 Day 1 (n=130, 31)","categories":[{"measurements":[{"groupId":"OG000","value":"80.84","spread":"14.150"},{"groupId":"OG001","value":"75.19","spread":"22.020"}]}]},{"title":"Cycle 12 Day 28 (n=128, 31)","categories":[{"measurements":[{"groupId":"OG000","value":"76.71","spread":"14.986"},{"groupId":"OG001","value":"73.84","spread":"20.775"}]}]},{"title":"Cycle 13 Day 1 (n=114, 27)","categories":[{"measurements":[{"groupId":"OG000","value":"80.59","spread":"14.875"},{"groupId":"OG001","value":"77.52","spread":"17.738"}]}]},{"title":"Cycle 13 Day 28 (n=115, 27)","categories":[{"measurements":[{"groupId":"OG000","value":"77.22","spread":"14.715"},{"groupId":"OG001","value":"73.56","spread":"23.523"}]}]},{"title":"Cycle 14 Day 1 (n=114, 26)","categories":[{"measurements":[{"groupId":"OG000","value":"80.39","spread":"14.477"},{"groupId":"OG001","value":"76.69","spread":"16.601"}]}]},{"title":"Cycle 14 Day 28 (n=107, 25)","categories":[{"measurements":[{"groupId":"OG000","value":"76.53","spread":"15.933"},{"groupId":"OG001","value":"76.44","spread":"18.890"}]}]},{"title":"Cycle 15 Day 1 (n=101, 21)","categories":[{"measurements":[{"groupId":"OG000","value":"80.50","spread":"14.361"},{"groupId":"OG001","value":"76.62","spread":"19.075"}]}]},{"title":"Cycle 15 Day 28 (n=96, 20)","categories":[{"measurements":[{"groupId":"OG000","value":"76.51","spread":"15.141"},{"groupId":"OG001","value":"76.50","spread":"18.841"}]}]},{"title":"Cycle 16 Day 1 (n=96, 19)","categories":[{"measurements":[{"groupId":"OG000","value":"79.85","spread":"15.632"},{"groupId":"OG001","value":"74.84","spread":"21.680"}]}]},{"title":"Cycle 16 Day 28 (n=92, 18)","categories":[{"measurements":[{"groupId":"OG000","value":"75.51","spread":"17.687"},{"groupId":"OG001","value":"73.11","spread":"21.202"}]}]},{"title":"Cycle 17 Day 1 (n=84, 17)","categories":[{"measurements":[{"groupId":"OG000","value":"80.74","spread":"15.706"},{"groupId":"OG001","value":"76.94","spread":"21.256"}]}]},{"title":"Cycle 17 Day 28 (n=82, 14)","categories":[{"measurements":[{"groupId":"OG000","value":"77.10","spread":"16.612"},{"groupId":"OG001","value":"72.86","spread":"22.593"}]}]},{"title":"Cycle 18 Day 1 (n=78, 12)","categories":[{"measurements":[{"groupId":"OG000","value":"80.40","spread":"14.658"},{"groupId":"OG001","value":"74.42","spread":"25.065"}]}]},{"title":"Cycle 18 Day 28 (n=70, 11)","categories":[{"measurements":[{"groupId":"OG000","value":"77.76","spread":"16.142"},{"groupId":"OG001","value":"73.82","spread":"24.140"}]}]},{"title":"Cycle 19 Day 1 (n=70, 11)","categories":[{"measurements":[{"groupId":"OG000","value":"81.47","spread":"15.330"},{"groupId":"OG001","value":"79.27","spread":"20.283"}]}]},{"title":"Cycle 19 Day 28 (n=62, 11)","categories":[{"measurements":[{"groupId":"OG000","value":"77.05","spread":"18.676"},{"groupId":"OG001","value":"68.55","spread":"29.717"}]}]},{"title":"Cycle 20 Day 1 (n=65, 9)","categories":[{"measurements":[{"groupId":"OG000","value":"81.10","spread":"15.404"},{"groupId":"OG001","value":"76.00","spread":"21.494"}]}]},{"title":"Cycle 20 Day 28 (n=54, 9)","categories":[{"measurements":[{"groupId":"OG000","value":"76.85","spread":"16.863"},{"groupId":"OG001","value":"75.44","spread":"25.060"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 1 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline Euro-QoL Visual Analog Scale (EQ-VAS) baseline score (intercept and time since randomization are included as random effects).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"4.026","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.088","ciUpperLimit":"5.965"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 1 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-VAS baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"4.165","ciPctValue":"95","ciLowerLimit":"2.269","ciUpperLimit":"6.061"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 2 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-VAS baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"4.243","ciPctValue":"95","ciLowerLimit":"2.358","ciUpperLimit":"6.128"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 2 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-VAS baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"4.382","ciPctValue":"95","ciLowerLimit":"2.494","ciUpperLimit":"6.269"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 3 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-VAS baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"4.459","ciPctValue":"95","ciLowerLimit":"2.558","ciUpperLimit":"6.361"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 3 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-VAS baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"4.598","ciPctValue":"95","ciLowerLimit":"2.650","ciUpperLimit":"6.547"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 4 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-VAS baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"4.676","ciPctValue":"95","ciLowerLimit":"2.689","ciUpperLimit":"6.662"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 4 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-VAS baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"4.815","ciPctValue":"95","ciLowerLimit":"2.741","ciUpperLimit":"6.889"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 5 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-VAS baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"4.892","ciPctValue":"95","ciLowerLimit":"2.760","ciUpperLimit":"7.024"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 5 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-VAS baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"5.031","ciPctValue":"95","ciLowerLimit":"2.780","ciUpperLimit":"7.283"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 6 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-VAS baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"5.109","ciPctValue":"95","ciLowerLimit":"2.783","ciUpperLimit":"7.435"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 6 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-VAS baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"5.248","ciPctValue":"95","ciLowerLimit":"2.776","ciUpperLimit":"7.720"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 7 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-VAS baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"5.325","ciPctValue":"95","ciLowerLimit":"2.767","ciUpperLimit":"7.884"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 7 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-VAS baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"5.464","ciPctValue":"95","ciLowerLimit":"2.741","ciUpperLimit":"8.188"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 8 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-VAS baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"5.542","ciPctValue":"95","ciLowerLimit":"2.723","ciUpperLimit":"8.361"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 8 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-VAS baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0002","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"5.681","ciPctValue":"95","ciLowerLimit":"2.683","ciUpperLimit":"8.679"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 9 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-VAS baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0003","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"5.758","ciPctValue":"95","ciLowerLimit":"2.657","ciUpperLimit":"8.859"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 9 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-VAS baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0004","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"5.898","ciPctValue":"95","ciLowerLimit":"2.607","ciUpperLimit":"9.188"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 10 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-VAS baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0006","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"5.975","ciPctValue":"95","ciLowerLimit":"2.576","ciUpperLimit":"9.374"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 10 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-VAS baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0009","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"6.114","ciPctValue":"95","ciLowerLimit":"2.517","ciUpperLimit":"9.711"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 11 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-VAS baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0011","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"6.191","ciPctValue":"95","ciLowerLimit":"2.482","ciUpperLimit":"9.900"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 11 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-VAS baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0015","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"6.331","ciPctValue":"95","ciLowerLimit":"2.417","ciUpperLimit":"10.244"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 12 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-VAS baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0018","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"6.408","ciPctValue":"95","ciLowerLimit":"2.379","ciUpperLimit":"10.436"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 12 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-VAS baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0025","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"6.547","ciPctValue":"95","ciLowerLimit":"2.309","ciUpperLimit":"10.785"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 13 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-VAS baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0029","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"6.624","ciPctValue":"95","ciLowerLimit":"2.269","ciUpperLimit":"10.980"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 13 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-VAS baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0037","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"6.764","ciPctValue":"95","ciLowerLimit":"2.195","ciUpperLimit":"11.332"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 14 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-VAS baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0042","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"6.841","ciPctValue":"95","ciLowerLimit":"2.153","ciUpperLimit":"11.529"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 14 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-VAS baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0053","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"6.980","ciPctValue":"95","ciLowerLimit":"2.076","ciUpperLimit":"11.884"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 15 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-VAS baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0059","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"7.057","ciPctValue":"95","ciLowerLimit":"2.032","ciUpperLimit":"12.083"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 15 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-VAS baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0072","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"7.197","ciPctValue":"95","ciLowerLimit":"1.953","ciUpperLimit":"12.441"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 16 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-VAS baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0079","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"7.274","ciPctValue":"95","ciLowerLimit":"1.908","ciUpperLimit":"12.640"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 16 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-VAS baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0093","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"7.413","ciPctValue":"95","ciLowerLimit":"1.826","ciUpperLimit":"13.000"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 17 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-VAS baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0101","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"7.491","ciPctValue":"95","ciLowerLimit":"1.780","ciUpperLimit":"13.201"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 17 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-VAS baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0117","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"7.630","ciPctValue":"95","ciLowerLimit":"1.697","ciUpperLimit":"13.562"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 18 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-VAS baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0126","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"7.707","ciPctValue":"95","ciLowerLimit":"1.650","ciUpperLimit":"13.764"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 18 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-VAS baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0144","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"7.846","ciPctValue":"95","ciLowerLimit":"1.565","ciUpperLimit":"14.127"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 19 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-VAS baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0153","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"7.924","ciPctValue":"95","ciLowerLimit":"1.518","ciUpperLimit":"14.329"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 19 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-VAS baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0172","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"8.063","ciPctValue":"95","ciLowerLimit":"1.432","ciUpperLimit":"14.693"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 20 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-VAS baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0182","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"8.140","ciPctValue":"95","ciLowerLimit":"1.384","ciUpperLimit":"14.896"},{"groupIds":["OG000","OG001"],"groupDescription":"Cycle 20 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed-effects model with an intercept term, treatment, time since randomization, treatment-by-time interaction, and baseline EQ-VAS baseline score (intercept and time since randomization are included as random effects)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0201","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"8.279","ciPctValue":"95","ciLowerLimit":"1.297","ciUpperLimit":"15.261"}]},{"type":"SECONDARY","title":"Plasma Concentrations of Soluble Proteins: Plasma VEGF-A, Plasma VEGF-C, Plasma sVEGFR-3, PLASMA IL-8, and PLASMA bFGF That May be Associated With Tumor Proliferation or Angiogenesis","description":"Plasma concentrations of soluble proteins that may be associated with tumor proliferation or angiogenesis collected from a subset of patients were analyzed by enzyme-linked immunosorbent assay (ELISA) analysis. Soluble protein values: Baseline concentration (pM) and ratio to Baseline at each timepoint; ratio = plasma concentration of soluble protein (picograms per milliliter \\[pg/ml\\]) at timepoint / concentration of soluble protein (pg/ml) at baseline. Samples below the limit of quantitation and samples with insufficient volume available were excluded.","populationDescription":"Pharmacodynamic analyses performed at selected sites on AT population who had at least one pharmacokinetic sample; n= SU011248, INF-α; Abbreviations: C: Cycle, D: Day, VEGF: vascular endothelial growth factor, sVEGFR-3: soluble vascular endothelial growth factor Receptor-3, IL-8: interleukin-8, bFGF: basic fibroblast growth factor.\n\n.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"pg/ml and ratio to Baseline","timeFrame":"Day 1 & Day 28, Cycle 1 to Cycle 4","groups":[{"id":"OG000","title":"SU011248","description":"50 mg taken orally once a day for 4 weeks followed by a 2-week off treatment cycle to form a 6-week treatment cycle. Intra-subject dose reduction to 37.5 mg/day and 25 mg/day was allowed depending on type and severity of toxicity encountered."},{"id":"OG001","title":"IFN-α","description":"Subcutaneous (SC) injection in 6-week cycles on 3 non-consecutive days per week; 3 million units (MU) per dose Week 1; 6 MU per dose Week 2; 9 MU per dose Week 3 until completion of therapy or development of toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"31"}]}],"classes":[{"title":"Plasma VEGF-A: Baseline (n=33, 31)","categories":[{"measurements":[{"groupId":"OG000","value":"101.9","spread":"184.3"},{"groupId":"OG001","value":"109.0","spread":"242.4"}]}]},{"title":"Plasma VEGF-A: C1D28: C1D1 (n=31, 26)","categories":[{"measurements":[{"groupId":"OG000","value":"4.280","spread":"2.619"},{"groupId":"OG001","value":"1.134","spread":"0.683"}]}]},{"title":"Plasma VEGF-A: C2D1: C1D1 (n=32, 21)","categories":[{"measurements":[{"groupId":"OG000","value":"1.161","spread":"0.624"},{"groupId":"OG001","value":"1.171","spread":"0.527"}]}]},{"title":"Plasma VEGF-A: C2D28: C1D1 (n=31, 20)","categories":[{"measurements":[{"groupId":"OG000","value":"5.851","spread":"4.345"},{"groupId":"OG001","value":"1.153","spread":"0.517"}]}]},{"title":"Plasma VEGF-A: C3D1: C1D1 (n=27, 15)","categories":[{"measurements":[{"groupId":"OG000","value":"1.630","spread":"1.685"},{"groupId":"OG001","value":"1.253","spread":"0.483"}]}]},{"title":"Plasma VEGF-A: C3D28: C1D1 (n=28, 15)","categories":[{"measurements":[{"groupId":"OG000","value":"5.236","spread":"3.333"},{"groupId":"OG001","value":"1.149","spread":"0.570"}]}]},{"title":"Plasma VEGF-A: C4D1: C1D1 (n=27, 12)","categories":[{"measurements":[{"groupId":"OG000","value":"1.486","spread":"1.125"},{"groupId":"OG001","value":"1.209","spread":"0.654"}]}]},{"title":"Plasma VEGF-A: C4D28: C1D1 (n=25, 11)","categories":[{"measurements":[{"groupId":"OG000","value":"4.924","spread":"3.679"},{"groupId":"OG001","value":"1.008","spread":"0.372"}]}]},{"title":"Plasma VEGF-C: Baseline (n=35, 31)","categories":[{"measurements":[{"groupId":"OG000","value":"556.4","spread":"311.7"},{"groupId":"OG001","value":"651.2","spread":"552.3"}]}]},{"title":"Plasma VEGF-C: C1D28: C1D1 (n=31, 26)","categories":[{"measurements":[{"groupId":"OG000","value":"0.945","spread":"0.428"},{"groupId":"OG001","value":"1.165","spread":"0.606"}]}]},{"title":"Plasma VEGF-C: C2D1:C1D1 (n=30, 21)","categories":[{"measurements":[{"groupId":"OG000","value":"1.045","spread":"0.623"},{"groupId":"OG001","value":"1.177","spread":"0.464"}]}]},{"title":"Plasma VEGF-C: C2D28:C1D1 (n=31, 19)","categories":[{"measurements":[{"groupId":"OG000","value":"0.871","spread":"0.511"},{"groupId":"OG001","value":"1.081","spread":"0.410"}]}]},{"title":"Plasma VEGF-C: C3D1:C1D1 (n=28, 15)","categories":[{"measurements":[{"groupId":"OG000","value":"1.159","spread":"0.659"},{"groupId":"OG001","value":"1.174","spread":"0.588"}]}]},{"title":"Plasma VEGF-C: C3D28:C1D1 (n=28, 15)","categories":[{"measurements":[{"groupId":"OG000","value":"1.043","spread":"0.926"},{"groupId":"OG001","value":"1.054","spread":"0.586"}]}]},{"title":"Plasma VEGF-C: C4D1:C1D1 (n=28, 12)","categories":[{"measurements":[{"groupId":"OG000","value":"1.243","spread":"1.304"},{"groupId":"OG001","value":"1.382","spread":"0.799"}]}]},{"title":"Plasma VEGF-C: C4:D28:C1D1 (n=26, 11)","categories":[{"measurements":[{"groupId":"OG000","value":"1.207","spread":"1.269"},{"groupId":"OG001","value":"1.139","spread":"0.403"}]}]},{"title":"PLASMA sVEGFR-3: Baseline (n=29, 30)","categories":[{"measurements":[{"groupId":"OG000","value":"44049.3","spread":"20168.2"},{"groupId":"OG001","value":"40317.7","spread":"12938.3"}]}]},{"title":"PLASMA sVEGFR-3: C1D28:C1D1 (n=27, 25)","categories":[{"measurements":[{"groupId":"OG000","value":"0.473","spread":"0.185"},{"groupId":"OG001","value":"1.068","spread":"0.292"}]}]},{"title":"PLASMA sVEGFR-3: C2D1:C1D1 (n=28, 20)","categories":[{"measurements":[{"groupId":"OG000","value":"0.787","spread":"0.172"},{"groupId":"OG001","value":"1.075","spread":"0.331"}]}]},{"title":"PLASMA sVEGFR-3: C2D28:C1D1 (n=28, 19)","categories":[{"measurements":[{"groupId":"OG000","value":"0.407","spread":"0.173"},{"groupId":"OG001","value":"1.150","spread":"0.355"}]}]},{"title":"PLASMA sVEGFR-3: C3D1:C1D1 (n=25, 14)","categories":[{"measurements":[{"groupId":"OG000","value":"0.800","spread":"0.309"},{"groupId":"OG001","value":"1.015","spread":"0.210"}]}]},{"title":"PLASMA sVEGFR-3: C3D28:C1D1 (n=25, 14)","categories":[{"measurements":[{"groupId":"OG000","value":"0.427","spread":"0.194"},{"groupId":"OG001","value":"1.042","spread":"0.349"}]}]},{"title":"PLASMA sVEGFR-3: C4D1:C1D1 (n=24, 11)","categories":[{"measurements":[{"groupId":"OG000","value":"0.846","spread":"0.380"},{"groupId":"OG001","value":"1.183","spread":"0.333"}]}]},{"title":"PLASMA sVEGFR-3: C4:D28:C1D1 (n=23, 10)","categories":[{"measurements":[{"groupId":"OG000","value":"0.486","spread":"0.265"},{"groupId":"OG001","value":"1.044","spread":"0.141"}]}]},{"title":"PLASMA IL-8: Baseline (n=31, 29)","categories":[{"measurements":[{"groupId":"OG000","value":"10.1","spread":"9.7"},{"groupId":"OG001","value":"18.6","spread":"32.0"}]}]},{"title":"PLASMA IL-8: C1D28:C1D1 (n=29, 25)","categories":[{"measurements":[{"groupId":"OG000","value":"2.815","spread":"1.340"},{"groupId":"OG001","value":"2.297","spread":"2.036"}]}]},{"title":"PLASMA IL-8: C2D1:C1D1 (n=29, 20)","categories":[{"measurements":[{"groupId":"OG000","value":"1.716","spread":"0.630"},{"groupId":"OG001","value":"1.579","spread":"0.688"}]}]},{"title":"PLASMA IL-8: C2D28:C1D1 (n=29, 19)","categories":[{"measurements":[{"groupId":"OG000","value":"2.423","spread":"1.514"},{"groupId":"OG001","value":"1.858","spread":"0.849"}]}]},{"title":"PLASMA IL-8: C3D1:C1D1 (n=26, 15)","categories":[{"measurements":[{"groupId":"OG000","value":"2.788","spread":"2.781"},{"groupId":"OG001","value":"1.531","spread":"0.693"}]}]},{"title":"PLASMA IL-8: C3D28:C1D1 (n=26, 14)","categories":[{"measurements":[{"groupId":"OG000","value":"2.574","spread":"1.726"},{"groupId":"OG001","value":"1.999","spread":"0.964"}]}]},{"title":"PLASMA IL-8: C4D1:C1D1 (n=26, 12)","categories":[{"measurements":[{"groupId":"OG000","value":"1.934","spread":"1.372"},{"groupId":"OG001","value":"1.662","spread":"0.736"}]}]},{"title":"PLASMA IL-8: C4:D28:C1D1 (n=25, 11)","categories":[{"measurements":[{"groupId":"OG000","value":"2.549","spread":"1.489"},{"groupId":"OG001","value":"2.492","spread":"2.023"}]}]},{"title":"PLASMA bFGF: Baseline (n=21, 2)","categories":[{"measurements":[{"groupId":"OG000","value":"13.1","spread":"13.1"},{"groupId":"OG001","value":"13.6","spread":"16.8"}]}]},{"title":"PLASMA bFGF: C1D28:C1D1 (n=15, 1)","categories":[{"measurements":[{"groupId":"OG000","value":"2.762","spread":"5.087"},{"groupId":"OG001","value":"0.429","spread":"0"}]}]},{"title":"PLASMA bFGF: C2D1:C1D1 (n=13, 1)","categories":[{"measurements":[{"groupId":"OG000","value":"1.370","spread":"1.800"},{"groupId":"OG001","value":"0.157","spread":"0"}]}]}]},{"type":"SECONDARY","title":"Plasma Concentrations of Soluble Proteins: Plasma Basic Fibroblast Growth Factor (bFGF) That May be Associated With Tumor Proliferation or Angiogenesis","description":"Plasma concentrations of soluble proteins that may be associated with tumor proliferation or angiogenesis collected from a subset of patients were analyzed by enzyme-linked immunosorbent assay (ELISA) analysis. Soluble protein values: Baseline concentration (pM) and ratio to Baseline at each timepoint; ratio = plasma concentration of soluble protein (picograms per milliliter \\[pg/ml\\]) at timepoint / concentration of soluble protein (pg/ml) at baseline. Samples below the limit of quantitation and samples with insufficient volume available were excluded.","populationDescription":"Pharmacodynamic analyses performed at selected sites on AT population who had at least one PK (pharmacokinetic) sample; n = subjects with evaluable data at observation, SU011248 and INF-α treatment groups, respectively. Abbreviations: C = Cycle, D = Day, bFGF: basic fibroblast growth factor.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"pg/ml and ratio to Baseline","timeFrame":"Day 1 & Day 28, Cycle 1 to Cycle 4","groups":[{"id":"OG000","title":"SU011248","description":"50 mg taken orally once a day for 4 weeks followed by a 2-week off treatment cycle to form a 6-week treatment cycle. Intra-subject dose reduction to 37.5 mg/day and 25 mg/day was allowed depending on type and severity of toxicity encountered."},{"id":"OG001","title":"IFN-α","description":"Subcutaneous (SC) injection in 6-week cycles on 3 non-consecutive days per week; 3 million units (MU) per dose Week 1; 6 MU per dose Week 2; 9 MU per dose Week 3 until completion of therapy or development of toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"0"}]}],"classes":[{"title":"PLASMA bFGF: C2D28:C1D1 (n=14, 0)","categories":[{"measurements":[{"groupId":"OG000","value":"0.760","spread":"0.604"}]}]},{"title":"PLASMA bFGF: C3D1:C1D1 (n=12, 0)","categories":[{"measurements":[{"groupId":"OG000","value":"1.582","spread":"2.622"}]}]},{"title":"PLASMA bFGF: C3D28:C1D1 (n=12, 0)","categories":[{"measurements":[{"groupId":"OG000","value":"1.671","spread":"2.109"}]}]},{"title":"PLASMA bFGF: C4D1:C1D1 (n=14, 0)","categories":[{"measurements":[{"groupId":"OG000","value":"2.895","spread":"4.252"}]}]},{"title":"PLASMA bFGF: C4:D28:C1D1 (n=10, 0)","categories":[{"measurements":[{"groupId":"OG000","value":"0.803","spread":"0.799"}]}]}]},{"type":"SECONDARY","title":"Incremental Cost Effectiveness Ratio (ICER)","description":"Incremental cost effectiveness ratio (ICER) of sunitinib compared to IFN-a as first-line treatment for MRCC, defined as the ratio of the incremental cost of treatment over the incremental effectiveness; effectiveness measured as quality adjusted life year (QALY) gain. This objective was not addressed in the clinical study report, but an interim analysis of cost-effectiveness was presented separately. These results were not available for inclusion at the time of this posting.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"ratio","timeFrame":"post study measurement","groups":[{"id":"OG000","title":"SU011248","description":"50 mg taken orally once a day for 4 weeks followed by a 2-week off treatment cycle to form a 6-week treatment cycle. Intra-subject dose reduction to 37.5 mg/day and 25 mg/day was allowed depending on type and severity of toxicity encountered."},{"id":"OG001","title":"IFN-α","description":"Subcutaneous (SC) injection in 6-week cycles on 3 non-consecutive days per week; 3 million units (MU) per dose Week 1; 6 MU per dose Week 2; 9 MU per dose Week 3 until completion of therapy or development of toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"375"},{"groupId":"OG001","value":"375"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Ctrough Concentrations of SU011248","description":"Subject observed Ctrough (trough drug) concentrations of SU011248 per cycle and study day determined by plasma trough samples collected from a subset of patients. Steady-state observed trough concentrations were dose corrected to the starting dose (reference dose) where appropriate. Concentrations below the limits of quantitation (BLQ) were set to 0. Ctrough = minimum (trough) plasma concentration (nanograms per milliliter \\[ng/mL\\]).","populationDescription":"As treated (AT) population: all patients who received at least 1 dose of study medication with treatment assignments designated according to actual study treatment received. Pharmacokinetic (PK) analyses were performed on the AT population who had at least one PK sample. n=number of subjects with evaluable trough samples.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"ng/mL","timeFrame":"Day 28 of Cycle 1 to Cycle 4","groups":[{"id":"OG000","title":"SU011248","description":"50 mg taken orally once a day for 4 weeks followed by a 2-week off treatment cycle. Intra-subject dose reduction to 35.5 mg/day and 25 mg/day was allowed depending on type and severity of toxicity encountered."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"45"}]}],"classes":[{"title":"Cycle 1, Day 28 (n=31)","categories":[{"measurements":[{"groupId":"OG000","value":"57.26","spread":"31.37"}]}]},{"title":"Cycle 2, Day 28 (n=36)","categories":[{"measurements":[{"groupId":"OG000","value":"57.59","spread":"28.59"}]}]},{"title":"Cycle 3, Day 28 (n=36)","categories":[{"measurements":[{"groupId":"OG000","value":"50.26","spread":"24.89"}]}]},{"title":"Cycle 4, Day 28 (n=32)","categories":[{"measurements":[{"groupId":"OG000","value":"45.05","spread":"23.76"}]}]},{"title":"Dose-Corrected: Cycle 1, Day 28 (n=24)","categories":[{"measurements":[{"groupId":"OG000","value":"64.22","spread":"31.40"}]}]},{"title":"Dose-Corrected: Cycle 2, Day 28 (n=28)","categories":[{"measurements":[{"groupId":"OG000","value":"59.90","spread":"26.42"}]}]},{"title":"Dose-Corrected: Cycle 3, Day 28 (n=27)","categories":[{"measurements":[{"groupId":"OG000","value":"58.45","spread":"29.39"}]}]},{"title":"Dose-Corrected: Cycle 4, Day 28 (n=26)","categories":[{"measurements":[{"groupId":"OG000","value":"54.31","spread":"30.70"}]}]}]},{"type":"SECONDARY","title":"Ctrough Concentrations of Metabolite SU012662","description":"Subject observed Ctrough (trough drug) concentrations of active metabolite SU012662 per cycle and study day determined by plasma trough samples collected from a subset of patients. Steady-state observed trough concentrations were dose corrected to the starting dose (reference dose) where appropriate. Concentrations below the limits of quantitation (BLQ) were set to 0. Ctrough = minimum (trough) plasma concentration (nanograms per milliliter \\[ng/mL\\]).","populationDescription":"As treated (AT) population: all patients who received at least 1 dose of study medication with treatment assignments designated according to actual study treatment received. Pharmacokinetic (PK) analyses were performed on the AT population who had at least one PK sample. n=number of subjects with evaluable trough samples","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"ng/mL","timeFrame":"Day 28 of Cycle 1 to Cycle 4","groups":[{"id":"OG000","title":"SU012662","description":"Active metabolite of SU011248"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"45"}]}],"classes":[{"title":"Cycle 1, Day 28 (n=31)","categories":[{"measurements":[{"groupId":"OG000","value":"27.10","spread":"17.28"}]}]},{"title":"Cycle 2, Day 28 (n=36)","categories":[{"measurements":[{"groupId":"OG000","value":"27.35","spread":"15.42"}]}]},{"title":"Cycle 3, Day 28 (n=36)","categories":[{"measurements":[{"groupId":"OG000","value":"26.11","spread":"16.15"}]}]},{"title":"Cycle 4, Day 28 (n=32)","categories":[{"measurements":[{"groupId":"OG000","value":"22.11","spread":"12.67"}]}]},{"title":"Dose-Corrected: Cycle 1, Day 28 (n=24)","categories":[{"measurements":[{"groupId":"OG000","value":"28.21","spread":"19.01"}]}]},{"title":"Dose-Corrected: Cycle 2, Day 28 (n=28)","categories":[{"measurements":[{"groupId":"OG000","value":"28.32","spread":"13.74"}]}]},{"title":"Dose-Corrected: Cycle 3, Day 28 (n=27)","categories":[{"measurements":[{"groupId":"OG000","value":"29.04","spread":"19.07"}]}]},{"title":"Dose-Corrected: Cycle 4, Day 28 (n=26)","categories":[{"measurements":[{"groupId":"OG000","value":"25.99","spread":"16.25"}]}]}]},{"type":"SECONDARY","title":"Ctrough Concentrations of SU011248 and Active Metabolite SU012662","description":"Subject observed Ctrough (trough drug) concentrations of total drug (SU011248 and its active metabolite SU012662) per cycle and study day determined by plasma trough samples collected from a subset of patients. Steady-state observed trough concentrations were dose corrected to the starting dose (reference dose) where appropriate. Concentrations below the limits of quantitation (BLQ) were set to 0. Ctrough = minimum (trough) plasma concentration (nanograms per milliliter \\[ng/mL\\]).","populationDescription":"As treated (AT) population: all patients who received at least 1 dose of study medication with treatment assignments designated according to actual study treatment received. Pharmacokinetic (PK) analyses were performed on the AT population who had at least one PK sample. n=number of subjects with evaluable trough samples at observation.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"ng/mL","timeFrame":"Day 28 of Cycle 1 to Cycle 4","groups":[{"id":"OG000","title":"Total Drug: SU011248 and SU012662","description":"SU011248 and active metabolite SU012662"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"45"}]}],"classes":[{"title":"Cycle 1, Day 28 (n=31)","categories":[{"measurements":[{"groupId":"OG000","value":"84.36","spread":"46.06"}]}]},{"title":"Cycle 2, Day 28 (n=36)","categories":[{"measurements":[{"groupId":"OG000","value":"84.94","spread":"41.18"}]}]},{"title":"Cycle 3, Day 28 (n=36)","categories":[{"measurements":[{"groupId":"OG000","value":"76.37","spread":"38.86"}]}]},{"title":"Cycle 4, Day 28 (n=32)","categories":[{"measurements":[{"groupId":"OG000","value":"67.15","spread":"34.13"}]}]},{"title":"Dose-Corrected: Cycle 1, Day 28 (n=24)","categories":[{"measurements":[{"groupId":"OG000","value":"92.43","spread":"48.08"}]}]},{"title":"Dose-Corrected: Cycle 2, Day 28 (n=28)","categories":[{"measurements":[{"groupId":"OG000","value":"88.22","spread":"36.34"}]}]},{"title":"Dose-Corrected: Cycle 3, Day 28 (n=27)","categories":[{"measurements":[{"groupId":"OG000","value":"87.49","spread":"45.85"}]}]},{"title":"Dose-Corrected: Cycle 4, Day 28 (n=27)","categories":[{"measurements":[{"groupId":"OG000","value":"80.30","spread":"44.76"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","eventGroups":[{"id":"EG000","title":"SU011248","description":"50 mg taken orally once a day for 4 weeks followed by a 2-week off treatment cycle to form a 6-week treatment cycle. Intra-subject dose reduction to 37.5 mg/day and 25 mg/day was allowed depending on type and severity of toxicity encountered.","seriousNumAffected":170,"seriousNumAtRisk":375,"otherNumAffected":368,"otherNumAtRisk":375},{"id":"EG001","title":"IFN-α","description":"Subcutaneous (SC) injection in 6-week cycles on 3 non-consecutive days per week; 3 million units (MU) per dose Week 1; 6 MU per dose Week 2; 9 MU per dose Week 3 until completion of therapy or development of toxicity.","seriousNumAffected":93,"seriousNumAtRisk":360,"otherNumAffected":344,"otherNumAtRisk":360}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (v11.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":375},{"groupId":"EG001","numAffected":12,"numAtRisk":360}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Idiopathic thrombocytopenic purpura","organSystem":"Blood and lymphatic system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Thrombotic thrombocytopenic purpura","organSystem":"Blood and lymphatic system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":375},{"groupId":"EG001","numAffected":2,"numAtRisk":360}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Coronary artery disease","organSystem":"Cardiac disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Pericardial effusion","organSystem":"Cardiac disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":375},{"groupId":"EG001","numAffected":1,"numAtRisk":360}]},{"term":"Atrial flutter","organSystem":"Cardiac disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Cardiac arrest","organSystem":"Cardiac disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Cardiac failure congestive","organSystem":"Cardiac disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":1,"numAtRisk":360}]},{"term":"Left ventricular dysfunction","organSystem":"Cardiac disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Myocardial ischaemia","organSystem":"Cardiac disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Palpitations","organSystem":"Cardiac disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":375},{"groupId":"EG001","numAffected":1,"numAtRisk":360}]},{"term":"Cardiac disorder","organSystem":"Cardiac disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":375},{"groupId":"EG001","numAffected":1,"numAtRisk":360}]},{"term":"Deafness","organSystem":"Ear and labyrinth disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Vertigo positional","organSystem":"Ear and labyrinth disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":375},{"groupId":"EG001","numAffected":1,"numAtRisk":360}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Hyperthyroidism","organSystem":"Endocrine disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":375},{"groupId":"EG001","numAffected":1,"numAtRisk":360}]},{"term":"Visual impairment","organSystem":"Eye disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Retinal artery occlusion","organSystem":"Eye disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":375},{"groupId":"EG001","numAffected":3,"numAtRisk":360}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":375},{"groupId":"EG001","numAffected":3,"numAtRisk":360}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":375},{"groupId":"EG001","numAffected":3,"numAtRisk":360}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Gastric haemorrhage","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Intestinal obstruction","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Intestinal perforation","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":375},{"groupId":"EG001","numAffected":1,"numAtRisk":360}]},{"term":"Pancreatitis","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Abdominal pain lower","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Anal fistula","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Ascites","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":1,"numAtRisk":360}]},{"term":"Gastric ulcer haemorrhage","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Gastrointestinal obstruction","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Glossodynia","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Haematemesis","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Haematochezia","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Haemorrhoidal haemorrhage","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Ileus","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Intestinal fistula","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Mouth ulceration","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Rectal haemorrhage","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":1,"numAtRisk":360}]},{"term":"Small intestinal obstruction","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Tongue oedema","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":375},{"groupId":"EG001","numAffected":2,"numAtRisk":360}]},{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":375},{"groupId":"EG001","numAffected":1,"numAtRisk":360}]},{"term":"Large intestine perforation","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":375},{"groupId":"EG001","numAffected":1,"numAtRisk":360}]},{"term":"Upper gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":375},{"groupId":"EG001","numAffected":1,"numAtRisk":360}]},{"term":"Disease progression","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":17,"numAtRisk":375},{"groupId":"EG001","numAffected":15,"numAtRisk":360}]},{"term":"Asthenia","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":16,"numAtRisk":375},{"groupId":"EG001","numAffected":5,"numAtRisk":360}]},{"term":"Chest pain","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":375},{"groupId":"EG001","numAffected":6,"numAtRisk":360}]},{"term":"General physical health deterioration","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Pyrexia","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Condition aggravated","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":375},{"groupId":"EG001","numAffected":2,"numAtRisk":360}]},{"term":"Fatigue","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":375},{"groupId":"EG001","numAffected":5,"numAtRisk":360}]},{"term":"Oedema peripheral","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Pain","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Chills","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Face oedema","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Hypothermia","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Sudden death","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Performance status decreased","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":375},{"groupId":"EG001","numAffected":2,"numAtRisk":360}]},{"term":"Biliary tract disorder","organSystem":"Hepatobiliary disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Cholecystitis","organSystem":"Hepatobiliary disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Cholecystitis acute","organSystem":"Hepatobiliary disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Cholelithiasis","organSystem":"Hepatobiliary disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Hepatitis","organSystem":"Hepatobiliary disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Bile duct stone","organSystem":"Hepatobiliary disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":375},{"groupId":"EG001","numAffected":1,"numAtRisk":360}]},{"term":"Cellulitis","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Pneumonia","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":375},{"groupId":"EG001","numAffected":2,"numAtRisk":360}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Urosepsis","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Arthritis bacterial","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Arthritis infective","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Fungal infection","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Herpes zoster","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Infected skin ulcer","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Localised infection","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Lung infection","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Oesophageal candidiasis","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Otitis externa","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Perirectal abscess","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Pleural infection","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Pyothorax","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Sepsis","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":2,"numAtRisk":360}]},{"term":"Sinusitis","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":1,"numAtRisk":360}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":1,"numAtRisk":360}]},{"term":"Wound infection","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Diverticulitis","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":375},{"groupId":"EG001","numAffected":1,"numAtRisk":360}]},{"term":"Infection","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":375},{"groupId":"EG001","numAffected":1,"numAtRisk":360}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":375},{"groupId":"EG001","numAffected":1,"numAtRisk":360}]},{"term":"Staphylococcal infection","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":375},{"groupId":"EG001","numAffected":1,"numAtRisk":360}]},{"term":"Cervical vertebral fracture","organSystem":"Injury, poisoning and procedural complications","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Dislocation of joint prosthesis","organSystem":"Injury, poisoning and procedural complications","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Head injury","organSystem":"Injury, poisoning and procedural complications","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Hip fracture","organSystem":"Injury, poisoning and procedural complications","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Humerus fracture","organSystem":"Injury, poisoning and procedural complications","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":1,"numAtRisk":360}]},{"term":"Lumbar vertebral fracture","organSystem":"Injury, poisoning and procedural complications","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Wound dehiscence","organSystem":"Injury, poisoning and procedural complications","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Brain herniation","organSystem":"Injury, poisoning and procedural complications","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":375},{"groupId":"EG001","numAffected":1,"numAtRisk":360}]},{"term":"Pelvic fracture","organSystem":"Injury, poisoning and procedural complications","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":375},{"groupId":"EG001","numAffected":1,"numAtRisk":360}]},{"term":"Blood bilirubin increased","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Ejection fraction decreased","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Platelet count decreased","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Blood creatine phosphokinase increased","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Electrocardiogram change","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Haemoglobin decreased","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Urine output decreased","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Blood creatinine increased","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":375},{"groupId":"EG001","numAffected":1,"numAtRisk":360}]},{"term":"Weight decreased","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":375},{"groupId":"EG001","numAffected":1,"numAtRisk":360}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":375},{"groupId":"EG001","numAffected":6,"numAtRisk":360}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Anorexia","organSystem":"Metabolism and nutrition disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Hypoglycaemia","organSystem":"Metabolism and nutrition disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Hyperkalaemia","organSystem":"Metabolism and nutrition disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":1,"numAtRisk":360}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Diabetes mellitus","organSystem":"Metabolism and nutrition disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":375},{"groupId":"EG001","numAffected":3,"numAtRisk":360}]},{"term":"Hypercalcaemia","organSystem":"Metabolism and nutrition disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":375},{"groupId":"EG001","numAffected":2,"numAtRisk":360}]},{"term":"Hyperuricaemia","organSystem":"Metabolism and nutrition disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":375},{"groupId":"EG001","numAffected":1,"numAtRisk":360}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":375},{"groupId":"EG001","numAffected":1,"numAtRisk":360}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":375},{"groupId":"EG001","numAffected":1,"numAtRisk":360}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Pathological fracture","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":375},{"groupId":"EG001","numAffected":5,"numAtRisk":360}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":1,"numAtRisk":360}]},{"term":"Groin pain","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Hypercreatinaemia","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":1,"numAtRisk":360}]},{"term":"Fistula","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":375},{"groupId":"EG001","numAffected":1,"numAtRisk":360}]},{"term":"Cancer pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Colon cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Prostate cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":1,"numAtRisk":360}]},{"term":"Intracranial tumour haemorrhage","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":375},{"groupId":"EG001","numAffected":1,"numAtRisk":360}]},{"term":"Convulsion","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":375},{"groupId":"EG001","numAffected":1,"numAtRisk":360}]},{"term":"Spinal cord compression","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":375},{"groupId":"EG001","numAffected":1,"numAtRisk":360}]},{"term":"Epilepsy","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":375},{"groupId":"EG001","numAffected":1,"numAtRisk":360}]},{"term":"Headache","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Monoparesis","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Syncope","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":375},{"groupId":"EG001","numAffected":1,"numAtRisk":360}]},{"term":"Aphasia","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Cerebellar syndrome","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Cerebral haematoma","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Cerebral ischaemia","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Facial palsy","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Hemiparesis","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":1,"numAtRisk":360}]},{"term":"Incoherent","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Memory impairment","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Nervous system disorder","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Paresis","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Peripheral sensory neuropathy","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Reversible posterior leukoencephalopathy syndrome","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Transient ischaemic attack","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":1,"numAtRisk":360}]},{"term":"Cerebral haemorrhage","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":375},{"groupId":"EG001","numAffected":1,"numAtRisk":360}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":375},{"groupId":"EG001","numAffected":1,"numAtRisk":360}]},{"term":"Dizziness","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":375},{"groupId":"EG001","numAffected":1,"numAtRisk":360}]},{"term":"Haemorrhage intracranial","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":375},{"groupId":"EG001","numAffected":1,"numAtRisk":360}]},{"term":"Motor dysfunction","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":375},{"groupId":"EG001","numAffected":1,"numAtRisk":360}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Mental status changes","organSystem":"Psychiatric disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":375},{"groupId":"EG001","numAffected":2,"numAtRisk":360}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Delirium","organSystem":"Psychiatric disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Depression","organSystem":"Psychiatric disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":375},{"groupId":"EG001","numAffected":1,"numAtRisk":360}]},{"term":"Emotional disorder","organSystem":"Psychiatric disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":375},{"groupId":"EG001","numAffected":1,"numAtRisk":360}]},{"term":"Haematuria","organSystem":"Renal and urinary disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":375},{"groupId":"EG001","numAffected":1,"numAtRisk":360}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":375},{"groupId":"EG001","numAffected":1,"numAtRisk":360}]},{"term":"Renal failure acute","organSystem":"Renal and urinary disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":375},{"groupId":"EG001","numAffected":1,"numAtRisk":360}]},{"term":"Urinary retention","organSystem":"Renal and urinary disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":375},{"groupId":"EG001","numAffected":2,"numAtRisk":360}]},{"term":"Nephrotic syndrome","organSystem":"Renal and urinary disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Pollakiuria","organSystem":"Renal and urinary disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Urinary bladder haemorrhage","organSystem":"Renal and urinary disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Metrorrhagia","organSystem":"Reproductive system and breast disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Uterine haemorrhage","organSystem":"Reproductive system and breast disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Vaginal haemorrhage","organSystem":"Reproductive system and breast disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":375},{"groupId":"EG001","numAffected":9,"numAtRisk":360}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":375},{"groupId":"EG001","numAffected":1,"numAtRisk":360}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":375},{"groupId":"EG001","numAffected":4,"numAtRisk":360}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Dyspnoea exertional","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":1,"numAtRisk":360}]},{"term":"Lung disorder","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Respiratory arrest","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Respiratory distress","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":1,"numAtRisk":360}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":375},{"groupId":"EG001","numAffected":1,"numAtRisk":360}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":375},{"groupId":"EG001","numAffected":2,"numAtRisk":360}]},{"term":"Lung infiltration","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":375},{"groupId":"EG001","numAffected":1,"numAtRisk":360}]},{"term":"Pulmonary oedema","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":375},{"groupId":"EG001","numAffected":2,"numAtRisk":360}]},{"term":"Dermatitis","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Diabetic ulcer","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Palmar-plantar erythrodysaesthesia syndrome","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Stevens-Johnson syndrome","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Bone graft","organSystem":"Surgical and medical procedures","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Hepatectomy","organSystem":"Surgical and medical procedures","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Hip arthroplasty","organSystem":"Surgical and medical procedures","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Inguinal hernia repair","organSystem":"Surgical and medical procedures","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Pleurectomy","organSystem":"Surgical and medical procedures","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Vertebroplasty","organSystem":"Surgical and medical procedures","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Hypertension","organSystem":"Vascular disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":375},{"groupId":"EG001","numAffected":1,"numAtRisk":360}]},{"term":"Malignant hypertension","organSystem":"Vascular disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Phlebitis","organSystem":"Vascular disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Superior vena caval occlusion","organSystem":"Vascular disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Vasculitis","organSystem":"Vascular disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Hypotension","organSystem":"Vascular disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":375},{"groupId":"EG001","numAffected":1,"numAtRisk":360}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (v11.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":75,"numAtRisk":375},{"groupId":"EG001","numAffected":55,"numAtRisk":360}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":40,"numAtRisk":375},{"groupId":"EG001","numAffected":16,"numAtRisk":360}]},{"term":"Lymphopenia","organSystem":"Blood and lymphatic system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":19,"numAtRisk":375},{"groupId":"EG001","numAffected":21,"numAtRisk":360}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":69,"numAtRisk":375},{"groupId":"EG001","numAffected":33,"numAtRisk":360}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":69,"numAtRisk":375},{"groupId":"EG001","numAffected":15,"numAtRisk":360}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":57,"numAtRisk":375},{"groupId":"EG001","numAffected":3,"numAtRisk":360}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":64,"numAtRisk":375},{"groupId":"EG001","numAffected":28,"numAtRisk":360}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":52,"numAtRisk":375},{"groupId":"EG001","numAffected":10,"numAtRisk":360}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":85,"numAtRisk":375},{"groupId":"EG001","numAffected":48,"numAtRisk":360}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":245,"numAtRisk":375},{"groupId":"EG001","numAffected":76,"numAtRisk":360}]},{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":50,"numAtRisk":375},{"groupId":"EG001","numAffected":27,"numAtRisk":360}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":128,"numAtRisk":375},{"groupId":"EG001","numAffected":16,"numAtRisk":360}]},{"term":"Flatulence","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":52,"numAtRisk":375},{"groupId":"EG001","numAffected":8,"numAtRisk":360}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":47,"numAtRisk":375},{"groupId":"EG001","numAffected":3,"numAtRisk":360}]},{"term":"Glossodynia","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":39,"numAtRisk":375},{"groupId":"EG001","numAffected":2,"numAtRisk":360}]},{"term":"Haemorrhoids","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":38,"numAtRisk":375},{"groupId":"EG001","numAffected":6,"numAtRisk":360}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":215,"numAtRisk":375},{"groupId":"EG001","numAffected":146,"numAtRisk":360}]},{"term":"Oral pain","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":54,"numAtRisk":375},{"groupId":"EG001","numAffected":2,"numAtRisk":360}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":113,"numAtRisk":375},{"groupId":"EG001","numAffected":12,"numAtRisk":360}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":144,"numAtRisk":375},{"groupId":"EG001","numAffected":60,"numAtRisk":360}]},{"term":"Asthenia","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":91,"numAtRisk":375},{"groupId":"EG001","numAffected":79,"numAtRisk":360}]},{"term":"Chest pain","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":45,"numAtRisk":375},{"groupId":"EG001","numAffected":21,"numAtRisk":360}]},{"term":"Chills","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":52,"numAtRisk":375},{"groupId":"EG001","numAffected":111,"numAtRisk":360}]},{"term":"Fatigue","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":230,"numAtRisk":375},{"groupId":"EG001","numAffected":200,"numAtRisk":360}]},{"term":"Influenza like illness","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":18,"numAtRisk":375},{"groupId":"EG001","numAffected":54,"numAtRisk":360}]},{"term":"Mucosal inflammation","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":100,"numAtRisk":375},{"groupId":"EG001","numAffected":7,"numAtRisk":360}]},{"term":"Oedema peripheral","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":90,"numAtRisk":375},{"groupId":"EG001","numAffected":17,"numAtRisk":360}]},{"term":"Pain","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":35,"numAtRisk":375},{"groupId":"EG001","numAffected":20,"numAtRisk":360}]},{"term":"Pyrexia","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":80,"numAtRisk":375},{"groupId":"EG001","numAffected":134,"numAtRisk":360}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":54,"numAtRisk":375},{"groupId":"EG001","numAffected":8,"numAtRisk":360}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":42,"numAtRisk":375},{"groupId":"EG001","numAffected":9,"numAtRisk":360}]},{"term":"Ejection fraction decreased","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":60,"numAtRisk":375},{"groupId":"EG001","numAffected":19,"numAtRisk":360}]},{"term":"Weight decreased","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":60,"numAtRisk":375},{"groupId":"EG001","numAffected":59,"numAtRisk":360}]},{"term":"Anorexia","organSystem":"Metabolism and nutrition disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":154,"numAtRisk":375},{"groupId":"EG001","numAffected":112,"numAtRisk":360}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":44,"numAtRisk":375},{"groupId":"EG001","numAffected":44,"numAtRisk":360}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":27,"numAtRisk":375},{"groupId":"EG001","numAffected":14,"numAtRisk":360}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":110,"numAtRisk":375},{"groupId":"EG001","numAffected":68,"numAtRisk":360}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":103,"numAtRisk":375},{"groupId":"EG001","numAffected":52,"numAtRisk":360}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":27,"numAtRisk":375},{"groupId":"EG001","numAffected":14,"numAtRisk":360}]},{"term":"Muscle spasms","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":28,"numAtRisk":375},{"groupId":"EG001","numAffected":9,"numAtRisk":360}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":28,"numAtRisk":375},{"groupId":"EG001","numAffected":14,"numAtRisk":360}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":50,"numAtRisk":375},{"groupId":"EG001","numAffected":23,"numAtRisk":360}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":46,"numAtRisk":375},{"groupId":"EG001","numAffected":68,"numAtRisk":360}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":100,"numAtRisk":375},{"groupId":"EG001","numAffected":30,"numAtRisk":360}]},{"term":"Dizziness","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":43,"numAtRisk":375},{"groupId":"EG001","numAffected":50,"numAtRisk":360}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":174,"numAtRisk":375},{"groupId":"EG001","numAffected":53,"numAtRisk":360}]},{"term":"Headache","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":86,"numAtRisk":375},{"groupId":"EG001","numAffected":69,"numAtRisk":360}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":35,"numAtRisk":375},{"groupId":"EG001","numAffected":7,"numAtRisk":360}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":24,"numAtRisk":375},{"groupId":"EG001","numAffected":18,"numAtRisk":360}]},{"term":"Depression","organSystem":"Psychiatric disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":40,"numAtRisk":375},{"groupId":"EG001","numAffected":51,"numAtRisk":360}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":56,"numAtRisk":375},{"groupId":"EG001","numAffected":37,"numAtRisk":360}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":100,"numAtRisk":375},{"groupId":"EG001","numAffected":50,"numAtRisk":360}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":95,"numAtRisk":375},{"groupId":"EG001","numAffected":67,"numAtRisk":360}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":79,"numAtRisk":375},{"groupId":"EG001","numAffected":9,"numAtRisk":360}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":51,"numAtRisk":375},{"groupId":"EG001","numAffected":9,"numAtRisk":360}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":51,"numAtRisk":375},{"groupId":"EG001","numAffected":34,"numAtRisk":360}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":85,"numAtRisk":375},{"groupId":"EG001","numAffected":26,"numAtRisk":360}]},{"term":"Erythema","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":46,"numAtRisk":375},{"groupId":"EG001","numAffected":5,"numAtRisk":360}]},{"term":"Hair colour changes","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":75,"numAtRisk":375},{"groupId":"EG001","numAffected":1,"numAtRisk":360}]},{"term":"Palmar-plantar erythrodysaesthesia syndrome","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":108,"numAtRisk":375},{"groupId":"EG001","numAffected":3,"numAtRisk":360}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":44,"numAtRisk":375},{"groupId":"EG001","numAffected":24,"numAtRisk":360}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":109,"numAtRisk":375},{"groupId":"EG001","numAffected":39,"numAtRisk":360}]},{"term":"Skin discolouration","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":94,"numAtRisk":375},{"groupId":"EG001","numAffected":0,"numAtRisk":360}]},{"term":"Skin exfoliation","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":37,"numAtRisk":375},{"groupId":"EG001","numAffected":5,"numAtRisk":360}]},{"term":"Hypertension","organSystem":"Vascular disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":125,"numAtRisk":375},{"groupId":"EG001","numAffected":13,"numAtRisk":360}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Pfizer has the right to review disclosures, requesting a delay of \\< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \\< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results."},"pointOfContact":{"title":"Pfizer ClinicalTrials.gov Call Center","organization":"Pfizer, Inc.","email":"ClinicalTrials.govCallCenter@pfizer.com","phone":"1-800-718-1021"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-04-02"},"conditionBrowseModule":{"meshes":[{"id":"D002277","term":"Carcinoma"},{"id":"D002292","term":"Carcinoma, Renal Cell"}],"ancestors":[{"id":"D009375","term":"Neoplasms, Glandular and Epithelial"},{"id":"D009370","term":"Neoplasms by Histologic Type"},{"id":"D009369","term":"Neoplasms"},{"id":"D000230","term":"Adenocarcinoma"},{"id":"D007680","term":"Kidney Neoplasms"},{"id":"D014571","term":"Urologic Neoplasms"},{"id":"D014565","term":"Urogenital Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D052776","term":"Female Urogenital Diseases"},{"id":"D005261","term":"Female Urogenital Diseases and Pregnancy Complications"},{"id":"D000091642","term":"Urogenital Diseases"},{"id":"D007674","term":"Kidney Diseases"},{"id":"D014570","term":"Urologic Diseases"},{"id":"D052801","term":"Male Urogenital Diseases"}],"browseLeaves":[{"id":"M5534","name":"Carcinoma","asFound":"Carcinoma","relevance":"HIGH"},{"id":"M5548","name":"Carcinoma, Renal Cell","asFound":"Carcinoma, Renal Cell","relevance":"HIGH"},{"id":"M12320","name":"Neoplasms, Glandular and Epithelial","relevance":"LOW"},{"id":"M12315","name":"Neoplasms by Histologic Type","relevance":"LOW"},{"id":"M3585","name":"Adenocarcinoma","relevance":"LOW"},{"id":"M10703","name":"Kidney Neoplasms","relevance":"LOW"},{"id":"M17320","name":"Urologic Neoplasms","relevance":"LOW"},{"id":"M17315","name":"Urogenital Neoplasms","relevance":"LOW"},{"id":"M2875","name":"Urogenital Diseases","relevance":"LOW"},{"id":"M27093","name":"Female Urogenital Diseases","relevance":"LOW"},{"id":"M14127","name":"Pregnancy Complications","relevance":"LOW"},{"id":"M8399","name":"Female Urogenital Diseases and Pregnancy Complications","relevance":"LOW"},{"id":"M10698","name":"Kidney Diseases","relevance":"LOW"},{"id":"M17319","name":"Urologic Diseases","relevance":"LOW"},{"id":"M27095","name":"Male Urogenital Diseases","relevance":"LOW"},{"id":"T4906","name":"Renal Cell Carcinoma","asFound":"Renal Cell Carcinoma","relevance":"HIGH"},{"id":"T1341","name":"Clear Cell Renal Cell Carcinoma","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC04","name":"Neoplasms"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BXS","name":"Urinary Tract, Sexual Organs, and Pregnancy Conditions"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D007372","term":"Interferons"},{"id":"D016898","term":"Interferon-alpha"},{"id":"D000077210","term":"Sunitinib"}],"ancestors":[{"id":"D000970","term":"Antineoplastic Agents"},{"id":"D000998","term":"Antiviral Agents"},{"id":"D000890","term":"Anti-Infective Agents"},{"id":"D007155","term":"Immunologic Factors"},{"id":"D045505","term":"Physiological Effects of Drugs"},{"id":"D020533","term":"Angiogenesis Inhibitors"},{"id":"D043924","term":"Angiogenesis Modulating Agents"},{"id":"D006133","term":"Growth Substances"},{"id":"D006131","term":"Growth Inhibitors"},{"id":"D047428","term":"Protein Kinase Inhibitors"},{"id":"D004791","term":"Enzyme Inhibitors"},{"id":"D045504","term":"Molecular Mechanisms of Pharmacological Action"}],"browseLeaves":[{"id":"M19243","name":"Interferon-alpha","asFound":"Repeated","relevance":"HIGH"},{"id":"M10407","name":"Interferons","asFound":"Receiving","relevance":"HIGH"},{"id":"M1698","name":"Sunitinib","asFound":"Squamous","relevance":"HIGH"},{"id":"M4314","name":"Antiviral Agents","relevance":"LOW"},{"id":"M4214","name":"Anti-Infective Agents","relevance":"LOW"},{"id":"M10201","name":"Immunologic Factors","relevance":"LOW"},{"id":"M22318","name":"Angiogenesis Inhibitors","relevance":"LOW"},{"id":"M9231","name":"Growth Inhibitors","relevance":"LOW"},{"id":"M25820","name":"Protein Kinase Inhibitors","relevance":"LOW"},{"id":"M7951","name":"Enzyme Inhibitors","relevance":"LOW"}],"browseBranches":[{"abbrev":"Infe","name":"Anti-Infective Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"ANeo","name":"Antineoplastic Agents"}]}},"hasResults":true}